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Summary 
Hydrogen sulfide (H2S) is the simplest endogenously produced thiol and has 
an indispensable role in cardiovascular homeostasis. It has been shown that 
exogenous H2S supplementation protected the heart against myocardial 
ischaemia/reperfusion injury through a mechanism which is yet to be defined. 
In this thesis, it was hypothesised that controlled application of thiol/H2S donors 
at reperfusion would mitigate acute myocardial infarction. We sought to 
characterise the cardioprotection and molecular targets of three H2S donors 
(mesna, GYY4137 (a slow-releasing, non-mitochondrial targeted H2S donor) 
and AP39 (a mitochondria-targeting H2S donor). This characterisation was 
conducted using a broad range of experimental models and techniques 
including anaesthetised rat model of ischaemia/reperfusion injury, Western 
blotting and mitochondrial studies using isolated cardiomyocyte mitochondria, 
namely subsarcolemmal and interfibrillar mitochondria. 
Mesna did not limit infarct size when it was given pre-ischaemia or at 
reperfusion. GYY4137 and AP39 significantly limited infarct size when given 
specifically at the time of reperfusion through different mechanisms. 
Cardioprotection established by GYY4137 was mediated mainly by triggering 
of PI3K/Akt/GSK-3β signalling at reperfusion with partial dependency on eNOS 
activity. Selective mitochondrial delivery of H2S at reperfusion using AP39 had 
no effect on Akt, eNOS, GSK-3β and ERK1/2. In isolated mitochondria, AP39 
inhibited Ca2+-sensitive opening of PTP in subsarcolemmal and interfibrillar 
mitochondria through attenuation of mitochondrial reactive oxygen species 
generation. 
The studies presented in this thesis provided novel mechanistic insights into 
cardioprotection by H2S. These studies suggest that targeted delivery of H2S 
represents a novel and effective adjunctive therapy to ameliorate the injurious 
effects of reperfusion which contribute to acute myocardial infarction.  
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1.1 Introduction 
1.1.1  Coronary heart disease (CHD) 
Cardiovascular disease (CVD) is the main cause of death and disability 
worldwide according to the World Health Organization (2014). Globally, it was 
responsible for 30% of deaths (more than 17 million) in 2008 (Mendis et al., 
2011) and it is predicted to cause more than 23 million deaths by 2030 (World 
Health Organisation 2014). Approximately half of these deaths (8 millions) were 
caused by coronary heart disease (CHD) which is an umbrella term for an 
impairment in the coronary circulation. CHD is most commonly caused by 
accumulation of atherosclerotic plaques inside the coronary arteries. Plaques 
causes vascular stenosis impairing the blood flow to the cardiac tissue through 
the coronary artery. In the United Kingdom, CHD caused around 74,000 deaths 
among 127,000 acute myocardial infarctions (AMIs) that patients suffered in 
2012 (Bhatnagar et al., 2015). The mortality rate for CHD has significantly 
decreased in recent years where 7 out of 10 people survive the heart attack by 
the virtue of risk factor reduction, new pharmacological protocols for primary 
prevention and earlier diagnosis (Bhatnagar et al., 2015). However, 1 in every 4 
patients currently admitted for early reperfusion treatment will either die or 
develop heart failure within a year of the treatment (Cung et al., 2015). There 
are 1.5 million people in the UK living with either heart failure or other after 
effects of AMI (Bhatnagar et al., 2015). Therefore, there is still a great global 
demand for safe and effective therapies for CHD.  
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1.1.2 Acute myocardial infarction (AMI)  
The rupture of an unstable atherosclerotic plaque in the coronary artery is the 
principal contributor to AMI. The exact mechanism by which atherosclerotic 
plaque develops in the coronary artery is not yet known. However, it is thought 
to involve an intricate interaction between the inflammatory/innate immune cells 
and the innermost layer of the coronary artery intima. High levels of low-density 
lipoprotein cholesterol (LDL) is proposed to cause damage to the intima and 
trigger a series of inflammatory responses which lead to further accumulation of 
blood-borne inflammatory and immune cells such as macrophage and T-
lymphocyte, forming what is so-called “foam cells” (Stary et al., 1995). Foam 
cells comprise the core of the atheroma, along with dead cells, debris and 
connective tissue (Stary et al., 1995), while the outer fibrous cover of the plaque 
is composed of connective tissue and smooth muscle (Ross, 1993). Rupture of 
the fibrous cap usually occurs suddenly and triggers platelet aggregation and 
thrombus formation that can block the vessel lumen and cause myocardial 
ischaemia. If the thrombotic occlusion is sustained, it will cause irreversible 
myocardial damage that is termed as “infarction”. The clinical manifestation of 
infarction is dependent upon the degree and duration of thrombotic coronary 
artery occlusion. When the occlusion affects a major vessel, a myocardial 
ischaemic risk zone (area at risk, AAR) will rapidly develop with a high propensity 
of arrhythmia and decrease in contractility. In the United Kingdom, 190 out of 
the daily 515 patients presenting to the hospital with AMI will not survive the first 
few hours and the survivors will live with chronic irreversible myocardial damage 
in the AAR predisposing to development of chronic heart failure (Bhatnagar et 
al., 2014).  
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1.2 Pathogenesis of myocardial ischaemia  
Ischaemia causes several biochemical alterations in the myocardium (Figure 
1.1). The levels of adenosine tri- (ATP) and di-phosphates (ADP) rapidly fall after 
the onset of ischaemia as a result of cessation of oxidative phosphorylation, the 
main source of ATP. Glycogen swiftly becomes the main source of energy 
production by anaerobic metabolism (i.e. glycolysis) which leads to intracellular 
acidosis due to accumulation of hydrogen ion (H+), lactate and inorganic 
phosphate. Acidosis itself can inhibit glycolysis and residual energy metabolism 
as well as disturbs ions transport across the sarcolemma. Na+-H+ exchanger is 
activated in an attempt to extrude the excess H+ ion in exchange for Na+ which 
associated with more water and Cl- entering the cell, leading to cell swelling 
(Reimer et al., 1981). The sarcoplasmic reticulum tries to extrude the 
accumulated Na+ ions by activating the 2Na+-Ca2+ exchanger and that results in 
intracellular Ca2+ overload (Pisarenko et al., 1988). The reduction in the energy 
yield of glycolysis impairs the activity of 3Na+-K+ ATPase (sodium pump) which 
limits Na+ extrusion and aggravates Na+ overload in the sarcolemma. Energy 
shortage also limits the activity of sarcoplasmic/endoplasmic Ca2+–ATPase 
reducing sequestration of cytoplasmic Ca2+ (Kaplan et al., 1992). Despite the 
high intracellular Ca2+ concentration, there is a decline in the contractility due to 
the desensitisation of the contractile proteins by acidosis, phosphate and Ca2+ 
overload (Fiolet and Baartscheer, 2000). Ischaemia-induced acidosis maintains 
mitochondrial permeability transition pore (PTP) closed during ischaemia. PTP 
is a nonselective protein pore generated in the inner membrane of the 
mitochondria during pathological conditions such as stress or ischaemia (Ong et 
al., 2015). The PTP opening could be triggered during the first few minutes of 
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reperfusion due to restoration of cytosolic pH and the overwhelming ROS 
generation as well as further Ca2+ overload. 
 
 
Figure 1.1 Scheme of major cellular changes in the cardiomyocyte during ischaemia. 
Ischaemia suppresses mitochondrial oxidative phosphorylation and glycolysis rapidly 
becomes the major source of energy. Anaerobic metabolism results in intracellular 
acidosis that activates Na+-H+ exchanger to extrude H+ outside the cell and causing Na+ 
overload. Activation of 2Na+-Ca2+ exchanger reduces the Na+ overload and results in 
Ca2+ overload instead that cannot be sequestered inside the sarcoplasmic reticulum by 
Ca2+ pump due to the ATP limitation. In acute myocardial ischaemia, acidosis prevents 
the opening of the mitochondrial permeability transition pore (PTP). ATP shortage and 
Ca2+ overload also inhibit the contractility of the cardiomyocyte.  
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1.3 Reperfusion injury 
Reperfusion refers to re-introducing the blood through a previously occluded 
vessel. If applied in a timely fashion, reperfusion can ensure viability of the 
ischaemic tissue and limit the cellular damage. Paradoxically, reperfusion has 
been termed a "double-edged sword" because it has a pivotal role in maintaining 
viable myocardium and at the same time it is associated with deleterious effects 
collectively termed “reperfusion injury” (Braunwald and Kloner, 1985). It has long 
been understood that the main mediators of reperfusion injury are generation of 
reactive oxygen species (ROS), Ca2+ overload and pH restoration at early 
reperfusion (Figure 1.2). Rapid restoration of physiological pH in early 
reperfusion removes the inhibitory effect of acidosis on the PTP opening while 
ROS generation and Ca2+ overload are believed to trigger its opening 
(Hausenloy et al., 2003).  
The mechanism of reperfusion injury is not yet fully understood but there are 
four recognized forms of myocardial reperfusion injury: two of them cause 
reversible damage and the others cause irreversible insult. 
1.3.1 Reperfusion-induced arrhythmia 
It was first reported by Hearse’s group in the early 1980s that early reperfusion 
of an acutely ischaemic heart can induce arrhythmias in different experimental 
models and in the clinic. The type and severity of induced-arrhythmias can vary 
according to the severity and duration of the proceeding ischaemia (Manning 
and Hearse, 1984). After brief ischaemia, there are severe reperfusion 
arrhythmias while prolonged ischaemia is associated with mild reperfusion 
arrhythmia due to the fact that dead tissue does not contract. The underlying 
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cause of these arrhythmias is suggested to be the oxidative stress during early 
reperfusion (Hearse and Tosaki, 1987). This type of arrhythmia can be self-
terminating or can be easily controlled in a clinical environment.  
 
Figure 1.2 Scheme illustrating the major components the reperfusion injury. Re-
oxygenation of the mitochondria restores the ATP level and reactivates the electron 
transport chain which is believed to be the main source of reactive oxygen species (ROS) 
generation. Reperfusion also activates the H+ extruding mechanisms (Na+-H+ exchanger 
and Na+-HCO3- symporter), normalising the intracellular pH. The H+ extrusion 
combines with Na+ influx that can, unless sufficiently removed by Na+ extrusion 
machinery, reverse the 2Na+-Ca2+ exchanger mode of action again and exacerbate the 
existing Ca2+ overload. The overload of Ca2+ is initially sequestered by the sarcoplasmic 
reticulum by Ca2+-ATPase that then releases via the ryanodine receptor 2 (RyR2) 
because overwhelms its capacity, creating cyclic Ca2+ oscillation. Rapid pH 
normalisation and Ca2+oscillation cause hypercontracture and sarcoplasmic reticulum 
rupture. Collectively, these events mediate the opening of the mitochondrial permeability 
transition pore (PTP) which initiates cell apoptosis and necrosis. 
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1.3.2 Myocardial stunning 
Stunning is a reversible dysfunction of the contractile apparatus after reperfusing 
acutely ischaemic myocardium and resolves within days or weeks. It has been 
suggested that impairment in myocardial contractility is caused by the 
overwhelming generation of ROS and Ca2+ overload at reperfusion, leading to 
temporary insensitivity of the myofilament to Ca2+ (Bolli and Marban, 1999).  
1.3.3  Microvascular obstruction (MVO) 
Krug et al. (1966) first documented microvascular obstruction in cat heart 
describing this phenomenon as “inability to reperfuse a previously ischaemic 
region” after temporary occlusion of the coronary artery. Microvessel 
abnormalities within the infarcted area have been reported in around 30-40% of 
patients after primary percutaneous coronary intervention (PPCI) with no 
effective therapy currently available (Bogaert et al., 2007, White et al., 2012). 
The main causes of MVO include: capillary collapse; impaired vasodilation; 
vessel plugging with neutrophil and debris from atherosclerotic plaque; platelet 
aggregation; external compression due to endothelial and cardiac cells swelling; 
release of inflammatory; vasoconstrictor and thrombogenic mediators (Ito, 2006, 
Heusch et al., 2009). MVO has a significant impact on clinical outcome by 
increasing the cell damage by continued ischaemia, reducing left ventricular 
ejection and promoting adverse remodelling (Hombach et al., 2005).  
1.3.4 Lethal myocardial reperfusion injury 
Lethal reperfusion injury refers to the cell death caused by reperfusion itself that 
is additive to the preceding irreversible tissue damage caused during ischaemia. 
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The existence of reperfusion injury and whether it compromises the salutary 
effects of reperfusion were topics of debate in the 1990s. There is no direct 
method to either quantify the cells which injured irreversibly during ischaemia or 
distinguish the cells which survived the ischaemic event. However, different 
mechanical and pharmacological interventions applied solely at the 
commencement of reperfusion have significantly limited the extent of cell death 
by 40-50% in different experimental models of myocardial ischaemia/reperfusion 
injury and in patients who underwent primary percutaneous coronary 
intervention (PPCI) (Hausenloy and Yellon, 2013). Moreover, those studies also 
helped in identifying possible mechanisms of reperfusion injury that can 
potentially be targeted to limit the lethal myocardial reperfusion injury and 
consequently, improve the clinical outcomes of PPCI. Unfortunately, there is no 
effective therapy currently used as adjunct to PPCI which could mitigate the 
reperfusion injury. Therefore, there is still a need to fulfil this gap. 
1.3.5 Oxidative stress 
ROS generation occurs normally during oxidative metabolism and is neutralised 
by the cellular antioxidant systems represented by endogenous reductants, such 
as glutathione (GSH) and thioredoxin-1 (Trx-1), and antioxidant enzymes, such 
as superoxide dismutase (SOD, EC 1.15.1.1) catalase (EC 1.11.1.6) and 
glutathione peroxidase (GPx, EC 1.11.1.9). However, endogenous antioxidant 
network could be overwhelmed during pathological conditions such as 
ischaemia or inflammation, leading to cellular stress. There is strong evidence 
that the first burst of superoxide (O2-) in the first few minutes of reperfusion is 
responsible for the detrimental changes at cellular and mitochondrial levels 
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which eventually leads to cell injury (Burwell et al., 2009). The mitochondrial 
respiratory chain in particular has long been recognised as the main source of 
ROS at early reperfusion (Chouchani et al., 2016). In addition, other cellular 
components have also been implicated in reperfusion-induced ROS such as 
xanthine oxidase (Xia and Zweier, 1995), NADPH oxidase (Braunersreuther et 
al., 2013) and catecholamines (Vishnevskii et al., 1995). Nevertheless, the 
contribution of these sources to the overall oxidative stress at reperfusion is 
suggested to be secondary and determined by the initial mitochondrial burst of 
ROS (Abramov et al., 2007). The general consensus over the last two decades 
has been that sudden entry of oxygen (O2) into the electron transport complexes 
at the commencement of reperfusion charges these complexes leading to a 
considerable leak of electrons. With the availability of O2, electrons which 
escaped from the respiratory chain will create O2- that can, by itself or through 
generating of hydroxyl radical (OH·), cause irreversible cellular damage 
(Hausenloy and Yellon, 2013, Chouchani et al., 2016). Among the five 
respiratory complexes, complex I has attracted considerable attention since 
there is a compelling evidence that selective shut-down of its activity limited ROS 
production and protected the heart against ischaemia/reperfusion injury 
(Lesnefsky et al., 2004, Chen et al., 2006).  
Seminal work by Murphy and colleagues (Chouchani et al., 2014) have recently 
revealed a more detailed and persuasive mechanism for ROS production 
through complex I at reperfusion. They showed that anaerobic metabolism 
during ischaemia could lead succinate dehydrogenase (SDH) to function in a 
reverse mode converting overproduced fumarate during ischaemia into 
succinate (Chouchani et al., 2014). In the first minutes of reperfusion, complexes 
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III and IV are at their full capability to maintain positive protonmotive force to 
derive ATP synthesis. Therefore, oxidation of accumulated succinate by SDH 
will cause backward flow of electrons from complex II to complex I in what is 
known as reverse electron transport (RET). RET into complex I leads to O2- 
generation possibly from its electron acceptor moiety, namely flavin 
mononucleotide moiety (Chouchani et al., 2014). Pharmacological blockade of 
ischaemia-induced succinate accumulation using dimethylmalonate, a SDH 
blocker, before ischaemia was demonstrated to limit mitochondrial ROS 
production and infarct size in vivo in a mouse ischaemia/reperfusion injury model 
(Chouchani et al., 2014). Garcia-Dorado’s group (Valls-Lacalle et al., 2016) 
recently reported that perfusing malonate for the first 15 minutes of reperfusion 
limited infarct size and improved post-ischaemia contractility in Langendorff 
perfused mouse heart. This cardioprotection was associated with attenuation in 
mitochondrial ROS (mito-ROS) generation at reperfusion (Valls-Lacalle et al., 
2016). Whether malonate at reperfusion could exert comparable 
cardioprotection in vivo is yet to be tested. In addition, whether succinate 
accumulation is of any clinical relevance is still to be determined. Furthermore, 
it is also yet to be investigated whether attenuation of succinate oxidation at 
reperfusion contributes to the cardioprotective mechanism of ischaemic 
conditioning, will be both discussed later in this Chapter. 
1.3.6 Mitochondrial permeability transition pore (PTP) 
The thorough characterisation studies undertaken by Haworth and Hunter in the 
late 1970s persuasively introduced the concept that Ca2+ overload induced loss 
of the inner mitochondrial membrane (IMM) which results in mitochondrial 
Chapter 1 
12 
permeability transition (Hunter and Haworth, 1979a, Haworth and Hunter, 1979, 
Hunter and Haworth, 1979b). In the late 1980s, these findings were confirmed 
using patch-clamp technique showing evidence of a megachannel in the IMM 
which is responsive to the cytosolic and mitochondrial Ca2+ contents, the basic 
features of what is recognised today as PTP (Kinnally et al., 1989, Petronilli et 
al., 1989). The seminal study by Al-Nasser and Crompton (1986) first showed 
the modulatory effect of cyclosporine A (CsA) on a mitochondrial Ca2+-sensitive 
permeability channel. The transient opening of PTP, also known as flickering, 
regulates important cellular and mitochondrial physiological functions including 
Ca2+ homeostasis (Bernardi and von Stockum, 2012) and ROS signalling (Zorov 
et al., 2000). However, prolonged opening of PTP has been demonstrated to 
have detrimental effects on mitochondrial integrity in particular and cell viability 
in general. The crucial role of pathological PTP opening in irreversible 
myocardial injury has been characterised by Griffiths and Halestrap (1993) even 
before recognition of the role of mitochondria in apoptosis (Susin et al., 1996). 
Griffiths and Halestrap (1993) first reported that pre-ischaemic CsA treatment 
improved post-ischaemia cardiac contractility and preserved ATP/ADP ratio in 
Langendorff perfused rat heat subjected to acute myocardial infarction. It should 
be mentioned here that the time of PTP opening during ischaemia/reperfusion 
injury was not known at that time. The same group later found that ischaemia-
induced acidosis maintains the PTP in close conformation during ischaemia 
despite existence of sufficient excitatory Ca2+ and oxidative stress in the matrix 
(Griffiths and Halestrap, 1995). However, rapid normalisation of cellular pH at 
early reperfusion removes this inhibition, permits the opening of PTP and 
initiates cell injury. Hausenloy et al. (2002) first reported that application of CsA 
specifically at reperfusion limited ischaemia/reperfusion-induced infarction in 
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isolated rat heart. This infarct limitation was absence when a PTP inhibitor, 
sanglifehrin-A, was applied 15 minutes post-reperfusion (Hausenloy et al., 
2003), emphasising the need to target PTP at the immediate onset of 
reperfusion.  
The composition of the PTP has been under debate since its discovery 30 years 
ago and is still unclear. However, a number of components have been 
suggested to either regulate its function or compose the pore itself. Early studies 
showed that the two mitochondrial membranes are connected with a number of 
protein-protein junctions which could comprise the PTP. These proteins included 
adenine nucleotide translocase (ANT) (Hunter and Haworth, 1979a, Haworth 
and Hunter, 1979, Hunter and Haworth, 1979b); voltage-dependent anion 
channel (VDAC) (Szabó et al., 1993); mitochondrial phosphate carrier (PiC) (Al-
Nasser and Crompton, 1986); hexokinase (Kottke et al., 1988); Bcl-2 related 
proteins (Marzo et al., 1998). Nevertheless, selective genetic ablation of these 
targets have ruled out the necessity for any of these components for the PTP to 
be formed (Kokoszka et al., 2004, Krauskopf et al., 2006). Instead, experimental 
studies have suggested that these components could act as modulators to the 
PTP opening. Cyclophilin D (CypD) has also been implicated with the PTP 
formation since it was first shown by Crompton’s group (Al-Nasser and 
Crompton, 1986) that the sensitivity of PTP to Ca2+ was attenuated by inhibiting 
the activity of CypD. In 2005, three independent laboratories came to the same 
conclusion regarding the critical role of CypD in the formation of PTP and cell 
death induced by its opening (Basso et al., 2005, Baines et al., 2005, Nakagawa 
et al., 2005). CypD-/- mitochondria were more tolerant to Ca2+-induced PTP 
opening and eventually cell death which was comparable to the effect of CsA. 
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However, PTP opening was still observed with higher concentrations of Ca2+ 
suggesting the formation of the pore in CypD-deficient mitochondria and that 
CypD could act as a facilitator for PTP opening. This hypothesis was then 
supported by the work of Giorgio et al. (2009) who proposed that mitochondrial 
F0F1 ATP synthase, which is the fifth mitochondrial respiratory complex (complex 
V), could play a major role in PTP formation. They suggested that, in response 
to Ca2+ overload or oxidative stress, CypD can bind to ATP synthase at its lateral 
stalk and decrease complex activity. This binding was enhanced by inorganic 
phosphate and abrogated by CsA, principle features of PTP. A subsequent study 
by Bonora et al. (2013) showed that ablation of the c-subunit of F0 ATP synthase 
rendered the mitochondria more resistant to Ca2+ overload and oxidative stress. 
Alavian et al. (2014) further demonstrated that purified reconstructed c-subunit 
ring of F0 ATP synthase was enlarged in response to high concentrations of 
Ca2+, forming a voltage sensitive channel similar to PTP. More interestingly, 
deletion of the c-subunit enhanced mitochondrial tolerance against Ca2+ 
overload and oxidative stress while, conversely, c-subunit overexpression or 
long exposure to Ca2+ promoted cell death.  
1.4 Ischaemic conditioning 
1.4.1 Ischaemic preconditioning (IPC) 
A major focus of research for the past 30 years has been to identify potential 
mechanism(s) or cellular target(s) that can be manipulated to mitigate 
ischaemia/reperfusion injury. Different approaches have been adopted to clearly 
understand the molecular pathology which underlies ischaemia/reperfusion 
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injury aiming to target its causes. The first milestone came from Reimer and 
Jenning’s laboratory, in a series of experiments carried out by Charles Murry. 
Murry et al. (1986) demonstrated that subjecting dog heart to four episodes of 5 
minutes ischaemia and 5 minutes reperfusion before sustained ischaemia (40 
minutes) and 3 hours reperfusion dramatically reduced the infarct size by 75%. 
In his seminal paper, Murry termed this manoeuvre as “preconditioning with 
ischaemia” (Murry et al., 1986) which was then termed as ischaemic 
preconditioning (IPC). IPC is demonstrated to have two discrete windows of 
protection. The first window affords cardioprotection immediately after the 
application of IPC and lasts for 2-3 hours and it is called classical IPC or acute 
IPC. The second window of protection (SWOP or delayed IPC) was 
simultaneously reported by Marber et al. (1993) and Kuzuya et al. (1993) and it 
becomes functional 12-24 hours after the IPC manoeuvre has been applied. 
Although it is less protective than the classic IPC, SWOP can last up to 72 hours 
(Baxter et al., 1997) which might have significant clinical implications. The 
cardioprotection of IPC has not been limited to infarct size reduction, but it can 
also protected against life-threatening ischaemia- and reperfusion-induced 
arrhythmia and myocardial stunning. These effects are reproducible in all animal 
models studied hitherto and even in man (Murry et al., 1986, Schott et al., 1990, 
Liu et al., 1991, Yellon et al., 1993, Sumeray and Yellon, 1998). Moreover, IPC 
protocols are shown to function in isolated tissue and organs, suggesting a 
neural-independent mechanism (Bulluck and Hausenloy, 2015).  
The mechanism of action of IPC is not yet fully understood. It was initially thought 
that the main salvage mechanism of IPC is mediated by slowing energy 
utilisation during ischaemia (Murry et al., 1990). Intriguingly, it has recently been 
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suggested that IPC could limit ATP depletion through its inhibitory effect on ATP 
synthase (complex V) (Murphy and Steenbergen, 2013). However, accumulated 
body of evidence suggests that the key endogenous survival mechanism 
activated by IPC act during reperfusion. Griffiths and Halestrap (1995) first 
documented that the PTP remains close during ischaemia and opens in the early 
reperfusion. Experimental studies showed that IPC could inhibit the opening of 
PTP through attenuating rapid intracellular pH restoration at reperfusion 
potentially through two different mechanisms. First, limitation in anaerobic 
metabolism mediated by IPC could result in less level of ischaemia-induced 
acidosis and eventually minimises the pH change at reperfusion (Asimakis et al., 
1992, Wolfe et al., 1993). Second, Xiao and Allen (1999) found that IPC inhibits 
the activity of Na+-H+ exchanger at reperfusion allowing a slow normalisation of 
intracellular pH. Several studies have also demonstrated that IPC could 
influence the activity of the PTP at reperfusion through attenuation of the 
oxidative stress at reperfusion, another major trigger of PTP opening 
(Crestanello et al., 1996, Hoek et al., 2000, Clarke et al., 2008). However, the 
exact antioxidant mechanism by which IPC inhibits oxidative stress awaits 
clarification. 
Yellon’s laboratory (Hausenloy et al., 2005) first showed that the 
cardioprotection of IPC could mainly be mediated by activation of pro-survival 
anti-apoptotic kinase signalling pathway at reperfusion. This pathway consisted 
of PI3K/Akt and Erk1/2 signalling cascades which were collectively called the 
Reperfusion Injury Salvage Kinase (RISK) pathway (Hausenloy and Yellon, 
2004). These data proposed an irrefutable role of the RISK pathway in IPC’s 
cardioprotection. However, the exact mechanism by which this signalling 
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pathway actually inhibits the opening of PTP to confer its cardioprotection 
remains to be directly tested. It seems more convincing that the activation of the 
RISK pathway components could inhibit the opening of PTP indirectly via 
modulating Ca2+ overload, oxidative stress and pH restoration at reperfusion. 
Furthermore, emerging evidence showed direct “mitochondrial preconditioning” 
by IPC through enhancing the activity of Connexin 43 (Cx43), a hemi-channel in 
the IMM, in a cytosol-independent fashion (Ruiz-Meana et al., 2014).  
1.4.2 Remote ischaemic preconditioning (RIPC) 
This intriguing phenomena was first described by Przyklenk et al. (1993) in dogs 
where application of transient ischaemia in one region of the heart paradoxically 
preconditioned a remote region of the myocardium (virgin myocardium). This 
intriguing phenomenon was later extended to remotely precondition other 
organs (Hausenloy et al., 2016). The exact mechanism of this cardioprotective 
manoeuvre remains unresolved but there is compelling evidence that it involves 
a complex neuro-humoral pathway. Pharmacological (Gho et al., 1996), surgical 
(Lim et al., 2010) or genetic (Mastitskaya et al., 2012) dissipation of the neuronal 
pathway in the preconditioned tissue has been demonstrated to abolish infarct 
limitation of RIPC. This emphasises the crucial role of neural transmission in 
exerting the cardioprotection of RIPC. Similarly, it has been shown 
experimentally that RIPC stimuli generate humoral factors which are proposed 
to be 3.0-8.5 kDa in size, heat-labile and lipophilic (Lang et al., 2006, Breivik et 
al., 2011). Several blood-borne molecules have been implicated in RIPC 
including nitrite (Rassaf et al., 2014), miRNA-144 (Li et al., 2014), leukotrienes 
(Singh et al., 2016). Interestingly, Redington and colleagues (2009) found that 
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humoral factors which are generated in preconditioned rabbit are transferable 
and can protect a Langendorff perfused naïve rabbit heart against myocardial 
infarction.  
1.4.3 Ischaemic postconditioning (IPost) 
Okamoto et al. (1986) first described that “gradual” or “staged” reperfusion can 
be cardioprotective against ischaemia/reperfusion injury in dog heart. Later work 
Zhao et al. (2003) demonstrated that early interruption of reperfusion with three 
cycles of a brief ischaemia/reperfusion (30 seconds) protected the heart against 
ischaemia/reperfusion injury in a canine model. The salvage effect (44%) was 
comparable to IPC protection (40%) in that study and accordingly, they called it 
“ischaemic postconditioning (IPost)” in their seminal paper referring to the 
similarity to IPC (Zhao et al., 2003). It has been proposed that maintaining acidic 
intracellular pH in the first minutes of reperfusion by interrupting reflow allows a 
gradual restoration of cellular osmosis and a slow reactivation of the respiratory 
machinery which, collectively, protected against myocardial infarction. Similar to 
IPC, Vinten-Johansen’s group (Zhao et al., 2003, Sun et al., 2005) also reported 
that hypoxic postconditioning exerted its salvage effects by mitigating oxidative 
stress via a mechanism which is yet to be determined. Moreover, IPost could 
also exert cardioprotection by attenuating Ca2+ overload at reperfusion (Sun et 
al., 2005). Nevertheless, the contribution of Ca2+ overload, compared to 
oxidative stress and pH, in PTP opening-induced injury at reperfusion has 
recently been questioned. Mitochondrial calcium uniporter (MCU) knockout mice 
had a similar infarct size to their wild-type littermates following acute myocardial 
infarction (Pan et al., 2013).  
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Unlike IPC, IPost-evoked cardioprotection has more potential for clinical 
application as it is applied after the ischaemic event, onset of which is 
unpredictable by nature. Interestingly, late application of IPost by 60 seconds 
results in complete loss of the cardioprotection (Kin et al., 2004). This further 
emphasises the importance of early events at the commencement of reperfusion 
in determination of the final infarct size. Furthermore, IPost-induced 
cardioprotection also provided persuasive evidence for the existence of 
reperfusion-induced cell death. Several studies have unravelled a number of 
cellular signalling circuits which could possibly be triggered at reperfusion by 
IPost to elicit its cardioprotection. Yellon’s laboratory (Tsang et al., 2004) was 
the first to provide evidence suggesting that IPost triggers the RISK pathway at 
early reperfusion to mediate protection similar to IPC. Inhibition of PI3K/Akt in 
isolated rat heart (Tsang et al., 2004) or Erk1/2 in isolated rabbit heart (Darling 
et al., 2005) abolished IPost-induced cardioprotection. Another signalling 
cascade has been associated with IPost cardioprotection which is called the 
Survival Activating Factor Enhancement (SAFE) pathway. The SAFE pathway 
is activated when proteins of the interleukin-6 family bind to cell surface 
receptors and trigger JAK/STAT phosphorylation. The level of phosphorylated 
STAT3 has been reported to directly relate to infarct-sparing effect of IPost as 
well as IPC (Lecour et al., 2005, Boengler et al., 2008b). Inhibition of the 
JAK/STAT3 cascade using AG490 abrogated the salvage effects of IPC (Negoro 
et al., 2001) as well as IPost (Lecour, 2009). Studies with STAT3 knockout mice 
reported that both IPC and IPost failed to show any infarct-sparing effect in these 
mice (Smith et al., 2004, Boengler et al., 2008a).  
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The relationship between the SAFE and the RISK pathways is not fully 
understood and requires further delineation. However, it can be postulated that 
there is a cross-talk between them under certain circumstances. STAT3 
phosphorylation was abolished by the PI3K/Akt inhibitor wortmannin (Suleman 
et al., 2008). In addition, IPC did not show a significant increase in Akt 
phosphorylation in STAT3 knockout mice (Suleman et al., 2008). Interestingly, 
work by Lecour and colleagues (Lecour et al., 2005) showed that the 
cardioprotection of IPC, which is mediated by activating the SAFE and the RISK 
pathways, was abolished by inhibition of either of these pathways. In addition, 
exogenous TNF-α has been shown to mimic the salvage effect of IPC in isolated 
rat heart (Deuchar et al., 2007) and IPost in isolated mouse heart (Lacerda et 
al., 2009). Whether targeting the downstream effectors of these pathways 
individually or simultaneously can potentiate the cardioprotection also remains 
to be investigated.  
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Figure 1.3 Schematic represents the cardioprotective signal transduction of the 
Reperfusion Injury Salvage Kinase (RISK) and the Survival Activating Factor 
Enhancement (SAFE) pathways modified from that presented in (Bulluck et al., 2016). 
PI3K: phosphatidylinositol 3-kinase; PDK: phosphoinositol-dependent kinase; Akt: 
protein kinase B; ERK: extracellular signal-regulated kinase; GSK-3β: glycogen 
synthase kinase-3 beta; GPCR: G-protein coupled receptor; TNFR: tumor necrosis factor 
receptor; gp130: glycoprotein 130; JAK: janus kinase; STAT: signal transducer and 
activator of transcription; eNOS: endothelial nitric oxide synthase; NO: nitric oxide; 
ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; NPR: natriuretic 
peptide receptor; PKG: protein kinase G; PKC: protein kinase C; GFR: growth factor 
receptor.        
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1.5 Hydrogen sulfide (H2S) 
1.5.1 The discovery of H2S and origin of life 
Hydrogen sulfide (H2S) is the simplest thiol-containing compound. It is thought 
to have served as the primordial energy source to support the earliest 
eukaryotes on earth in euxinic oceans (anoxic and sulfidic) more than 250 million 
years ago (Wille et al., 2008). With the gradual increase in O2 production by 
cyanobacteria and plants, eukaryotic mitochondria then started to energise the 
electron transport chains using O2 instead of oxidation of H2S (Olson and Straub, 
2016). However, an enzymatic sulfide oxidation system, represented by sulfide 
quinone reductase (SQR, EC 1.8.5.4), is still present in mammalian 
mitochondrion, supporting the long phylogenic relationship with their ancestors. 
Despite being long recognised as the unpleasant odour of rotten egg, the first 
investigation into the occupational hazard of H2S was carried out by Bernardino 
Ramazzini in early 18th century in cesspit workers presenting with irritated eyes 
and secondary blindness (Lambert et al., 2006). The discovery of endogenous 
H2S in rat (Warenycia et al., 1989), bovine (Savage and Gould, 1990) and 
human (Goodwin et al., 1989) brain in the early 1990s attracted great attention 
toward potential physiological actions of H2S. Since then, H2S has joined the 
family of gasotransmitters along with nitric oxide (NO) and carbon monoxide 
(CO) as a freely permeable gaseous signal transmitter exerting multiple versatile 
biological activities in the cell. 
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1.5.2 Production of H2S 
The level of endogenous H2S under normal physiological conditions is 
constantly maintained by enzymatic and non-enzymatic pathways. H2S can also 
be directly released from its intracellular sulfur stores, which is in the form of 
sulfane sulfur pools, under certain conditions (Ishigami et al., 2009). The non-
enzymatic generation of H2S occurs by reducing endogenous and exogenous 
thiol-containing molecules. There are four enzymes known so far which catalyse 
endogenous H2S production and maintain a stable H2S level in the cell. These 
enzymes have different localisation within the cell as well as diverse distribution 
in the body. Cystathionine-β-synthase (CBS, EC 4.2.1.22) and cystathionine-γ-
lyase (CSE, EC 4.4.1.1) are pyridoxal-5’-phosphate-dependent cytosolic 
enzymes and they are thought to be the primary contributors to the global H2S 
level. Although equally expressed in the liver and kidney, CBS is the dominant 
H2S synthase in the central nervous system while CSE is the main H2S synthase 
in the peripheral tissue including the cardiovascular system. Both CBS and CSE 
can separately condense L-homocysteine and L-cysteine molecules to produce 
L-cystathionine and H2S (Figure 1.4). Also, CBS alternatively catalyses the 
reaction between two L-homocysteine or two L-cysteine to generate H2S with 
either lanthionine or homolanthionine depending on the starting substrate 
conformation (Singh et al., 2009).  
The process of H2S production in the mitochondria is collaboratively governed 
by two enzymes, namely cysteine aminotransferase (CAT, EC 2.6.1.3) and 3-
mercaptopyruvate sulfurtransferase (3-MST, EC 2.8.1.2). The transamination 
from mitochondrial L-cysteine to α-ketoglutarate is mediated by CAT to produce 
3-mercaptopyruvate and L-glutamate. 3-MST then converts 3-mercaptopyruvate 
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into pyruvate and H2S in the presence of mitochondrial reductants such as 
dihydrolipoic acid or thioredoxin. In the absence of mitochondria reductants, 3-
MST could transfer 3-mercaptopyruvate into sulfane sulfur and pyruvate (Mikami 
et al., 2011). A similar mechanism has recently been unveiled which mediates 
the H2S production in the mitochondria specifically in the brain and kidney. This 
pathway involves oxidation of dietary D-cysteine by D-aminoacid oxidase (DAO, 
EC 1.4.3.3) to produce 3-mercaptopyruvate which is then converted to H2S and 
pyruvate by 3-MST (Shibuya et al., 2013). It has also been shown that cytosolic 
CBS and CSE can be translocated to the mitochondria as an adaptation 
mechanism to maintain physiological level of H2S when the mitochondrial H2S-
producing system is dramatically compromised during oxidative stress (Fu et al., 
2012, Modis et al., 2013a, Szabo et al., 2013).
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Figure 1.4 Schematic of enzymatic pathways of H2S production. Cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE) utilise L-cysteine 
and homocysteine to generate H2S in the cytosol. In the mitochondria, cysteine aminotransferase (CAT) and 3-mercaptopyruvate sulfurtransferase 
(3-MST) are working in a concert to convert L-cysteine into H2S and pyruvate. D-aminoacid oxidase (DAO) could also participate to maintain 
mitochondrial H2S production in kidney and brain.  
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1.5.3 Metabolism of H2S 
H2S can be metabolised by a number of enzymatic pathways in the 
mitochondria, the major source of H2S production. There are different catabolic 
fates of H2S in the cell. In eukaryotes, H2S can easily diffuse in and out of the 
cell. However, there is a general consensus that the first step in H2S metabolism 
begins with oxidation of H2S by sulfide quinone reductase (SQR, Figure 1.5). 
This step generates two electrons which could be transferred to the ubiquinone 
pool by flavin adenine dinucleotide (FAD) and then passed forward to complex 
III and complex IV (Olson, 2012). Therefore, SQR is arguably the third source of 
electrons, in addition to NADH dehydrogenase and succinate dehydrogenase, 
to the mitochondrial respiratory chain which feeds the electrons directly to 
complex III.  
Oxidation of H2S by SQR also generates sulfane sulfur of SQR (SQR-sulfane 
sulfur) which could interact with mitochondrial GSH to produce glutathione 
persulfide. In the presence of O2, persulfide can be oxidised to sulfite (SO32-) by 
sulfur dioxygenase (SDO, EC 1.13.11.18). Alternatively, persufide could be 
converted to SO32- by thiosulfate sulfurtransferase (TST, EC 2.8.1.1). Further 
oxidation of sulfite by sulfite oxidase (SO, EC 1.8.3.1) could generate two 
electrons which add to the total electrons gain of H2S oxidation. This step also 
produces two protons (H+) which could be pumped into the intermembrane 
space to maintain positive protonmotive force that drives ATP synthesis. Sulfite 
might also interact with SQR to produce thiosulfate (S2O32-) in the presence of 
H2S (Helmy et al., 2014). S2O32- is considered as a reliable marker of H2S 
metabolism; it can also be reduced to pyruvate by thiosulfate-thiol 
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sulfurtransferase (TTST, EC 2.8.1.3) and releases H2S. An alternative catabolic 
pathway of S2O32- is by 3-MST in the presence of endogenous reductants, such 
as thioredoxin or dihydrolipoic acid, that also generates H2S and pyruvate.  
Although it is classified as an “emergency fuel” for electron transport chain, the 
process of H2S oxidation consumes more oxygen compared to other organic 
substrates as the oxidation of each molecule of sulfide utilises three moles of 
O2. In addition, oxidation of sulfide generates a lower yield of electrons (two 
sulfide molecules produce two electrons) in comparison with organic substrates. 
Thus, H2S oxidation arguably is an inefficient approach to energise the 
mitochondrial respiratory chain under normal physiological conditions. However, 
it can play a crucial in the cell survival during hypoxia.  
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Figure 1.5 Schematic illustrates the catabolic fates of H2S in the mitochondria.  H2S 
binds to Sulfide Quinone Oxidoreductase (SQR) forming SQR-sulfane sulfur and 
generating two electrons which feed into the respiratory chain at the level of CoenzymeQ 
to complex III. Sulfane sulfur is then transferred to sulfite by either thiosulfate 
sulfurtransferase (TST) or sulfur dioxygenase (SDO). H2S can be generated through 
sulfite oxidation by sulfite oxidase (SO) which also generates two electrons that add up 
to the total electronic gain. Interestingly, sulfite might consume H2S to convert to 
thiosulfate which could be metabolised by either thiosulfate-thiol sulfurtransferase 
(TTST) or 3-mercaptopyruvate sulfurtransferase (3-MST) to recover H2S. RX, 
endogenous reductant. 
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1.5.4 Toxicity of H2S 
In humans, acute exposure to H2S gas (>10000 ppm) can be fatal as it causes 
severe respiratory depression (Costigan, 2003). Low concentrations of H2S 
(lower than 10 µM) can stimulate mitochondrial oxygen consumption and ATP 
synthesis by entering the mitochondrial oxidative phosphorylation. However, 
high concentrations (10 µM-100 µM) inhibit the activity of mitochondrial 
cytochrome c oxidase (complex IV) by reversibly binding to its active heme-side 
and competitively prevents the binding O2 to this site. On a mole to mole basis, 
H2S is even more toxic than cyanide (Haouzi, 2016). The inhibition of complex 
IV leads to accumulation of electrons in the respiratory chain, disruption in the 
inner membrane potential and cessation of aerobic ATP synthesis (Szabo et al., 
2014). The activity of complex IV was demonstrated to be restored within 10-30 
minutes after acute H2S exposure in tissue homogenates (Di Meo et al., 2011). 
However, it has been reported that the complex IV inhibition might last longer in 
vivo (Khan et al., 1990). It seems conceivable that this prolonged inhibition of 
complex IV in vivo could be mediated by H2S release from the mitochondrial 
sulfane sulfur pool which forms following H2S administration, although this needs 
further investigation. H2S could also inhibit the activity of carbonic anhydrase 
with no specific consequences of this inhibition, although it could arguably 
contribute to the inhibition of mitochondrial respiratory chain and bioenergetics 
(Nicholson et al., 1998). Interestingly, the toxic dose of H2S (~100 µM) is almost 
twice the normal physiological concentration of H2S (45.2 µM) in the brain 
(Warenycia et al., 1989). This suggests a steep dose-response curve for H2S. In 
addition, it is also likely that there is tight control on constitutive H2S production. 
However, I still think that the reported level of H2S in the brain is actually 
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relatively high and this could be due to the limited accuracy of the method which 
has been used. 
1.6 The effects of H2S on the cardiovascular system 
1.6.1 H2S and vascular smooth muscle 
The crucial regulatory role of H2S on vascular bed homeostasis has been 
extensively studied. The expression of CSE as a H2S-producing enzyme in 
vascular smooth muscle was first demonstrated by Hosoki et al. (1997) in rat 
thoracic artery and portal vein. CSE was found to be localised in the endothelium 
and to mediate 70-80% of the cholinergic relaxation of the vasculature (Yang et 
al., 2008). Moreover, dose-dependent relaxation by H2S was present following 
vascular denervation but absent when the endothelium was removed (Zhao and 
Wang, 2002). Taken together, these results suggested that H2S could be 
another endothelium derived relaxing factor (EDRF) in addition to NO. There is 
an accumulating body of evidence suggests a complex interaction between H2S 
and NO in the vasculature. Low concentration of sodium hydrosulfide (NaHS) 
has been shown to synergise NO-induced relaxation of the thoracic aorta 
compared to high concentration of NaHS (Hosoki et al., 1997). Similar to eNOS 
knockout mice, CSE-/- mice showed an age-dependent increase in blood 
pressure (up to 20 mmHg) which emphasises the importance of a constitutive 
H2S-relaxing effect.  
The relaxing effect of H2S has been demonstrated to be related to the O2 partial 
pressure and to the vasculature under investigation as well as H2S tissue 
concentration (Koenitzer et al., 2007). Zhao et al. (2001) demonstrated that the 
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relaxing effect of NaHS on rat aortic tissue was via increased KATP channel 
permeability causing hyperpolarization of the tissue. This conclusion was 
derived from the observation that H2S-induced relaxation was mimicked by 
pinacidil, a KATP channel activator, and abolished by glibenclamide, a KATP 
channel blocker. Further work by the same group showed that the H2S-induced 
vasorelaxation was not attenuated by blocking soluble guanylyl cyclase (sGC) 
activity using ODQ or NS-2028 but in fact enhanced its effect (Zhao and Wang, 
2002). These results suggested a molecular mechanism which is, at least in 
vasculature, independent of cyclic guanosine monophosphate (cGMP). The 
conductance of KATP channel is physiologically regulated by 
phosphatidylinositol(4,5)bisphosphate (PIP2) which binds to the cysteine-43 
(Cys43) residue to open the channel. It has been shown that CSE-derived H2S is 
necessary for PIP2’s binding to KATP channel as it S-sulfhydrates Cys43 and 
facilitates its binding to PIP2 (Mustafa et al., 2011).  
1.6.2 H2S and atherosclerosis  
There is a convincing body of evidence suggesting that the reduction in H2S 
bioavailability has a major role in developing atherosclerotic plaque. Wang’s 
laboratory (Mani et al., 2013) demonstrated that CSE -/- mice had an elevation 
in blood levels of total cholesterol, low density lipoprotein (LDL) and 
homocysteine. H2S supplement with NaHS effectively corrected these levels 
(Mani et al., 2013, Mani et al., 2015). H2S also has anti-inflammatory properties 
and can attenuate the development of the atherosclerotic lesion. Macrophages 
have the capacity to release CSE-derived H2S when stimulated by inflammatory 
mediators, such as lipopolysaccharide, and inhibits the inflammation process 
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(Zhu et al., 2010). Moreover, it has been demonstrated that exogenous H2S 
limited leukocyte adhesion to the endothelium by inhibiting the expression of 
intracellular and extracellular adhesion molecules, such as ICAM-1 and P-
selectin (Wang et al., 2009), as well as chemokine receptors, such as CX3CL1 
and CX3CR1 (Zhang et al., 2012). The anti-atherogenic effects of H2S might 
also be attributable to its antioxidant activity. It has been reported that oxidative 
stress-induced endothelial damage was exacerbated in CSE-/- mice (Mani et al., 
2013). This endothelial damage was mitigated by GYY4137, a slow-releasing 
H2S donor (Liu et al., 2013b). 
1.6.3 H2S and angiogenesis 
Angiogenesis is mainly induced by hypoxia which provides a preferential 
environment for the activity of proangiogenic signalling kinases such as hypoxia 
inducible factor-1α (HIF-1α) and vascular endothelium growth factor (VEGF) 
(Rey and Semenza, 2010). The concept that tissue concentration of H2S is 
inversely proportion to the level of O2 has now become more acceptable 
whereby H2S can act as an inorganic fuel to energise oxidative phosphorylation 
during hypoxia (Olson et al., 2006). In addition, ischaemia–induced acidosis due 
to anaerobic metabolism could also facilitate the release of H2S from a cellular 
acid labile pool (Yuan and Kevil, 2016). It has been reported that H2S plays a 
crucial role in the signalling cascade of angiogenesis and can affect the stability 
of pro-angiogenic signalling kinases during ischaemia. Bir et al. (2012) reported 
that HIF-1 expression was upregulated in ischaemic skeletal muscle compared 
to normal tissue in a mouse model of hind-limb ischaemia. They also 
demonstrated that H2S treatment ameliorated the expression of HIF-1α and 
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VEGF expressions in the ischaemic tissue. Recent work by Flannigan and 
colleagues showed that decreased expression of CSE significantly 
compromised the stability of HIF-1 α and exacerbated the severity of colitis in a 
mouse model of dinitrobenzene sulfonic acid-induced colitis (Flannigan et al., 
2015). The severity of colitis was reduced by H2S treatment which substantiated 
the stability of HIF-1α and upregulated the hypoxia-responsive genes. 
Interestingly, stabilisation of HIF-1α resulted in a reduction in the endogenous 
production of H2S suggesting a negative feedback mechanism and emphasised 
the role of H2S/HIF-1α signalling in angiogenesis (Flannigan et al., 2015). 
Posttranslational modification (PTM) by H2S is also proposed to influence the 
signalling response to other proangiogenic factors. It has been suggested that 
constitutive H2S regulates the transcription of VEGF receptor (VEGFR2) and 
neuropilin-1 (NRP-1) through its influence on their transcription factor, namely 
specificity factor (SP-1) (Saha et al., 2016). S-sulfhydration of SP-1 at the Cys68 
and Cys755 residues enhanced its stability and upregulated VEGFR1 and NRP-
1. These effects were absent in CBS-/- endothelial cells and restored by NaHS 
application (Saha et al., 2016). These data further emphasise the critical role of 
H2S in the mediation of angiogenesis. 
1.6.4 H2S and hypertension 
The contribution of H2S in regulating the basal blood pressure was first 
characterised in spontaneously hypertensive rat (SHR) which was reported to 
have attenuated H2S level and suppressed CSE activity compared to 
normotensive rat (Yan et al., 2004). Further inhibition of constitutive H2S 
synthesis by CSE using propargylglycine (PAG) as an enzyme inhibitor caused 
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an additional elevation in the blood pressure and exacerbated vascular 
remodelling (Yan et al., 2004). This crucial role of H2S in the pathogenesis and 
development of hypertension is of a clinical relevance. Hypertensive patients of 
grades 2 and 3 (Whiteman et al., 2010a) and diabetic patient with hypertension 
(Sun et al., 2007) have been shown to have a low plasma level of H2S. Shi et al. 
(2007) reported that the protective effect of H2S against hypertension-induced 
vascular hypertrophy and tissue fibrosis in SHR was abolished by glibenclamide, 
suggesting a KATP channel-dependent mechanism. Recent work by (Sun et al., 
2015) demonstrated that NaHS upregulates the expression of KATP subunits in 
the vascular smooth muscle in the same animal model (i.e. SHR). The crosstalk 
between H2S and NO has also been studied in the context of hypertension. 
Zhong et al. (2003) found that hypertension induced by inhibiting NO synthase 
using L-NAME in rat downregulated CSE expression and limited H2S 
bioavailability which was reversed by H2S therapy. These results are consistent 
with a recent study by Al-Magableh et al. (2015) which showed that NaHS 
treatment corrected low NO level and reduced systolic blood pressure in an 
angiotensin II-induced hypertensive rat model. It has also been shown that in 
dexamethasone-induced hypertension, impaired arterial relaxation was 
associated with downregulation of constitutive H2S synthases (CSE and CBS) 
expression and low plasma H2S level. Subsequent work by the same group 
demonstrated that a sulfhydrated form of zofenoprilat (S-zofenoprilat) reduced 
blood pressure and restored the relaxation capacity of aorta and carotid artery 
in SHR through its H2S-releasing mechanism (Bucci et al., 2014). 
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1.6.5 H2S and myocardial ischaemia/reperfusion injury 
The contribution of impaired constitutive H2S levels to myocardial pathologies 
has been investigated in various ways. Geng and colleagues (2004) were the 
first to provide evidence that CSE-derived H2S could contribute in the pathology 
of isoproterenol-evoked cardiac injury. They also demonstrated that NaHS 
treatment mitigated the cardiac toxicity, as evidenced by an improved cardiac 
contractility and a decrease in the mortality rate. This observation is of clinical 
importance since patients with heart disease show low levels of H2S (Jiang et 
al., 2005). In line, Zhu et al. (2007) reported a 30% decrease in mortality rate 
and infarct size in NaHS-treated rats compared to PPG-treated ones following 
ischaemia/reperfusion injury. Work by Johansen et al. (2006) was the first to test 
the potential cardioprotection of exogenous H2S against ischaemia/reperfusion 
injury in isolated rat heart. As proof of concept, constant perfusion of NaHS pre-
ischaemia and up to 10 minutes of reperfusion showed a concentration-
dependent limitation in the infarct size. This infarct limitation was abolished in 
hearts which were pre-treated with either glibenclamide or 5-
hydroxydecannoate, suggesting the involvement of KATP channel in the 
observed cardioprotection. Later studies from Lefer’s laboratory sought to 
validate this observation in vivo and to elucidate the underlying mechanism(s). 
They first showed that overexpression of CSE synthase could be as protective 
as Na2S therapy, given at reperfusion, against myocardial ischaemia/reperfusion 
injury in mice (Elrod et al., 2007). Cardioprotection established by either 
approach was shown to preserve mitochondrial integrity and mitigate 
mitochondrial dysfunction following ischaemia/reperfusion injury. They then 
demonstrated that H2S could attenuate oxidative stress-induced mitochondrial 
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dysfunction when administered as a preconditioning mimetic before ischaemia 
via enhanced endogenous antioxidant expression (Calvert et al., 2009). 
Similarly, the same group later reported that overexpression of CSE or 
pharmacological H2S therapy, (Na2S 100 µg kg-1) started after the ischaemia 
episode, mitigated left ventricle hypertrophy and cardiac dysfunction in 
ischaemia-induced heart failure in mice (Calvert et al., 2010). This protection 
was associated with increased Akt phosphorylation, enhanced Nrf2 expression 
and promoted mitochondrial biogenesis.  
The involvement of NO in the cardioprotection mediated by H2S has been 
studied in different species. In mice, Minamishima et al. (2009) found that 
improved survival rate and cardiac function following cardiac arrest and 
cardiopulmonary resuscitation mediated by H2S treatment was absent in 
endothelial nitric oxide synthase (eNOS)-deficient mice. Consistently, enhanced 
NO bioavailability, as evidence by increased eNOS activation and plasma NO 
metabolites, was correlated with the infarct-limiting effect of garlic-derived diallyl 
trisulfide (DATS) as H2S donor (Predmore et al., 2012). Moreover, the injury-
limiting effect of H2S was also abrogated by abolishing NOS phosphorylation in 
isoproterenol-induced cardiac injury (Sojitra et al., 2012). Interestingly, impaired 
NO bioavailability and eNOS activity were associated with exacerbated 
myocardial infarction in CSE-/- mice which were restored with H2S therapy (King 
et al., 2014). In a head-to head comparison across species, Papapetropolus’s 
group (Bibli et al., 2015) demonstrated that infarct limitation by H2S was present 
when concomitantly administered with L-NAME in a rabbit model of acute 
myocardial infarction while it was absent in phospholamban (PLN) knockout 
mice.  
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It has been demonstrated that H2S could mediate its infarct limitation by 
triggering prosurvival signalling pathways at reperfusion. Several in vitro and in 
vivo studies have demonstrated that exogenous H2S mediated its 
cardioprotection via activation of the RISK signalling pathway at reperfusion 
(Yong et al., 2008, Osipov et al., 2009, Calvert et al., 2010, Yao et al., 2010, Hu 
et al., 2011, Predmore et al., 2011). This protective mechanism appears to 
function despite the existence of comorbidities such as diabetes (Peake et al., 
2013, Lambert et al., 2014) and in aged cardiomyocytes (Li et al., 2015b, Li et 
al., 2015a). Alternatively, the SAFE pathway is also implicated in H2S-induced 
cardioprotection (Luan et al., 2012, Li et al., 2016). Modulation of Ca2+ 
homeostasis is another proposed mechanism by which H2S can reduce cardiac 
contractility and inhibit ischaemia-induced Ca2+ overload to protect 
cardiomyocyte against simulated ischaemia/reperfusion in vitro (Sun et al., 
2008, Hu et al., 2011).  
1.7 Interaction between H2S and NO 
There is an increasing body of evidence supporting the possibility of chemical 
interaction between H2S and NO in the cellular milieu, although this remains to 
be detected in vivo. It has been proposed that the direct interaction between H2S 
with available NO under aerobic conditions could generate S-nitrosothiols which 
potentially limit NO-induced vasorelaxation. NO could also interact with the 
protein cysteine residue to produce S-nitrosothiols with the possibility of NO 
release from these complexes (King et al., 2013). Under aerobic conditions, the 
simplest S-nitrosothiol is thionitrous acid (HSNO) which has been proposed to 
restrict the availability of NO in the presence of low H2S concentration (Filipovic 
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et al., 2012, King, 2013). Under anaerobic conditions, HSNO itself could also 
interact with endogenous H2S to produce hydrogen disulfide (H2S2) and nitroxyl 
(HNO), the reduced form of NO (Cortese-Krott et al., 2015). Like NO, HNO could 
act as an activator of sGC and stimulates vasorelaxation. Nevertheless, it has 
superior activity over NO as it resists ROS-induced degradation and less 
tolerance develops following long exposure (Beltowski, 2015). It has also been 
reported that HNO increases myocardial contractility via increasing the 
availability of Ca2+ in the cytosol and increasing the sensitivity of myofibrils to 
Ca2+ (Gao et al., 2012). Moreover, Sivakumaran et al. (2013) found that HNO 
has not only a positive inotropic effect on the heart but also a lusitropic effect by 
allowing muscle relaxation following contraction by activating Ca2+-ATPase. 
These beneficial effects make HNO a potential therapy to treat heart failure. 
1.8 H2S and mitochondria 
H2S exerts two different effects on the mitochondrial respiratory chain depending 
on its local concentration. At low concentration, H2S can enter the oxidation 
process and feeds electrons into the electron transport chain at complex III. H2S-
derived electrons flow forward to bind to oxygen and aid in ATP production. 
Conversely, high concentration of H2S can inhibit the activity of complex IV and 
consequently hinder the flow of electrons through the mitochondrial respiratory 
chain. This toxic effect of H2S is seen as inhibition of ATP production and the 
accumulated pool of electrons in the respiratory chain which could be a potential 
source for ROS generation. Despite its narrow therapeutic window, it has been 
demonstrated that the basal level of H2S, maintained by the constitutive H2S 
production machinery, is essential for cell survival. Kondo et al. (2013) reported 
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that isolated mitochondria derived from CSE-/- mice exhibited severe malfunction 
which was improved with SG-1002 as H2S donor. Moreover, the cardiac 
dysfunction and mortality rate, following an acute myocardial infarction protocol, 
were markedly higher in CSE-/- mice compared to wild type (Miao et al., 2016).  
Alternative mechanisms by which endogenous H2S could stimulate the electron 
transport chain have been proposed which involves stimulation of mitochondrial 
cAMP/PKC signalling cascade. Apart from its cytosolic functions, mitochondrial 
cyclic AMP is shown to interact with different constituents in the mitochondria 
(Acin-Perez et al., 2009). Mitochondrial cAMP concentration is controlled by 
mitochondrial phosphodiesterases (PDEs) and can stimulate the electron 
transport chain by phosphorylation of respiratory complexes (Acin-Perez et al., 
2011). Szabo’s laboratory has recently reported that H2S abolished the inhibitory 
effect of mitochondrial PDE2A on cAMP in rat-derived liver mitochondria (Modis 
et al., 2013c). The resulting enhanced level of cAMP stimulated the 
mitochondrial respiratory chain through a PKC-dependent mechanism. 
Another modulatory role of H2S on mitochondrial bioenergetics in M2-polarized 
macrophage has recently been proposed by Miao et al. (2016). NaHS induced 
polarisation of M2-macrophage with significant enhancement of fatty acid 
oxidation (FAO) and lipolysis, the two main energy sources for these cells. This 
conclusion was drawn based on the observation that NaHS-treated M2-
macrophages showed an increase in oxygen consumption rate, spare 
respiratory capacity and ratio of oxidative phosphorylation to aerobic glycolysis. 
These data unveiled a novel pathway through which H2S could energise the 
mitochondria by stimulating lipolysis and FAO. 
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1.9 H2S and redox homeostasis 
It has been suggested that H2S is a potent reducing agent and mediates its 
cytoprotective effects, at least in part, through its direct quenching of ROS. 
Dissolved H2S under normal physiological conditions (37 °C, pH 7.4) is in fact 
present mainly as HS- which is known to be a strong reductant of ROS (Al-
Magableh et al., 2014) and reactive nitrogen species (RNS) (Whiteman et al., 
2006). However, a compelling body of evidence suggests that these effects 
could be artificial due to the supraphysiological concentration of H2S employed 
in these studies compared to the actual physiological level of H2S (Furne et al., 
2008). Rapid catabolism of sulfide maintains the tissue level in the low 
micromolar range which is far less than the high micromolar or even low 
millimolar range applied to explore the quenching effect of H2S on ROS and 
RNS. Moreover, tissue level of H2S in the various oragans (brain, heart, and 
kidney) is suggested to be maintained within the low micromolar range in vivo 
(Haouzi et al., 2016). Accordingly, it seems more convincing that H2S could have 
a modulatory/regulatory effect on the endogenous defence machinery against 
oxidative damage. 
Previous work by Kimura’s laboratory (Kimura and Kimura, 2004) showed that 
H2S protected primary cortical neurons against oxidative glutamate toxicity 
(oxytosis) by enhancing the production of GSH, a powerful endogenous 
reductant. Further work by the same group revealed that H2S promotes cysteine 
transport into the cell for GSH production, reduces cystine to cysteine in the 
extracellular space and enhances the redistribution and localisation of GSH to 
the mitochondria (Kimura et al., 2010). Furthermore, recent work by Jain et al. 
(2014) demonstrated that H2S enhanced GSH production by upregulating the 
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cellular glutamate/cysteine exchange mechanism, represented by 
glutamate/cysteine ligase catalytic subunit and glutamate/cysteine ligase 
modifier subunit. Trx-1 is another powerful endogenous reductant, along with 
GSH, which can modulate ROS signal transaction as well as directly scavenge 
ROS to protect the cell against oxidative stress (Nordberg and Arnér, 2001). 
Using a murine model of hepatic ischaemia/reperfusion injury, Lefer’s group (Jha 
et al., 2008) reported that the H2S donor, IK1001 at reperfusion protected the 
liver, as evaluated by reduction in liver injury biomarkers namely alanine 
aminotransferase and aspartate aminotransferase. The hepatoprotective 
mechanism was suggested to be through improving GSH/GSSG ratio and 
upregulated expression of Trx-1. These data were later confirmed by the same 
group in a murine model of myocardial ischaemia/reperfusion injury (Calvert et 
al., 2009) where Na2S treatment (100 µg kg-1) was given 24 hours before the 
onset of ischaemia. Preconditioning the heart with H2S resulted in infarct 
limitation, attenuation of oxidative stress and reduction in circulating troponin I 
via upregulated Trx-1 expression. Similarly, Bian and colleagues have 
demonstrated that H2S treatment before subjecting to oxidative stress could 
render the SH-SY5Y neuronal cells and MC3T3-E1 osteoblastic cells more 
tolerant against oxidative stress via stimulation of endogenous reductants 
including GSH and Trx-1 (Xu et al., 2011, Liu et al., 2013a). Trx-1 expression is 
of clinical relevance as its plasma level is elevated in patients with heart failure 
(Kishimoto et al., 2001). Calvert and colleagues (Nicholson et al., 2013) explored 
the potential salvage effect of H2S in a murine model of ischaemia-induced heart 
failure. In wild type mice, seven days Na2S treatment (100 µg kg-1 day-1) started 
at the onset of reperfusion improved cardiac contractility and limited cardiac 
remodelling by abolishing HF-activated apoptosis signalling kinase-1 and 
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histone deacetylase-4 expression. The same treatment failed to show any 
protection in dominant negative mutant Trx-1 mice which emphasises the crucial 
role of Trx-1 in H2S-induced cardioprotection.  
It has been shown that H2S could also mitigate oxidative stress by directly 
influencing endogenous enzymatic antioxidants. Early reports showed that 
direct interaction between H2S and SOD dramatically increased ROS quenching 
activity of this enzyme (Searcy et al., 1995). In different experimental models, 
enhanced level of H2S was shown to protect against oxidative stress-induced 
cell death via preserving the levels of SOD, catalase and GPx in vitro (Sun et 
al., 2012, Wen et al., 2013) and in vivo (Su et al., 2009, Zhu et al., 2013, Huang 
et al., 2013). However, it is still not fully understood how H2S actually upregulates 
these enzymes. One possibility could be through triggering specific transcription 
factors for endogenous antioxidant enzymes such as nuclear factor- КB (NF-КB). 
It has been reported that NF-КB regulates the activity of SOD (Kim et al., 1994) 
and modulate the transcription of catalase and GPx (Zhou et al., 2001). 
Interestingly, application of H2S was shown to suppress inflammatory mediators 
and oxidative stress through upregulation of NF-КB in an array of pathologies 
such as ischaemia/reperfusion injury (Guo et al., 2014), cardiac arrest (Wei et 
al., 2015) and sepsis (Chen et al., 2014). Attenuation of oxidative stress by H2S 
is also thought to signal through nuclear factor-2 (Nrf2) (Calvert et al., 2009). 
Wang’s laboratory provided a mechanistic insight into how H2S could promote 
Nrf2 signalling (Yang et al., 2013). They demonstrated that H2S S-sulfhydrated 
Klech-like ECH-associated protein1 (Keap1), an inhibitory modulator of Nrf2, at 
Cys151 allowing unrestricted expression of Nrf2 which attenuated aging-induced 
oxidative stress. Very recently, this signalling pathway has also been implicated 
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in GYY4137-induced suppression of accelerated atherosclerosis in diabetic 
mice (Xie et al., 2016). In the same study, dissipation of this signalling pathway 
by Nrf2 knockout or mutating the Cys151 residue of Keap1 in vitro was showed 
to suppress the salvage effect of GYY4137.  
S-sulfhydration (also called persulfidation) by H2S has also been proposed to 
specifically limit mito-ROS generation by modulating the activity of p66Shc, a 
Src homologous-collagen homologue (Shc) adaptor protein. It has been shown 
that cytosolic p66Shc is translocated into the mitochondria in response to cell 
stress after being phosphorylated at serine-36 (Ser36) by protein kinase C-βII 
(PKC- βII). Phosphorylated p66Shc disturbs the electron transfer in the 
mitochondrial respiratory chain, by cytochrome c (complex III) in particular, 
causing electron leakage from the respiratory complexes that leads to ROS 
generation (Giorgio et al., 2005). In SH-SY5Y neuroblastoma cells, enhanced 
level of H2S, either by NaHS or by overexpression of CBS, limited H2O2-induced 
mito-ROS generation by S-sulfhydration of p66Shc at Cys59 (Xie et al., 2014). S-
sulfhydration of this residue, which is in close proximity to Ser36, dissipates the 
association between p66Shc and PKC- βII and limits its translocation into the 
mitochondria.  
1.10 Rational and objectives of the studies presented in this thesis 
Ischaemic heart disease is still the main cause of death and disability in the 
world, projected to remain in the lead for the next 20 years according to the 
WHO. A major focus over the last two decades has been on developing 
therapeutic approaches which could be employed at the reperfusion phase, as 
a clinically relevant point of intervention, to protect against reperfusion injury and 
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improve the clinical outcome of thrombotic coronary artery occlusion. 
Compelling experimental evidence has identified endogenous salvage signalling 
cascades which could mitigate the cell injury when they are targeted at 
reperfusion including the RISK and SAFE pathways. Despite the tremendous 
efforts and the very promising preclinical data, the cardioprotection field has, 
hitherto, failed to introduce any drug which can be used clinically to reduce 
myocardial infarction. H2S is one of the endogenously produced gaseous 
mediators which plays key roles in cardiovascular homeostasis in health and 
disease. The growing interest in the biology of H2S over the last three decades 
has unveiled potential cardioprotective mechanisms which could have 
significant clinical applications. However, a general consensus has not been 
reached yet regarding the cardioprotective mechanism(s) of this gas. Moreover, 
the clinical translation of these beneficial effects has been hindered by the lack 
of potential H2S-releasing drug prototypes. 
1.11 Main points of interest 
The main objective of this work is to characterise the potential cardioprotective 
effect of thiol-containing compounds as potential H2S donors in vivo and to 
decipher the underlying mechanisms of cardioprotection.  
1.12 General thesis 
Elevation of H2S at reperfusion, through the use of thiol-containing compounds, 
limits myocardial infarct size. 
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1.13 Hypothesis and objectives 
The specific questions to be address in this work: 
1. Does Mesna at reperfusion protect the heart from ischaemia/reperfusion 
injury in vivo? 
2. Does Mesna trigger the RISK pathways at reperfusion to protect the heart 
against myocardial infarction in vivo? 
3. Does administration of GYY4137 at reperfusion limit acute myocardial 
infarction in vivo? 
4. Does GYY4137 activate the RISK pathway components to mediate its 
infarct limitation? 
5. Does GYY4137 reply on NO signalling to mediate its cardioprotection?  
6. Does mitochondrial delivery of H2S by AP39 protect against myocardial 
ischaemia/reperfusion in vivo? 
7. Does AP39 trigger any of the RISK pathway components to exert its 
protection against reperfusion injury? 
8. What effects does AP39 have on cardiomyocyte mitochondria? 
1.14 Synopsis of the thesis 
This work was dedicated to characterisation of the potential injury-limiting effect 
of three thiol-containing molecules, namely Mesna, GYY4137 and AP39, with 
different H2S-releasing profiles using an in vivo rat model of acute myocardial 
infarction. The onset of reperfusion was chosen as the time to apply these 
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compounds because it represents the most clinically relevant time point of 
intervention. The model of ischaemia/reperfusion injury in rat was developed in 
the early phase of this work and validated using IPC as a positive control 
(Chapter 3). Evaluation of infarct-limiting effect of Mesna was carried out using 
the well-known dual staining technique with Evans’ blue and tetrazolium chloride 
(Chapter 4). Likewise, the cardioprotection of GYY4137 (Chapter 5) and AP39 
(Chapter 6) was also characterised using the same approach. The influence of 
H2S donors, namely GYY4137 and AP39, on the phosphorylation of the RISK 
kinases in the left ventricle at early reperfusion was determined using Western 
blotting (Chapter 5 and 6). The direct effect of selective delivery of H2S into the 
mitochondria by AP39 was assessed using isolated cardiomyocyte 
mitochondria, namely subsarcolemmal and interfibrillar mitochondria (Chapter 
6). These mitochondrial studies included measuring mitochondrial oxygen 
consumption by complexes I and II using Clark oxygen electrode. It also 
incorporated assessing the direct effect of AP39 on the mito-ROS generation 
using Amplex UltraRed fluorescence dye. The effect of mitochondrially delivered 
H2S on the PTP opening was also evaluated as a function of mitochondrial Ca2+ 
retention capacity. 
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2.1 Materials and Methods 
2.1.1 Chemicals 
Chemical Source 
2,3,5-triphenyltetrazolium chloride (TTC) Sigma-Aldrich, UK 
3-(N-morpholino)propanesulfonic acid (MOPS) Sigma-Aldrich, Germany 
Acrylamide BioRad, UK 
ADT-OH (anethole dithiolethione, H2S-releasing 
moiety of AP39, MW = 226.3 g mol-1) 
A generous gift from Prof 
Matt Whiteman/Exeter 
University 
Ammonium persulfate (APS) BioRad, UK 
Amplex UltraRed reagent Thermo Fisher Scientific 
Inc., Germany 
AP219 (triphenylphosphonium, mitochondrial-
targeting scaffold of AP39, MW = 433.5 g mol-1) 
A generous gift from Prof 
Matt Whiteman/Exeter 
University 
AP39 (10-oxo-10-(4-(3-thioxo-3H-1, 2-dithiol-5-
yl)phenoxy)decyl) triphenylphosphonium 
bromide, MW = 722.2 g mol-1), mitochondria-
targeted H2S donor 
A generous gift from Prof 
Matt Whiteman/Exeter 
University 
Bovine serum albumin Sigma-Aldrich, Germany  
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Calcium green 5N Invitorgen, Canada 
Chemiluminescent substrate Thermo Scientific, UK 
Complete™ tablets (protease inhibitor cocktail 
tablets) 
Sigma-Aldrich, Germany 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, UK 
Evans’ blue dye Sigma-Aldrich, UK 
Ethylene diamine tetraacetic acid (EDTA) Sigma-Aldrich, UK 
Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid 
Sigma-Aldrich, UK 
Formalin Fisher Scientific, UK 
Heparin AAH hospital service, UK 
HEPES Roth, Germany 
Horseradish peroxidase (HRP) Roche Diagnostics, 
Germany 
S-nitrosoglutathione (GSNO) Sigma-Aldrich, Germany 
GYY4137 (morpholin-4-ium 4-methoxyphenyl-
morpholino-phosphinodithioate, MW = 376.7 g 
mol-1) 
A generous gift from Prof 
Matt Whiteman/Exeter 
University 
Isoflurane Forane® Abott GmbH, Germany 
Magnesium chloride (MgCl2) Fisher Scientific, UK 
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Magnesium sulfate (MgSO4) Roth, Germany 
Mesna (2-mercaptoethanesulfonate sodium) Sigma-Aldrich, UK 
Methanol Fisher Scientific, UK 
Nargase protease Sigma-Aldrich, Germany 
Neocuproine Sigma-Aldrich, Germany 
L-NAME, MW = 269.7 g mol-1 Sigma-Aldrich, UK 
LY294002, 343.8 g mol-1 Sigma-Aldrich, UK 
ODQ, 187.2 g mol-1 Sigma-Aldrich, UK 
Percoll GE Healthcare, Germany 
Phosphate buffered saline tablets Fisher Scientific, UK 
Phosphatase inhibitor cocktail 1 Sigma-Aldrich, UK 
PhosSTOP™ tablets (phosphatase inhibitor 
tablets) 
Sigma-Aldrich, Germany 
Ponceau S solution Serva, Germany 
Potassium chloride (KCl) Fisher Scientific, UK 
Potassium dihydrogen phosphate (KH2PO4) Merck, Germany 
Protease inhibitor cocktail Sigma-Aldrich, UK 
Protein marker Precision Plus ProteinTM BioRad, Germany 
Rotenone 123 Sigma-Aldrich, Germany 
S-nitrosoglutathione (GSNO) Santa Cruz, Germany 
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S-nitroso-N-acetyl-DL-penicillamine (SNAP) Life Technologies, 
Germany 
Sodium dodecyl sulfate (SDS) BioRad, UK 
Sodium chloride (NaCl) Fisher Scientific, UK 
Super Signal West Dura Extended Duration 
Substrate 
Thermo Scientific, UK 
Succinate Sigma-Aldrich, Germany 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, UK 
Thiobutabarbital sodium salt hydrate (Inactin® 
hydrate) 
Sigma-Aldrich, UK 
Tris-Base Fisher Scientific, UK 
Triton X-100 Sigma-Aldrich, UK 
Tween 20 Sigma-Aldrich, UK 
XT Sample buffer (4x) Bio-Rad, Germany 
2.1.2 Buffers and solutions 
30% Percoll solution 30% Percol (sterile filtered) in isolation 
buffer 1 
Incubation buffer 125 mM KCl, 10 mM MOPS, 1.2 mM 
KH2PO4, 1.2 mM MgCl2, 20 μM EGTA, 
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pH 7.4 
Blocking solution 5% w/v blotting grade blocker non-fat dry 
milk in TBST 
Buffer A 0.0551 g ATP in 100 mL incubation buffer 
Buffer B 80 mg bovine serum albumin (BSA) in 20 
mL incubation buffer 
Glutamate/Malate buffer 5 mM glutamate, 2.5 mM malate in 
incubation buffer 
HENS buffer 100 mM HEPES (pH 7.8), 1 mM EDTA, 
0.1 mM Neocuproine, and 1% SDS 
Isolation buffer 1 0.146 g EDTA, 1.19 g HEPES and 42.79 
g sucrose (for 500 mL), pH 7.4 adjusted 
with Tris-base 
Isolation buffer 2 Isolation buffer 1 with Complete® tablet 
Isolation buffer 3 25 µL of 200 mM Neocuproine, 3 tablets 
of Complete® and 3 tablets of 
PhosSTOP® (for 50 mL) 
2-(N-morpholino)ethanesulfonic 
acid (MES) buffer 
 0.1 M 2-(N-morpholino)ethanesulphonic 
acid, 0.05 M phosphate, and 1 nM EDTA, 
pH 6.0 
Physiological saline (NaCl 0.9% 
w/v) 
Fisher Scientific, UK 
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Lysis buffer 1.46 g NaCl, 0.91 g KCl, 0.15 g MgCl and 
0.93 g EDTA were first dissolved in 230 
mL distilled water, then 20 mL Tris-buffer 
(pH 7.6) and 0.3% (v/v) of Triton X-100 
were added with stirring 
Running (Tank) buffer 30.28 g Tris-base, 142.5 g Glycine and 5 
g SDS in 1 L distilled water (pH 8.3) 
Sample buffer (Laemmli) 2X-
concentrate 
4% SDS w/v, 20% v/v glycerol, 10% v/v 2-
mercaptoethanol, 0.004% v/v 
bromophenol blue and 0.125 M Tris HCl 
(pH approx. 6.8), Sigma-Aldrich, UK 
Separating gel 5.27 mL distilled water, 3.33 mL 
Acrylamide, 1.25 mL Tris-HCl, 100 µL of 
10% w/v SDS, 50 µL APS and 5 µL 
TEMED  
Stacking gel 5.77 mL distilled water, 1.67 mL 
acrylamide, Tris-HCL/SDS 2.5 mL, APS 
50 µL and 8 µL TEMED 
Succinate buffer 5 mM succinate, 2 µM rotenone 123 in 
incubation buffer 
Tris-buffered saline (TBS) 2.42 g Tris-Base and 8.8 g NaCl dissolved 
in 1 L distilled water (pH 7.5) 
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1% Tris-buffered saline with 
tween 20 (1% TBST) 
1 mL Tween 20 in 1 L TBS 
Transfer buffer 3.03 g Tris-buffer, 14.4 g Glycine and 200 
mL Methanol in 1 L distilled water (pH 8.3) 
Tris-HCl/SDS 0.4 g SDS and 6.056 g Tris-base 
dissolved in 100 mL distilled water and the 
pH was adjusted with concentrated HCl 
2.1.3 Antibodies 
Antibody Company Dilution 
Rabbit polyclonal anti-human Akt (#9272), Cell signalling, 
UK 
1:1000 
Rabbit polyclonal anti-human 
phosphor-Akt (Ser473) 
(#9271), Cell signalling, 
UK 
1:1000 
Rabbit polyclonal anti-human eNOS (9572), Cell signalling, 
UK 
1:500 
Rabbit polyclonal anti-human 
phospho-eNOS (Ser1177) 
(9571), Cell signalling, 
UK 
1:500 
Rabbit polyclonal anti-human GSK-3β (#9315), Cell signalling, 
UK 
1:1000 
Rabbit polyclonal anti-human 
phospho-GSK-3β (Ser9) 
(#9336), Cell signalling, 
UK 
1:1000 
Rabbit polyclonal anti-human ERK1/2 (#9102), Cell signalling, 
UK 
1:1000 
Rabbit polyclonal anti-human 
phosphor-ERK1/2 (Thr202/Tyr204) 
(#9101), Cell signalling, 
UK 
1:1000 
Rabbit polyclonal anti-human 
translocase of the outer membrane 20 
(Tom20) 
(sc-11415), Santa Cruz, 
USA 
1:2000 
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Rabbit polyclonal anti-human GAPDH (#2118), Cell signalling, 
UK 
1:50000 
Anti-rabbit IgG, HRP-linked (#7074) , Cell signalling, 
UK 
1:15000 
Anti-mouse IgG-HRP (#7076), Cell Signalling, 
Germany 
1:10000 
 
 
2.1.4 Kits  
DC protein assay kit II (for Lowry assay) 5000112, BioRad, Germany 
Glutathione assay kit 703002, Cayman chemical, 
USA 
PierceTM BCA Protein Assay Kit ThermoFisher Scientific, UK 
PierceTM S-nitrosylation Western blot kit 90105, Thermo Scientific, USA 
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2.2 Animals 
Male Sprague Dawley (SD) rats, 300-350 g (9-11 weeks), were obtained from 
Harlan, UK and used for infarct size and myocardial tissue sampling studies. For 
mitochondrial bioenergetics studies undertaken in Justus-Liebig University/ 
Giessen/Germany, male Wistar rats, 300-350 g (9-11 weeks), were purchased 
from Harlan, France. Rats were housed in the animal facility for at least 1 week 
after delivery before any procedure. All animals were housed in polyethylene 
cages in groups of 2-4 rats on wood shaving litter with free access for normal 
small animal food (Teklad global 14% protein rodent maintenance diet) and fresh 
tap water ad libitum. The temperature was maintained between 18-22 °C with 
relative humidity around 50% and 12 hours light/dark cycle was applied. Animals 
were housed in a small cardboard box on the day of experiment for a minimal 
time before being anaesthetised. All handling and procedures for in vivo 
experiments were carried out in accordance with UK Home Office Guidelines on 
the Animals (Scientific Procedures) Act 1986, (published by the Stationery 
Office, London, UK) and was approved by the Animal Welfare Ethical Review 
Board, Cardiff University. Studies involving mitochondria isolation were 
approved by the Animal Welfare Office of the Justus-Liebig University, Giessen, 
Germany. Animals studies were reported in accordance with ARRIVE guidelines 
(Kilkenny et al., 2010, McGrath et al., 2010). 
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2.3 General surgical procedures 
2.3.1 Anaesthesia 
Sodium thiobutobarbital (Inactin®, Sigma-Aldrich, UK) was chosen as the 
anaesthetic agent because it can provide a stable plane of anaesthesia for up 
to 6 hours with minimal interference with cardiovascular function and renal 
output (Buelke-Sam et al., 1978). Anaesthesia was induced by intraperitoneal 
injection of Inactin® (200 mg kg-1) and maintained by bolus doses of Inactin® (20 
mg kg-1) given intravenously as required to abolish reflexes. Depth of 
anaesthesia was monitored throughout the experiments to avoid insufficient 
anaesthesia or excessive cardiac or respiratory depression. The surgical plane 
of anaesthesia is characterized by muscle relaxation, lack of response to 
stimulation such as surgical stimulation or toe pinch (pedal reflex), slow depth 
and rate of spontaneous respiration. The body temperature was maintained at 
37 ± 1 °C using a thermo-regulated blanket unit (Harvard Apparatus Ltd, Kent, 
UK) and monitored by a rectal thermometer.  
2.3.2 Cannulation procedures 
Once the surgical plane of anaesthesia was achieved, the left jugular vein was 
carefully located and cannulated for intravenous administration of the 
anaesthetic agent and experimental treatments. The jugular vein was chosen as 
it allows drug administration directly into the heart first before it systematically 
circulated in around the body. The right common carotid artery was then 
cannulated and connected to fluid-filled pressure transducer, previously 
calibrated, to measure arterial blood pressure and heart rate using the Powerlab 
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data acquisition system (AD instruments, Abington, UK). Cannulations of arterial 
and venous vessels were performed using polyethylene tube 50 (PE 50) of 0.5 
mm internal diameter, 0.9 mm outer diameter (AD Instruments Ltd, Oxford, UK), 
connected to a 23G (0.6 x 25 mm) syringe needle and attached to three way 
taps. Cannulae were filled with heparinized saline solution (0.9% w/v NaCl and 
10 IU ml-1 heparin) to maintain patency and for flushing the cannula as required. 
The trachea was separated from the surrounding tissue, a tracheotomy was 
performed and the trachea intubated with a Y-shaped polyethylene tube. The 
lungs were inflated with room air using a small rodent volume controlled 
ventilator (Hugo Sachs Elektronik, March, Germany) at a rate of 75 strokes min-
1 and with tidal volume of 1.0 to 1.25 mL 100 g-1. 
Heart rhythm was monitored and recorded during each experiment using 
standard lead lI electrodes inserted subcutaneously into the rat’s limbs and 
connected to the Powerlab data acquisition system (AD instruments, Abington, 
UK). Electrocardiogram (ECG) was used to identify any arrhythmia during 
stabilisation period and to confirm induction of myocardial ischaemia and 
reperfusion.  
2.3.3 Coronary artery occlusion (CAO) 
After cannulating the arterial and venous lines and commencing artificial 
respiration, a longitudinal incision was made along the midline of the chest to 
separate the muscle layers over the sternum using a scalpel. A midline 
sternotomy was then performed with Mayo scissors from xiphoid process up to 
the manubrium and the two side of the chest were separated using a metal 
retractor in order to visualize the heart. The pericardium was then carefully 
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dissected from the heart. A 4/0 braided thread, attached to a 17 mm 3/8 circle 
taper point needle (Mersilk W581, Ethicon Ltd, Edinburgh, UK), was placed 
around the left anterior descending (LAD) coronary artery close to its origin and 
below the pulmonary conus with 2-3 mm margins around the LAD (Figure 2.1). 
 
 
Figure 2.1 Close-up image of the rat heart during the stabilisation period with a ligature 
around the left anterior descending coronary artery. At this period, the ligature was loose 
without any interference and inclusion/exclusion criteria were applied. LADCA, left 
anterior descending coronary artery. 
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2.3.4 Stabilization period 
After successfully placing the ligature around the left coronary artery, the animal 
was left to stabilise for 20 minutes during which the two ends of the ligature 
remained loose with no further interference (Figure 2.1). This period allowed 
adjustment of ventilation, normal sinus rhythm to be re-established, and 
evaluation of baseline haemodynamics. At the end of this period it was 
determined if animal had met the inclusion criteria for the study which were the 
following:  
Heart rate greater than 250 beat per minutes (BPM), diastolic blood pressure 
greater than 50 mmHg, steady sinus rhythm, no visual signs of ischaemia, no 
arrhythmia during the stabilisation period.  
These criteria were chosen based on previous conventions and to ensure that 
the rat has reasonable haemodynamics be subjected to ischaemia/reperfusion 
protocol. They also aimed to minimise intra- and inter-assay variation between 
the series of experiments and compare the data with others. 
2.3.5 Induction of regional myocardial ischaemia 
Two shortened pipette tips were used to form a snare around the left coronary 
artery to induce regional myocardial ischaemia. After 20 minutes of stabilisation, 
both ends of the ligature were passed through one of the shortened pipette tips 
and regional ischaemia was induced by pulling the two ends of the snare taut 
against the epicardium. The snare was then secured by placing the second 
pipette tip inside the first one (Figure 2.2). Ischaemia was induced for 30 minutes 
and confirmed by a drop in the mean arterial pressure (MAP), a colour change 
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of the left ventricle (from red to pale purple), and ECG changes (ST-segment 
elevation). The duration of myocardial ischaemia was chosen based on a 
preliminary series of experiments (Figure 2.3) used different ischaemia periods 
(20, 25 and 30 minutes) aimed to produce a reproducible area at risk (about 50-
60% of the total ventricular area) and a survivable infarct size (about 50% of the 
ischaemic zone). Infarct size produced by 20, 25 and 30 minutes of ischaemia 
was 12.7 ± 4.0, 36.2 ± 3.6 and 52.4 ± 3.1, respectively. Therefore, 30 minutes 
period of ischaemia was chosen and used for the subsequent series of 
experiments.  
Haemodynamic and ischaemia-induced arrhythmias were monitored and 
recorded during the 30 minutes of regional ischaemia. During this time the core 
temperature was maintained at 37 ± 1 °C and the chest opening was covered 
with a layer of cotton gauze to maintain cardiac temperature. 
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Figure 2.2 Close-up image showing the regional ischaemia in rat heart. The ischaemic 
bed appears as a pale purple area while the normally perfused tissue appears in red 
colour. The coronary artery was occluded by pulling the snare against the epicardium 
and securing it with another shortened pipette tip. The artery was occluded for 30 
minutes, then the snare was released to reperfuse the ischaemic area for 120 minutes. 
LADCA, left anterior descending coronary artery. 
 
 
Figure 2.3 Infarct data for the preliminary study with different periods of regional 
myocardial ischaemia. Ischaemia was established by occluding the left descending 
coronary artery for 20 minutes (n=3), 25 minutes (n=5) and 30 minutes (n=5). 
Infarction was delineated using TTC staining and the infarct size was expressed as a 
percentage of the area at risk. Data are presented as mean ±SEM.  
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2.3.6 Reperfusion 
If the animal survived the 30 minutes of regional ischaemia, the snare was 
released to allow the blood to reflow through the left coronary artery again, 
initiating the reperfusion phase for 120 minutes. Successful reperfusion was 
confirmed by colour change of the ischaemic bed (from pale purple to bright red), 
occurrence of reperfusion-induced arrhythmia in the first minutes of reperfusion, 
and increase in the mean arterial pressure (MAP). Two hours of reperfusion was 
sufficient for the reperfusion injury to be developed. It also allows the co-factors 
and reducing enzymes to be cleared from the ischaemic bed which could 
interfere with the tertazolium staining procedure and to have a good red/white 
contrast within the risk zone. Cardiodynamics were recorded and respiratory 
adjustments was made, as required, throughout the reperfusion period. Any 
animal that failed to survive 120 minutes reperfusion was excluded. 
2.4 Histology of myocardial infarction 
Infarct size measurements were obtained using dual staining technique with 
Evans’ blue and triphenyltetrazolium chloride (TTC). This is a gold-standard 
technique employed to determine infarct size in the setting of myocardial 
ischaemia reperfusion injury ex vivo and in vivo (Csonka et al., 2010, Bell et al., 
2011). When the animal successfully survived the reperfusion period, the heart 
was excised with sufficient length of ascending aorta. The beating heart was 
washed with cold phosphate buffered saline (PBS) then transfer to a petri dish 
to remove any extra-cardiac tissue. The heart was then picked up by the aortic 
root using fine forceps and cannulated with a metal cannula to a modified 
Langendorff apparatus (Figure 2.4). The heart was perfused with PBS at 
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hydrostatic pressure of 74 mmHg (100 cm H2O) at room temperature to remove 
the blood/heme residues trapped in the heart chambers. Removal of heme-
containing proteins at this stage is important as any heme-residue might appear 
as a brownish colour and affect the red/white contrast with TTC staining later on 
(Pitts et al., 2007). The ligature around the LAD coronary artery was re-occluded 
with a surgeon’s knot using fine forceps and 0.5-1.0 mL of 2% Evans blue dye 
slowly perfused through the aortic root to stain the non-ischaemic tissue (Figure 
2.5). The stained heart was then detached from the cannula, suspended in a 
small plastic pot to maintain its shape and frozen at -20 °C for 3-72 hours. It is 
worth mentioning that this could be considered as a relatively slow freezing 
process for a very sensitive PTMs but this needs to be direct tested, however. 
 
Figure 2.4 Diagram of the modified Langendorff constant pressure rig used to stain the 
non-ischaemic area of the heart with Evan's blue dye. At the end of ischaemia and 
reperfusion protocol, the heart was excised and perfused with phosphate buffer saline at 
74 mmHg constant pressure ex. vivo. The ligature was permanently tied off using a 
surgeon’s knot before perfusing the non-ischaemic area with 2% Evan’s blue dye. The 
heart was then frozen at -20 ºC for 3-72 hours.  
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Figure 2.5 Perfusing the heart with Evan's blue dye through the artic root to demarcate 
the non-ischaemic area after permanently occluding the left coronary artery. At this 
stage, the ischaemic area is delineated and highlighted in red colour. 
 
The frozen heart was placed on a glass surface and left for 2-3 minutes to thaw 
slightly before being transversely sliced at 2 mm thickness into 5-6 sections from 
apex to base using metal scalpel. Sections were blotted on absorbent surface 
and left to fully thaw at room temperature before incubating them with the TTC 
solution. This step is important for two reasons: (1) to avoid any 
“smearing/leaching” from Evans’ blue dye from its territories which might affect 
the delineation of the non-ischaemic area (2) incubating the sections in 1% TTC 
solution at 37 °C whilst they are cool will lead to tissue contraction which affects 
the geometry of the sections. 
TTC is used in biochemical analysis as a redox indicator to differentiate between 
metabolically active and inactive cells. TTC is a colourless dye but is 
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enzymatically reduced to brick-red 1,3,5, triphenylformazan in viable tissue by 
dehydrogenases (such as NADH), while necrotic tissue does not retain these 
enzymes and remains unstained (Birnbaum et al., 1997, Schwarz et al., 2000). 
Therefore, it is crucial that the reperfusion phase is of adequate duration to 
wash-out the dehydrogenases from the infarcted area to have proper delineation 
of the infarcted territories. Sections were then incubated with 1% solution of TTC 
in PBS (pH=7.4) in a small conical flask at 37 °C for 15 minutes in a water bath. 
It is important to agitate the sections every minute as the side of the section 
which faces the flask wall would not be stained. Sections were then fixed in 4% 
formalin in PBS for 24 hours to improve red/white contrast between the viable 
tissue and the infarcted area within the risk zone. This step also removes the 
fatty surface gloss of the section which might affect the contrast when the section 
is scanned (Bohl et al., 2009).  
2.4.1 Infarct size measurements 
Fixed sections were placed in order from the apex to the base over the glass of 
the digital scanner (HP Scanjet 4370, USA) with another piece of glass over 
them to keep them flat (Figure 2.6). A ruler was scanned with the sections to 
allow calibration of the image analysis program and transfer the area from pixel 
scale to metric scale (cm). Sections were then imaged from both sides and the 
images were coded using random number generator (https://www.random.org). 
Planimetry was conducted on coded sections (so that I was blind to the 
treatments to avoid any bias to any of the experimental groups) using the image 
analysis program Image J (version 1.48, National institute of Health, USA). 
Infarct size quantification included measuring the total ventricular area of the 
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heart (TVA, Evans’ blue and TTC stained areas), area at risk (AAR, Evans’ blue-
negative area), and the infarcted area (I, TTC-negative stained area) (Figure 
2.8). Infarct size was reported as a percentage of the area at risk (I/AAR %). 
 
 
Figure 2.6 Scanned image for the heart slices after being stained with 
triphenyltetrazolium chloride (TTC) and fixed for 24 hours in formalin. Non ischaemic 
tissue appears as blue area while the ischaemic bed is delineated by the brick-red colour. 
Infarcted tissue is indicated by the white colour. Area at risk (risk zone) includes the red 
and white areas. Sections were traced using an image analysis program (Image J) to 
calculate the total ventricular volume (i.e. left and right ventricles area), area at risk, 
and the infarcted area. These values were then converted into volumes by multiplying 
the total of each area by 0.2. Infarct size was reported as a percentage of the area at risk. 
 
 
Figure 2.7 Representative heart sections which have been excluded at the level of 
planimetry due to poor delineation between non-infarcted and infarcted areas within the 
AAR. 
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Figure 2.8 Representative dual staining technique with Evans’ blue and TTC. Both sides 
of each heart section were scanned using digital scanner then the planimetry was 
performed using ImageJ software. Total ventricular area (ischaemic and non-ischaemic 
area), area at risk (Evans’ blue negative area) and the infarction (TTC negative area) 
were quantified in cm after calibrating the software with the known scale roller scanned 
with each image. Area at risk was reported as a percentage of the total ventricular volume 
and the infarct size was expressed as a percentage of the area at risk. 
2.5 Inclusion/exclusion criteria 
In order to ensure that data were reproducible and to avoid any kind of bias 
between the experimental groups, strict criteria of inclusion/exclusion were 
followed. For each animal to be included and employed to the 
ischaemia/reperfusion protocol it had to achieve the haemodynamic parameters 
which were mentioned in section (2.3.4) during the stabilisation period. 
During ischaemia, the animal was excluded if there was no evidence of 
developed ischaemia after tightening the ligature, such as ST-segment 
elevation, change in the colour of the left ventricle. This could be either because 
the snare was not tight enough to restrict the blood supply through the left 
Area at risk 
Infarction
Non-Ischaemic 
tissue
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coronary artery or the ligature was not placed around the coronary artery. 
Moreover, the animal was excluded if ventricular fibrillation persisted for more 
than 2 minutes during ischaemia despite attempts to defibrillate it by gentle 
flicking of the heart. Exclusions also occurred where there was no evidence of 
reperfusion, such as reperfusion arrhythmia after releasing the snare, no change 
in the colour of the left ventricle. The animal was excluded if it died any time 
before the end of 120 minutes reperfusion. 
The heart was also excluded during analysis when either the area at risk was < 
30% of total ventricular area (AAR/TVA %); or when there was failure of staining 
due to either leaching of Evan’s blue dye to the area at risk or poor red/white 
contrast between the viable and infarcted tissues within the area at risk (Figure 
2.7). 
2.6 Protein level determination 
2.6.1 Myocardial tissue sampling 
The effects of different hydrogen sulfide (H2S) donors and a number of other 
pharmacological interventions on the phosphorylation of the RISK pathway 
kinases in the ischaemic tissue was evaluated as will be discussed in more detail 
in Chapters 5 and 6. Generally, all the treatments were given either during 
ischaemia or before reperfusion and the heart was reperfused for 5 minutes. The 
heart was quickly excised, washed with saline to remove blood residues and 
placed on glass surface where the base, including both atria, was removed 
(Figure 2.9). The right ventricle was isolated then the left ventricle was cut into 
two halves and each half was cut further divided in two as it is explained in Figure 
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2.7. Sections 1 and 3 were then collected together in 2 mL Eppendorf tube in 
order to reduce the possible variability in the infarcted area between the 
sections. Sections 2 and 4 were treated similarly. It is worth mentioning that 
these extra cuts, to some extent, could probably subject the tissue to some extra 
stress, however, it was almost equal across all experimental groups. Biopsies 
were then snap frozen in liquid nitrogen then stored at -80 ºC until required for 
Western blotting. The time of tissue preparation was 40-60 seconds. 
 
Figure 2.9 Schematic illustrating the heart sectioning for western blotting. The heart 
was excised after 5 minutes of reperfusion and washed with phosphate buffer saline to 
remove any remaining blood in the heart chambers. The base was separated and 
discarded, while the apex and the right ventricle were isolated and each of them was cut 
into 3-4 pieces and snap frozen. The left ventricle was cut in half and each half was cut 
in half again. The produced sections 1 and 3 were collected together, cut into 3-4 pieces 
and snap frozen until required for analysis. Sections 2 and 4 were treated similarly to 1 
and 3.  
Base
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2.6.2 Tissue homogenisation  
Tissue homogenisation was carried out at ice-cold temperature to maintain the 
integrity and stability of the kinases. Frozen myocardial biopsies (40-60 mg) 
were placed in 2 mL Precellys tube (Bertin, UK) with 200 µL lysis buffer, 20 µL 
phosphate inhibitor cocktail and 10 µL protease inhibitor cocktail. Samples were 
homogenised with 3 cycles of 20 seconds homogenisation period at (5500 rpm) 
using a Precellys 24 (Bertin, UK). Homogenate was recovered and centrifuged 
at 14000 rpm for 15 minutes at 4 ºC. The supernatant was then collected in 2 
mL Eppendorf tube and kept on ice. To prepare samples for Western blotting, 
the tissue homogenate (supernatant) was mixed with Laemmli buffer (2X-
concentrated) in 1:1 ratio and heated in a dry bath at 90 ºC for 10 minutes then 
stored at -20 ºC until required. 
2.6.3 Protein determination of myocardial samples 
Bicinchoninic acid (BCA) assay was used to determine the total concentration of 
proteins in the myocardial samples. This assay is based on the interaction 
between the peptide bonds with the alkaline copper media (Cu2+) medium. The 
product of this interaction is Cu+ ion which is chelated by two molecules of 
bicinchoninic acid, forming a purple complex (Smith et al., 1985). The amount of 
this complex is directly proportional to the protein concentration in the sample 
and can be measured using colorimetric techniques at 560 nm. Serial dilutions 
of bovine serum albumin were prepared (0, 0.125, 0.25, 0.5, 1, 2, 4, 8 mg mL-1) 
in lysis buffer and used to construct the standard curve. Standards and samples 
(10 µL) were loaded in duplicate onto a 96-well plate. Reagents A and B of 
PierceTM BCA protein assay kit were mixed in 50:1 ratio, according to 
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manufacturer’s instructions, and (200 µL) of the mixture was added to each well. 
The plate was incubated for 30 minutes at 37 ºC then the absorbance was 
measured at 560 nm using an ELISA reader (LT-5000MS, LabTech, UK). 
2.7 Western Blotting 
2.7.1 Protein Separation 
Protein samples were routinely separated using 10% w/v sodium dodecyl 
sulfate-polyacylamide gel (SDS-PAGE) using Mini-PROTEAN® Tetra Handcast 
system (Bio-Rad, UK). Handcasting was carried out by pouring the separating 
gel between two glass plates, which are fixed in a cassettes stand. A thin layer 
methanol was overlaid on the top of the gel to ensure that the top of the 
separating layer is flat and left to set for 20-30 minutes. Methanol was then 
decanted once the gel set and washed with distilled water. The stacking gel was 
then freshly prepared and added on the top of the separating gel before a well 
comb quickly inserted into it to create the protein loading lanes. The stacking gel 
was left to set for 15-20 minutes then the comb was gently removed. The created 
loading lanes were washed with tank buffer then the cassettes were placed in 
the electrode assembly which was then placed in the buffer tank. Protein 
samples were heated at 70 °C for 5 minutes before equal amounts (30 µg) from 
each sample were loaded in each well. A protein ladder (Precision Plus 
ProteinTM All Blue Standards, Bio-Rad, UK) was added to each gel to enable 
protein bands sizing. Electrophoresis of protein samples was carried out at 50 
mV for 15 minutes then at 120 mV for 2.5 hours in an ice bath.  
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2.7.2 Proteins blotting 
Once the proteins were separated, the cassettes were opened and the gels were 
removed and placed in transfer buffer. Nitrocellulose membrane (Amersham, 
Germany), two precut thick blot filter papers (Bio-Rad, UK) and two cotton pads 
were used to build each transfer sandwich. They were immersed in transfer 
buffer for 10 minutes before building the transfer sandwich to transfer the 
separated proteins. The separated proteins were transfer onto nitrocellulose 
membrane using a wet electrophoresis system (Mini Trans-Blot® Cell, Bio-Rad, 
UK). The transfer sandwich was built by placing a cotton pad on the cathode 
side of the gel holder cassette (Bio-Rad, UK) then a wet filter paper upon it. The 
nitrocellulose membrane was then place on the top followed the gel. Another 
filter paper was added upon the gel and any trapped air between the layers was 
removed by gently rolling a plastic rod on the top of the filter paper. Finally, the 
other cotton pad was placed on the top and the cassette was place the 
transferring Assembly. The assembly was placed in the transfer tank and the 
tank was filled with the transfer buffer. Proteins were transferred at 400 mA for 
90 minutes in an ice bath. 
2.7.3 Immunodetection 
The membrane was incubated with 5% skimmed milk on a gyratory rocker 
(Stuart Scientific, UK) for 2 hours. The rationale of this step is to block any 
nonspecific binding of the antibodies to the membrane surface. This will 
subsequently reduce the background signal that might appear when the protein 
bands are visualised on an X-ray film. In some cases, the membrane was cut 
horizontally with 20 kDa margin based on the molecular weight for the protein of 
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interest. This approach was used to allow the detection of different proteins with 
different molecular weights at the same. Nevertheless, the main disadvantage 
of cutting the immunoblot is that it prevents the detection of any other protein 
modifications which could be detectable by the primary antibody but appear 
outside the limited range of screened molecular weight. The transferred proteins 
were probed with a specific primary antibody, which is diluted with 1% TBST and 
1 % skimmed milk to a final volume of 1 mL, against each protein of interest 
overnight at 4 ºC on a roller mixer (Stuart Scientific, UK). The probed membrane 
was then washed 3 X 15 minutes with 1% TBST on a gyratory rocker to remove 
the unbound residues of primary antibody. Probed proteins were detected 
indirectly by probing the primary antibody with an enzyme-labelled secondary 
antibody. To do so, the immunoblot was transferred to a 50 mL Falcon tube and 
incubated with the secondary antibody. Secondary antibody was diluted with 1% 
TBST and 1% skimmed milk to a final volume of 15 mL. The probed membrane 
was incubated with the secondary antibody on a roller mixer for 1 hour at room 
temperature. The immunoblot was then washed three times with 1% TBST for 
15 minutes on a gyratory rocker to remove the excess and unbound secondary 
antibody. 
Protein bands were visualised using Enhanced Chemiluminescence (ECL) 
detection technique. The probed membrane was place on a polyethylene film in 
the developing cassette with the probed side of the membrane up. Solutions A 
and B of the chemiluminescent substrate kit (Super Signal West Dura Extended 
Duration Substrate, Pierce Biotechnology, UK) were mixed in 1:1 ratio, added to 
the probed side of the immunoblot and incubated for 5 minutes at room 
temperature. Chemiluminescent substrate produces photons as a by-product 
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when it is oxidised by the peroxidase. Protein bands were visualised on ECL 
Hyperfilm (GE Healthcare, Buckinghamshire, UK) placed against the 
immunoblot in a dark room for different exposure time to optimise the clarity of 
the developed film. The film was then developed using X-ray developer and fixer 
(Photo Imaging Systems, UK). The intensity of each band is directly correlated 
to the abundance of the protein on the immunoblot and ultimately, to its level in 
the harvested tissue.  
The developed film was scanned using a digital scanner (HP scanjet 4370, USA) 
and the images were coded using random number generator 
(https://www.random.org). Densitometry was conducted in a blinded fashion 
using Image J software. Phosphorylated and total protein bands were 
normalised to corresponding GAPDH bands as an internal control to minimise 
the intra-assay variability which might occur due to the protein loading variation 
in the same immunoblot. Nevertheless, it needs to be acknowledge that there 
might be some inevitable changes in GAPDH level as a metabolic enzyme due 
to ischaemia/reperfusion injury and that requires further investigation. Protein 
bands were then normalised to a “baseline sample”, which was a myocardial 
sample harvested from the left ventricle after 20 minutes of stabilisation and 
before the regional myocardial ischaemia, loaded at either side of each gel. The 
rational of normalising the protein bands to the baseline sample was to minimise 
the possible inter-assay variations which could occur due to difference in the 
exposure time for each developed x-ray film. 
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2.8 Statistical analysis 
Sample size for infarct size and mitochondrial studies was determined using R 
package for statistical analysis (R 3.3.3 version, www.stats.bris.ac.uk). Data 
were analysed using GraphPad software (Prism® 2007, Version 5.01). All 
numerical data were reported as arithmetic mean values ± standard error of the 
mean (SEM) and passed the Kolmogorov-Smirnov normality test of distribution 
except when the sample size was small (n=4). For small sample size (n=4), non-
parametric test (Kruskal-Wallis) was used as these data were not normally 
disturbed. Unless otherwise indicated, two-tailed student’s t-test was used to 
statistically compare between two experimental groups while one-way ANOVA 
followed by Newman Keuls post hoc test was employed for multiple comparison. 
Cardiodynamics, including mean arterial pressure (MAP) and rate pressure 
product (RPP), and mitochondrial data were analysed using repeated measures 
ANOVA followed by Bonferroni post hoc test. Differences between groups were 
considered significant if the p-value was <0.05. Post hoc tests were only carried 
out if p value <0.05 was achieved in the ANOVA. 
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Chapter 3 Experimental Model: Development and 
Validation 
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3.1 Introduction 
The in vivo model of myocardial ischaemia and reperfusion in the anaesthetized rat 
has been employed in this work. The rat has been used as a model of choice for 
cardiac ischaemia and reperfusion studies for more than four decades due to its 
relatively low cost compared to other species such as rabbits and dogs. Rat heart also 
has a negligible collateral circulation, which are minor blood vessels that can bypass 
the coronary vessel occlusion and provide adequate blood supply to the ischaemic 
area (Ytrehus, 2000, Ytrehus, 2006). In addition, it affords a high degree of 
standardization and repeated validation of the model in multiple laboratories confirms 
the homogeneity of response (Ytrehus, 2000, Ytrehus, 2006). Furthermore, it offers 
the possibility of measuring the cardiodynamics (for example: blood pressure, heart 
rate), cardiac electrophysiology and arrhythmias and assessment of therapeutic 
interventions (Hearse and Sutherland, 2000). The rat heart, however, has a major 
limitation which is its exceptionally short action potential duration that may influence 
electrophysiological assessments (Hearse and Sutherland, 2000). 
Myocardial ischaemia could be simulated in this model by occlusion of the LAD 
coronary artery to establish regional ischaemia in the left ventricle. Regional ischaemia 
is associated with ventricular tachycardia and ventricular fibrillation. The severity of 
ischaemia-induced arrhythmias varies depending on the position of the ligature and 
the duration of ischaemia (Clark et al., 1980, Curtis et al., 1987). This model also offers 
the possibility to simulate early reperfusion treatment as restoration of the blood supply 
to the ischaemic myocardium can be achieved by releasing the ligature around the 
coronary artery. Reperfusion is also associated with ventricular arrhythmias which can 
vary depending on the duration of preceding ischaemia and how successfully 
reperfusion was achieved.  
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The early phase of this work aimed to develop the model of myocardial 
ischaemia/reperfusion injury in anaesthetised rat for the first time in the Cardiff 
laboratory. Initially, preliminary studies were carried out to validate my surgical skills 
and to build confidence in having consistent area at risk and infarct size. Different 
periods of regional ischaemia were employed (20-40 minutes) aiming to induce 
reproducible area at risk (~ 50% of the total ventricular volume) and survivable infarct 
size (~ 50% of the area at risk). 
3.1.1 Aims  
The main aims of this study were to: 
1- Develop a model of ischaemia/reperfusion injury in anaesthetised rat with 
stable haemodynamics and reproducible myocardial infarction. 
2- Investigate the feasibility to produce and detect potential infarct limitation using 
ischaemic preconditioning as a positive infarct-limiting approach, to validate the 
model.  
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3.2 Materials and Methods 
3.2.1 Model development: preliminary study 
The preliminary study aimed to develop the in vivo model of myocardial 
ischaemia/reperfusion injury in anesthetised rat for the first time in Cardiff University. 
This series of experiments was used to validate the skills of the experimentalist in 
executing the surgical procedures and to ensure the reproducibility of data due to the 
complexity of this model.  
3.2.1.1 Experimental protocol 
In the preliminary series, rats underwent 30 minutes regional ischaemia and 120 
minutes of reperfusion after stabilisation period for 20 minutes (Figure 3.1). 
 
Figure 3.1 Experimental protocol for the preliminary study. After the surgical procedure, 
animals were stabilised for 20 minutes then subjected to 30 minutes coronary artery occlusion 
followed by 2 hours of reperfusion.   
 
3.2.2 Model validation: using ischaemic preconditioning 
An ischaemic preconditioning (IPC) manoeuvre was used, as a positive control, to 
validate the model of myocardial ischaemia/reperfusion injury in anaesthetized rat. IPC 
refers to brief episodes of ischaemia and reperfusion which render the myocardium 
more tolerant to acute myocardial infarction (see Chapter 1, section 1.4.1). This 
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manoeuvre is considered a gold standard cardioprotective intervention in the field of 
cardioprotection and has reproducibly protected the myocardium against 
ischaemia/reperfusion injury in all animal models and human studied hitherto (Murry 
et al., 1986, Schott et al., 1990, Liu et al., 1991, Yellon et al., 1993, Sumeray and 
Yellon, 1998). 
3.2.2.1 Experimental protocol 
During the stabilisation period and after meeting the inclusion criteria, animals were 
randomly assigned to one of the following groups (Figure 3.2): 
Group 1: Control (n=15). Animals received no intervention and were subjected to 30 
minutes of regional myocardial ischaemia followed by 120 minutes reperfusion. 
Group 2: IPC (n=10). Animals underwent 2 cycles of 3 minutes regional myocardial 
ischaemia/ 3 minutes reperfusion before the index regional myocardial ischaemia. 
 
Figure 3.2 Experimental protocol for the model validation study with ischaemic 
preconditioning (IPC). During stabilisation period, animals were received either no further 
intervention or 2 episodes of 3 minutes regional myocardial ischaemia followed by 3 minutes 
reperfusion. Animals in both groups were underwent 30 minutes regional myocardial 
ischaemia and 120 minutes reperfusion. 
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3.3 Results 
3.3.1 Preliminary study 
3.3.1.1 Inclusion/exclusion criteria 
In the preliminary experiments, a total of 44 rats underwent the ischaemia/reperfusion 
protocol. Twenty animals were excluded; 11 rats died before completion of the 
ischaemia/reperfusion protocol (8 animals due to VF during ischaemia and 3 animals 
because of ventilation failure); 2 animals due to problems with the ligature that led 
either to unsuccessful occlusion of the coronary artery or unsuccessful reperfusion; 7 
experiments were excluded during analysis due to poor delineation between the area 
at risk and the infarcted tissue. Therefore, data for 24 successfully completed 
experiments are reported in this study. 
3.3.1.2 The effect of coronary artery occlusion on cardiodynamics 
Baseline parameters and haemodynamics throughout the ischaemia and reperfusion 
protocol are presented in Table 3.1. RPP and MAP were reported at the baseline 
before occluding the coronary artery, at 20 minutes of ischaemia as it is the time of 
intervention and at the end of the reperfusion. Successful occlusion of the left coronary 
artery caused a gradual decrease in the mean arterial pressure (MAP) and rate 
pressure product (RPP) which continued until the end of ischaemia (Figure 3.3). The 
induced ischaemia caused an increase in the R wave amplitude (Figure 3.4A) and ST 
segment elevation (Figure 3.4B) with a particular pattern of arrhythmias. The onset of 
arrhythmias typically occurred 4 minutes after coronary occlusion and lasted until 
around 15 minutes of ischaemia. The types of arrhythmias were: ventricular premature 
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beats (VPBs, discrete premature, in relation to P-wave, QRS complexes, Figure 3.5), 
ventricular tachycardia (VT, run of four or more consecutive VPBs, Figure 3.6), and 
ventricular fibrillation (VF, signal from which individual QRS deflections cannot longer 
be distinguished, Figure 3.7). Mean arterial pressure [MAP, diastolic blood pressure + 
1/3 (systolic blood pressure/diastolic blood pressure)] and rate pressure product [RPP, 
heart rate X systolic blood pressure] initially recovered gradually during the early 
phase of reperfusion before declining toward the end of reperfusion. 
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Figure 3.3 Example of the cardiodynamics changes following the coronary artery occlusion (CAO). The x-axis represent the time (second).
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Figure 3.4 Examples of (A) the increase in R wave amplitude following coronary artery occlusion and (B) the ST-segment elevation. 
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Figure 3.5 Representative blood pressure (BP), heart rate (HR) and electrocardiography (ECG) traces during a single ventricular premature beat 
(VPB) that occurs during ischaemia/reperfusion protocol. The arrow indicates the time of the single VPB and the x-axis represent the time (0.5 
second).
Ventricular Premature Beat (VPB)
BP
HR
ECG
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Figure 3.6 Representative blood pressure (BP), heart rate (HR) and electrocardiograhy (ECG) traces during ventricular tachycardia (VT) that occurs 
during ischaemia/reperfusion protocol. The episode of VT is underlined by the dotted red line. The decrease in the heart rate during the episode of 
VT is an artefact as a result of measuring the heart rate based on the ECG trace by Labchart® software and it does not mean that there was a real 
drop in the heart rate during this period. The x-axis represent the time ( 0.5 second).
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HR
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Figure 3.7 Representative blood pressure (BP), heart rate (HR) and electrocardiograhy (ECG) records during ventricular fibrillation (VF) that 
occurs during ischaemia/reperfusion protocol. The episode of VF is underlined by the dotted red line. This record also shows how VF can 
spontaneously reverses to normal rhythm which is a common feature of this model in rat. The drop in the heart rate during ventricular fibrillation 
is an artefact as the Labchart® software was measuring the heart rate based on the ECG trace and it does not mean that the heart rate was almost 
zero during this period. The x-axis represent the time (second).
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HR
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Table 3.1 Baselines and haemodynamic measurements throughout ischaemia/reperfusion protocol for the preliminary series of experiments 
Experimental 
Protocol 
n BW (g) 
Baseline 20 min Ischaemia 120 min Reperfusion 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
Control 24 339 ± 11 42.3 ± 1.8 97 ± 4 28.9 ± 1.2 66 ± 3 18.0 ± 1.5 61 ± 5 
n number of animals per group; BW body weight; RPP rate pressure product; MAP mean arterial pressure. Data are reported as mean ± SEM. 
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3.3.1.3 Infarct data 
In the preliminary study, the area at risk (AAR/T %) for the 24 reported experiments 
was 60.6 ± 2.8 % of the total ventricular volume. Infarct size (I/AAR %) was 50.7 ± 2.6 
%, expressed as a percentage of area at risk. 
3.3.2 Model validation study with IPC 
3.3.2.1  Inclusion/exclusion criteria 
In IPC experiments, a total of 40 animals were used. Fifteen rats were excluded; 5 
died before the completion of ischaemia/reperfusion protocol (4 animals due to 
ischaemia-induced VF and one animal due to respiratory failure); 5 were excluded due 
to problems with the ligature that caused either unsuccessful occlusion of the left 
coronary artery or unsuccessful reperfusion; 5 were excluded during analysis due to 
poor staining. Therefore, data from 25 successful experiments are reported.  
3.3.2.2 The effect of IPC on cardiodynamics 
The baselines and changes in haemodynamic parameters of the model validation 
study with IPC are presented in Table 3.2. Statistical analysis showed no significant 
difference between groups for any of the baseline parameters. The two cycles of short 
ischaemia/reperfusion significantly caused a reduction in the pre-ischaemic MAP (67 
± 4 versus 93 ± 5, p<0.05) and RPP (32.1 ± 1.0 versus 40.1 ± 1.0, p<0.01). There was 
no significant difference in either MAP or RPP during ischaemia and at the end of the 
reperfusion phase between the experimental groups. The variation in RPP and MAP 
among the rats in each experimental group is shown in Figures 3.9 and 3.10. 
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Moreover, IPC manoeuvre limited ischaemia- and reperfusion-induced arrhythmia 
compared to the control (Figure 3.8).   
 
 
Figure 3.8 Examples of cardiodynamics (blood pressure, heart rate and ECG) for (A) the control 
and (B) preconditioned hearts at early reperfusion. There is a significant limitation in 
reperfusion induced arrhythmia in the early phase of reperfusion by IPC. The arrow indicates 
the time at which the ligature was released to commence the reperfusion phase for two hours. 
The x-axis represents the time (second).  
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Table 3.2 Summary of baseline parameters and haemodynamics throughout ischaemia-reperfusion injury protocol for Ischaemic preconditioning 
study 
Experimental 
Protocol 
n BW (g) 
Baseline 20 min Ischaemia 120 min Reperfusion 
SBP 
mmHg 
HR 
BPM 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
Control 15 403 ± 18 126 ± 13 318 ± 17 40.1 ± 1.0 93 ± 5 27.6 ± 1.3 63 ± 6 24.0 ± 0.9 48 ± 5 
IPC 10 453 ± 31 100 ± 15 321 ± 14 32.1 ± 1.0 * 67 ± 4** 25.3 ± 1.4 53 ± 7 25.5 ± 1.0 45 ± 4 
n number of animals per group; BW body weight; RPP rate pressure product; MAP mean arterial pressure; IPC ischaemic preconditioning. 
Data are reported as mean ± SEM. (Two way ANOVA with Bonferroni post hoc test), *p < 0.05, **p< 0.01 vs the control group.
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Figure 3.9 Comparison of (A) rate pressure product (RPP) and (B) mean arterial pressure (MAP) among the control group. The figure shows the 
possible variability in haemodynamics in the same experimental group when longitudinally paired. RPP and MAP were reported at the baseline, 20 
minutes of ischaemia and at the end of reperfusion.
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Figure 3.10 Comparison of (A) rate pressure product and (B) mean arterial pressure among ischaemic preconditioned rats. The figure illustrates the 
possible variability in cardiodynamics among the rats in the same experimental group when they longitudinally paired. RPP and MAP were reported 
at the baseline, 20 minutes of ischaemia and at the end of reperfusion.   
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3.3.2.3 Infarct size data 
IPC was used to validate the model’s potential for infarct size limitation in 
response to a gold standard cardioprotective manoeuvre. There was no 
significant difference in the area at risk between the experimental groups (Figure 
3.11C). Two cycles of 3 minutes ischaemia/3 minutes reperfusion applied before 
the index regional ischaemia (30 minutes) significantly limited the infarct size 
from 51.4 ± 6.5% to 16.8 ± 3.7% of the area at risk (p < 0.001, Figure 3.11D). 
This represents 67% limitation in infarct size. 
 
Figure 3.11 Infarct size data for the model validation study with ischaemic 
preconditioning (IPC). Representative heart sections for (A) Control (n=15) and (B) 
IPC group (n=10). Ischaemic preconditioning significantly limited the infarct size in the 
in vivo model of ischaemia-reperfusion injury. Heart was stained using Evans’ 
blue/TTC staining. (C) Area at risk is expressed as a percentage of the total myocardium 
and (D) the infarction is reported as a percentage of the area at risk. Data were analysed 
using unpaired student t-test and expressed as mean ± SEM, ***p<0.001 vs control. The 
mean of infarct size for each group is represented by a filled circle (with error bar) next 
to the individual values (open circles).   
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3.4  Discussion 
Rat has been employed extensively to characterise the pathophysiology of 
ischaemic heart disease. The rat model of myocardial ischaemia/reperfusion 
injury was first characterised by Johns and Olson in (1954). It has then become 
the model of choice (Curtis et al., 1987) to study myocardial infarction and 
associated arrhythmia during ischaemia and reperfusion. This model has 
several advantages over other animal models including simple instrumentation 
requited compared to the larger animals (Ytrehus, 2000). In addition, cannulation 
of the arterial and venous lines enables monitoring of arterial-venous differences 
throughout the ischaemia/reperfusion experiments, drug delivery and blood 
sampling compared to mouse model (Ytrehus, 2000). Rat model also affords the 
possibility to expose the heart either by left or mid-line thoracotomy to occlude 
the left coronary artery with minimum interventions compared to large animals 
(Hearse and Sutherland, 2000). Permanent occlusion of the rat left coronary 
artery has also been used to develop heart failure and study post-infarction 
modelling and inflammation (Qvigstad et al., 2005). Furthermore, rat heart also 
has a sparse collateral circulation (Maxwell et al., 1987) which is important for 
reproducible ischaemic area (risk zone) that determines the severity of 
arrhythmia and infarct size (Curtis et al., 1987). Therefore, a reperfusion phase 
is essential to study the infarct development and limitation (Ytrehus, 2006). 
Nevertheless, there are some limitations to the rat model which have to be 
acknowledge when compared to human. The rat considerably has a high heart 
rate compared to human. In addition, rat’s heart has a short action potential 
which means that there is a long inter-AP duration (i.e. prolonged phase 0). 
Taken together, these elements have a considerable impact on the incidence of 
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ventricular arrhythmias and the reversibility of ischaemia- and reperfusion-
induced VF. Furthermore, the heart size/body size is higher in rat compared to 
this ration in human. Transient ligation of the proximal left coronary artery for 30 
minutes followed by reperfusion leads to an infarct which is reported to be 40-
60% of the ischaemic area (are at risk) (Dillmann, 2008), which is in line with our 
results.  
Another characteristic feature of the in vivo rat model is the pattern of ischaemia- 
and reperfusion-induced arrhythmias which is similar to that seen in large 
animals (dog and pig) compared to other small animal models (mouse and 
rabbit) in terms of vulnerability and reversibility. Regional ischaemia induces a 
first phase of arrhythmias after 4-5 minutes which lasts up to 15 minutes of 
ischaemia; a second phase of arrhythmia after 1.5-2.5 hours of occlusion; and a 
third phase occurs after 24 hours (Clark et al., 1980, Curtis et al., 1987). In our 
study, the first phase of ischaemia-induced arrhythmias was experienced only. 
Reperfusion also induces even more severe arrhythmias in comparison with 
ischaemia-induced arrhythmias but over a short period (first 1-5 minutes of 
reperfusion). However, variability in the incidence of ventricular tachycardia 
(VT), ventricular fibrillation (VF) and mortality emphasises that researchers need 
to randomise control experiments parallel to the treated group aiming to 
minimise that variation and to avoid any possible bias (Hearse and Sutherland, 
2000).  
The preliminary series of experiments were used to optimise the in vivo model 
of myocardial ischaemia/reperfusion injury in terms of haemodynamic 
parameters, successful induction of ischaemia and reperfusion, achieving a 
survivable infarct size, and having sufficient delineation for infarct size 
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determination. Regional myocardial ischaemia was induced in 60.6 ± 2.8 % of 
the total ventricular volume of the heart. Ischaemia was established by a 
transient occlusion of the left coronary artery for 30 minutes and followed by 2 
hours of reperfusion. It should be acknowledged here that the AAR is relatively 
large which might have its implications on the resulted infarction. The incidence 
and pattern of VT and VF during ischaemia did not significantly vary with an 
onset 4-5 minutes that is consistent with others (Clark et al., 1980). Irreversible 
VF during ischaemia and shortly after 30 seconds of reperfusion was the main 
cause of death during ischaemia/reperfusion protocol. Myocardial infarction 
resulting from this protocol represented 50.7 ± 2.6 % of the area at risk which is 
consistent with other investigators using the same protocol (Wajima et al., 2006, 
Baker et al., 2007, De Paulis et al., 2013). Infarct size quantification was 
performed using a dual staining technique with Evans’ blue and 
triphenyltetrazolium chloride. This technique has been used routinely in 
myocardial infarction studies where regional myocardial ischaemia was induced. 
Indirect delineation of the ischaemic myocardium is performed by staining the 
non-ischaemic area with Evans’ blue to ascertain that the area at risk was similar 
between experimental groups (Black and Rodger, 1996). Infarcted tissue was 
then demarcated using TTC which precipitates as white particles in the dead 
(infarcted) tissue within the territories of the area at risk.   
Ischaemic preconditioning (IPC) is the first cardioprotective mechanical 
manoeuvre introduced by Murry et al (1986). In the canine model, Murry et al. 
(1986) reported that applying a series of ischaemic episodes before the onset of 
long ischaemia can render the heart more resistant to ischaemia/reperfusion 
injury. The cardioprotective effects of IPC were then demonstrated in different 
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animal models including rabbit (Liu et al., 1991), rat (Li and Kloner, 1993), mouse 
(Suveren et al., 2012), swine (Schott et al., 1990) and in human (Kloner and 
Yellon, 1994). Therefore, we utilised IPC in the second phase of this study as a 
positive control to validate the model and ascertain that the cardioprotection of 
IPC can be detected. Two cycles of 3 minutes ischaemia/3 minutes reperfusion 
before the index ischaemia caused a significant limitation in the infarct size by 
67%. It also showed a powerful antiarrhythmic effect on both ischaemia- and 
reperfusion-induced VT and VF. None of the preconditioned hearts suffered from 
VF during ischaemia in comparison to the control group. It is worth noting that 
this IPC protocol (2x3 min IPC cycles) is non-standard protocol and it is first time 
to report cardioprotection with this protocol in an in vivo rat model of myocardial 
ischaemia/reperfusion injury. Accordingly, it needs to be acknowledged that 
whether other IPC protocols could show similar cardioprotection is yet to be 
characterised. These results confirm that the established model can be used as 
a preclinical model and it is valid for screening potential cardioprotective agents. 
3.5 Conclusion 
These data show that the experimentalist had acquired the necessary skills to 
perform the surgical procedures required to establish the model of acute 
myocardial infarction in rat. The effects of IPC on haemodynamic parameters 
and infarct size were both detectable in our rat model. This demonstrates the 
validity of this model as a preclinical model to test the cardioprotection of any 
other potential targets or molecules. 
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Chapter 4 Investigating the potential infarct-
limiting effect of 2-mercaptoethanesulfonate 
(Mesna) against myocardial ischaemia/reperfusion 
injury in vivo 
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4.1 Introduction 
4.1.1 Mesna: 2-mercaptoethanesulfonate sodium 
The first clinical trial of Mesna was conducted in the early 1970s by UBC 
Pharmaceuticals to test its mucolytic efficacy for bronchial diseases (Figure 4.1). After 
successful results, it was launched as an inhaled dosage form (Mistabron®) in France 
for treatment of respiratory disorders such as cough and chronic bronchitis, especially 
for children. The free thiol group of Mesna is suggested to disrupt the disulfide bonds 
between the mucus glycoproteins, rendering the secretion less viscous and more 
readily able to be eliminated from the respiratory airways (Shaw and Graham, 1987). 
This suggested that the sulfhydryl group of Mesna is prerequisite for its activity. 
Intriguingly, it has also been shown that Mesna is a co-enzyme in bacterial 
methanogenesis and is responsible for methyl transfer (Taylor and Wolfe, 1974).  
 
 
Figure 4.1 Chemical structure of 2-mercaptoethanesulfonate sodium (Mesna). 
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In the early 1980s, Brock and colleagues carried out a comprehensive study to identify 
the causative agent of haemorrhagic cystitis during oxazophosphorine cancer 
therapy, notably with cyclophosphamide and ifosfamide. They later reported in their 
seminal paper that the main causative factor was the renal excretion of the two 
urotoxic metabolites of oxazophosphorine, namely 4-hydroxy-oxazaphosphorines 
and acrolein (Brock et al., 1981a). The level of GSH in urine is very low which makes 
the bladder and the efferent urinary ducts vulnerable for these reactive chemicals that 
are renally excreted. Brock et al. (1981b) then conducted a comparative study using 
different thiol–containing compounds as potential adjunct therapies to 
oxazophosphorines without interfering with the anticancer activity. This screening 
study was the first to report uroprotection by Mesna and showed that Mesna can 
interact with the urotoxic chemicals, by virtue of the free sulfhydryl group, forming a 
nontoxic compound. The anticancer activity of oxazophosphorines was not affected 
by co-administration of Mesna as the latter does not enter most of the body tissues 
and has a small volume of distribution (Brock et al., 1982). This unique 
pharmacokinetic profile endorsed the addition of Mesna to the standard regimen of 
oxazophosphorine therapy which was confirmed by later clinical trials (Brock and 
Pohl, 1983). Since then, Mesna has revolutionized the use of high doses of 
oxazophosphorines in cancer therapy by abolishing the main adverse effect (i.e. 
haemolytic cystitis). Moreover, it has been demonstrated that Mesna can also prevent 
the chronic nephrotoxicity as well as the acute urotoxicity (Kempf and Ivankovic, 
1987). Although it has small volume of distribution, Mesna has also shown potential 
to mitigate the systemic adverse effects of doxorubicin in vitro (Aluise et al., 2011). 
Another form of Mesna-induced uroprotection was first demonstrated by Mashiach et 
al. (2001) where they reported that Mesna can protect against acute renal failure in 
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rat through its antioxidant activity. They showed that a bolus dose of Mesna (180 mg 
kg-1, i.v.) 5 minutes before reperfusing ischaemic renal tissue restored 90-100% of 
glomerular filtration rate (GFR) with 75% improvement in the fractional sodium 
excretion (FENa). Later work by Kabasakal et al. (2004) demonstrated that Mesna 
protected the kidney against renal ischaemia/reperfusion injury via enhancing 
endogenous antioxidant capacity to attenuate the oxidative stress. Similarly, Sener et 
al. (2004) found that Mesna restored the GSH level and reduce the oxidative stress-
induced damage in a rat model of burn-induced renal injury. The antioxidant effect of 
Mesna has also been tested against other types of ischaemia/reperfusion injury. 
Ypsilantis et al. (2006) reported that pre-ischaemia Mesna therapy protected the 
intestinal mucosa against intestinal ischaemia/reperfusion injury in a time-dependant 
manner. In addition to being directly antioxidant, later work by Ypsilantis’s group 
(Ypsilantis et al., 2008) showed that Mesna could indirectly inhibit oxidative stress by 
targeting NF-КB, which is involved in the inflammatory and immune responses, and 
inhibiting its activity following intestinal ischaemia/reperfusion. They also reported that 
a bolus dose of Mesna (400 mg kg-1, i.p.) ameliorated the peritoneal puncture-induced 
oxidative stress in other splanchnic organs (stomach, liver, and kidney) in a rat model 
(Ypsilantis et al., 2009b). The protective effect of Mesna was also investigated against 
hepatic ischaemia/reperfusion injury. Sener and colleagues (Sener et al., 2005b) 
showed that administration of two bolus doses of Mesna (150 mg kg-1, i.p.), one before 
ischaemia and the other at reperfusion, can improve hepatic function and structure by 
reducing the tissue damage in a rat model of hepatic ischaemia/reperfusion mediated 
via its antioxidant action. Later work by Ypsilantis’s group (2009a) reported that 
Mesna also protected the liver against the anti-mitotic effect of Pringle-manoeuvre, 
inducing hepatic ischaemia by interrupting the blood flow through the hepatic artery 
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and the portal vein, by suppressing the activity of NF-КB and scavenging of generated 
ROS. Interestingly, the protective effects of Mesna have also been shown in other 
pathologies. For instant, Shusterman et al. (2003) demonstrated that intrarectal 
administration of Mesna was protective against trinitrobenzene sulfonic acid-induced 
colitis in rat. 
To our best knowledge, the first work investigating the potential cardioprotective 
action of Mesna against myocardial ischaemia/reperfusion injury was carried out in 
our laboratory in 2009, by David Elsey (Elsey, 2009). Elsey was exploring the 
cardioprotective properties of hydrogen sulfide (H2S). As a part of his PhD work, 
Mesna was selected for comparison as an alternative sulfhydryl-containing compound 
and potentially a donor of H2S. He reported a significant reduction in infarct size when 
Mesna (50 µM) was perfused through the heart either pre-ischaemically or at 
reperfusion in an isolated buffer-perfused rat heart preparation. Further mechanistic 
study revealed that the cardioprotection established by Mesna was abrogated in the 
presence of the PI3K inhibitor, LY294002, suggesting that Mesna’s cardioprotection 
might be mediated by triggering the RISK pathway.  
In view of the significant contribution of oxidant stress to the development of lethal 
reperfusion injury and the preceding evidence suggesting that Mesna ameliorates 
oxidant stress, we sought to characterise the potential protective effect of Mesna as 
an adjunct to reperfusion against myocardial ischaemia/reperfusion injury in vivo. 
These studies are important because Mesna represents a drug with potential to be 
repurposed for clinical use as an adjunct to PPCI. 
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4.1.2 Aim 
The aims of this study were to: 
1. Test for the first time the cardioprotection of Mesna at early reperfusion when 
given specifically as an adjunct to reperfusion in an in vivo rat model of acute 
myocardial infarction.  
2. Elucidate the mechanism of Mesna’s cardioprotection in the early phase of 
reperfusion. 
4.1.3 Hypotheses 
We hypothesised the following: 
1- Mesna will limit ischaemia/reperfusion injury when given just prior to 
reperfusion, thereby limiting ultimate infarct size. 
2- The cardioprotective effect of Mesna is dependent on triggering the RISK 
pathway, namely PI3K/Akt and eNOS, at the commencement of reperfusion. 
4.1.4 Objectives 
The aforementioned hypotheses were tested with the following specific experimental 
objectives: 
1- Establish a dose-response study to determine the optimum cardioprotective 
dose of Mesna using an in vivo rat model of acute myocardial infarction. 
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2- Assess the phosphorylation of the key kinases and effector proteins of the 
RISK pathway, namely Akt, eNOS, GSK-3β and ERK1/2, at the first minutes of 
reperfusion using Western blot analysis. 
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4.2 Materials and Methods 
4.2.1 Animals  
Male Sprague Dawley rats, 300-350 g (9-11 weeks old), were sourced from Harlan, 
UK and used for Mesna study. Animals handling, housing and reporting are all 
explained in Chapter 2, section 2.2.  
4.2.2 The in vivo rat model of myocardial ischaemia/reperfusion injury 
Rats underwent 30 minutes of myocardial ischaemia and 2 hours reperfusion to 
induce survivable infarct size as described in Chapter 2, section 2.3. Infarct size 
determination was performed using dual staining with Evans’ blue/TTC staining 
technique as described in Chapter 2, section 2.4. 
4.2.3 Treatment protocols 
4.2.3.1 Mesna dose-response study 
This series of experiments was carried out to investigate the potential infarct-sparing 
effect of Mesna. A dose-response study was undertaken using different dosing 
regimens at different time points throughout the ischaemia/reperfusion protocol 
(Figure 4.1). Animals were subjected to 30 minutes regional myocardial ischaemia 
and 120 minutes reperfusion. Rats were randomised to receive one of the following 
treatments:  
Group 1: Control (n=10). Animals received saline as a bolus dose 5 minutes before 
reperfusion. 
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Group 2: Mesna pre-ischaemia infusion (800 mg kg-1) (n=8). After 10 minutes 
stabilisation, animals received Mesna (200 mg kg-1) as a bolus loading dose followed 
by intravenous infusion of Mesna (20 mg kg-1min-1, i.v.) until the first 20 minutes of 
ischaemia (total dose = 800 mg kg-1). 
Group 3-5: Mesna pre-reperfusion bolus (1, 10, 100 mg kg-1, i.v.) (Each group n=8) 
received a bolus dose of Mesna (1, 10,100 mg kg-1) 5 minute before reperfusion. 
Group 6: Mesna post-ischaemia infusion (1100 mg kg-1) (n=8). Rats received a bolus 
loading dose of Mesna (200 mg kg-1) at 15 minutes of ischaemia followed by 
intravenous infusion (20 mg kg min-1, i.v.) until 30’ minute of reperfusion (total dose = 
1100 mg kg-1). 
 
 
Figure 4.2 Treatment protocol for Mesna study. All hearts were subjected to regional 
ischaemia by tightening the snare around the left coronary artery. By releasing the snare, 
reperfusion was induced for 90-120 minutes following 30 minutes of ischaemia. Arrows and 
lines indicate the time of pharmacological interventions. n=8-10. 
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4.3 Results 
4.3.1 Inclusion/exclusion criteria 
In the dose-response study, 58 rats were employed, of which six did not successfully 
complete the ischaemia/reperfusion protocol and two were excluded due to failure in 
staining. Therefore, results of 50 successfully completed experiments were reported. 
4.3.2 Effect of Mesna on cardiodynamics 
There were no significant differences between the baseline parameters between 
experimental groups as can be seen in Table 4.1. Administration of Mesna in different 
doses of Mesna (1, 10, 100 mg kg-1) as a bolus at 25 minutes of ischaemia showed 
no significant change in any of the haemodynamic parameters. However, Mesna (10 
mg kg-1) improved both RPP and MAP at the end of reperfusion but did not reach a 
statistical significance. The pre-ischaemia dosing regimen with Mesna caused a 
significant drop in both MAP and RPP by 30% compared to the control group. RPP 
transiently improved toward the end of ischaemia while the MAP was significantly 
lower by 26% at 20 minutes of ischaemia compare to the control. Similarly, 
postischaemia dosing of Mesna resulted in a decrease in both MAP and RPP that 
continued till the end of reperfusion.  
4.3.3 Infarct size data 
There was no significant difference in the area at risk (AAR) between the experimental 
groups where AAR of the control group represented (53.9 ± 2.7%) of the total 
ventricular volume of the heart (Figure 4.3A). Application of Mesna 5 minutes before 
Chapter 4 
110 
reperfusion did not have a significant effect on infarct size (Figure 4.3B). Moreover, 
neither pre-ischaemic nor post-ischaemic infusion of Mesna exerted a detectable 
effect on the myocardial infarction compare to the control group. 
In the view of the failure to identify any cardioprotective dose of Mesna, no further 
mechanistic studies (Objective 2) were undertaken. 
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Table 4.1 Summary of the baseline parameters and haemodynamics throughout ischaemia/reperfusion injury protocol for dose-response study of 
Mesna 
Experimental Protocol 
n BW (g) Baseline 20 min Ischaemia 120 min Reperfusion 
  RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
Control 10 363 ± 10 45.9 ± 1.4 100 ± 4 28.5 ± 1.7 64 ± 4 25.6 ± 1.8 56 ± 4 
Mesna pre-ischaemia 
infusion (800 mg kg-1) 
8 359 ± 6 32.1 ± 2.6 *** 71 ± 5 *** 21.4 ± 1.6 47 ± 3 * 19.0 ± 2.0 * 42 ± 4 * 
Mesna pre-reperfusion 
bolus (1 mg kg-1) 
8 378 ± 12 43.1 ± 0.8 99 ± 4 28.0 ± 1.5 63 ± 8 22.1 ± 1.4 48 ± 6 
Mesna pre-reperfusion 
bolus (10 mg kg-1) 
8 346 ± 6 46.4 ± 0.3 102 ± 1 31.5 ± 1.1 75 ± 5 27.9 ± 0.7 63 ± 3 
Mesna pre-reperfusion 
bolus (100 mg kg-1) 
8 345 ± 7 41.7 ± 1.2 93 ± 7 26.9 ± 1.3 61 ± 6 23.4 ±0.8 47 ± 3 
Mesna post-ischaemia 
infusion(1100 mg kg-1) 
8 377 ± 9 47.2 ± 2.2 105 ± 5 28.9 ± 3.0 65 ± 5 18.2 ± 4.2 * 40 ± 7 * 
n number of animals per group; BW body weight; RPP rate pressure product; MAP mean arterial pressure. Data are presented as mean ± 
SEM and analysed using Two way ANOVA test with Bonferroni post hoc test, *p < 0.05, ***p<0.001 vs control.  
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Figure 4.3 Summary of infarct size measurements for Mesna dose-response study. (A) Area at risk was expressed as a percentage of the total 
ventricular area and (B) infarct size was reported as a percentage of the area at risk. There was no significant difference between groups (p value 
> 0.05). Data were presented as a mean ± SEM and analysed using one-way ANOVA. The mean of infarction for each group is represented a 
filled circle (with error bars) nest to the individual values (open circles). 
0
10
20
30
40
50
60
70
80
A
re
a
 a
t 
R
is
k
(%
 o
f 
th
e
 t
o
ta
l 
v
e
n
tr
ic
u
la
r 
a
re
a
)
0
10
20
30
40
50
60
70
80
In
fa
rc
t 
S
iz
e
(%
 o
f 
th
e
 a
re
a
 a
t 
ri
sk
)
A B
Chapter 4 
113 
4.4  Discussion 
Mesna has been used for almost four decades as an adjunct antioxidant therapy 
to prevent haemolytic cystitis induced by particular chemotherapy agents such 
as the oxazaphosphorines, cyclophosphamide and ifosfomide. It also elicits 
protection against different types of ischaemia/reperfusion injury in kidney, liver 
and intestine. Elsey was the first to show cardioprotection by Mesna against 
myocardial ischaemia/reperfusion injury in Langendorff perfused rat heart. In 
that work, Mesna showed infarct limitation when perfused before the onset of 
ischaemia or at reperfusion. Interestingly, the latter effect was abrogated by 
PI3K inhibitor, suggesting that Mesna mediates its protection by activating the 
RISK pathway. The next step was naturally to test Mesna cardioprotection in an 
in vivo model of myocardial ischaemia/reperfusion injury as a necessary step for 
further development. A series of dose-response experiments were conducted to 
determine the optimum dose with infarct size measurement as an end-point of 
interest. The dose range was estimated according to Elsey’s work and the 
pharmacokinetic profile of Mesna (Verschraagen et al., 2004). Mesna was 
administered across a wide dose range: (1) 10 minutes before ischaemia (200 
mg kg-1 as a bolus) followed by IV infusion (20 mg kg-1 min-1) till 20 minutes of 
ischaemia, (2) as a bolus of 1, 10, 100 mg kg-1 at 25 minutes of ischaemia, (3) 
at 15 minutes of ischaemia as a bolus (200 mg kg-1) followed by IV infusion (20 
mg kg-1 min-1) till 30 minutes of reperfusion. Mesna showed no infarct-limiting 
effect with any of the dosing schedules (p-value > 0.05).  
The first reason for the absence of any cardioprotective effect by Mesna in vivo 
might be the short plasma half-life of Mesna (~17 minutes) (Shaw and Graham, 
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1987). It has been reported that Mesna is almost immediately oxidised into its 
disulfide form (dimesna, Figure 4.4) once it enters the circulation by a metal-
dependent reaction (Shaw and Graham, 1987, Yilmaz et al., 2013). Alternatively, 
Mesna could also interact with endogenous thiol-containing compounds such as 
cysteine (a precursor for GSH) forming cysteine-Mesna complex, enhancing the 
excretion of cysteine in the urine. This has been detected in animals (Wright et 
al., 1985) and human (Duran et al., 1981, Sidau and Shaw, 1984, Jones et al., 
1985), causing GSH depletion (Smith et al., 2003a). The two sulfonate groups 
and large size of dimesna make it difficult to enter most cells, with a small volume 
of distribution estimated to be 0.3 L kg-1 (Shaw and Graham, 1987). Collectively, 
these inactivation reactions are beneficial for the use of Mesna as an adjunct to 
neoplastic therapies because it limits its potential interference with their 
anticancer activities as they both travel through the blood to reach their targets. 
However, this could limit the antioxidant activity of Mesna in other tissues which 
lack the ability to retrieve Mesna from dimesna in vivo. The cell permeability of 
Mesna has also been questioned due to its high hydrophilicity which possibility 
hinders passive crossing through the hydrophobic cellular membranes. It is also 
emphasises that its absorption into the cell might need a carrier system similar 
to what is happening in the kidney (Shaw and Graham, 1987). 
  
Chapter 4 
115 
 
 
Figure 4.4 The oxidation of Mesna to dimesna in the circulation. 
 
Taken together, these findings lead us to propose that the auto-oxidation of 
Mesna into disulfide forms in vivo limits antioxidant activity of Mesna only to the 
tissues which are able to retrieve Mesna from its inactive forms. This proposed 
model in fact can explain the majority of protective effect which have been 
associated with Mesna therapy. For example, it has been proposed that 
hepatocytes are not able to reuptake dimesna or reduce it to Mesna (Ormstad 
et al., 1983). However, later work by Goren et al. (1998) demonstrated that 
isolated liver has a glutathione-dependent capability of reducing perfused 
dimesna to Mesna. This evidence suggests that hepatoprotection established 
by Mesna treatment against ischaemia/reperfusion injury reported by a number 
of investigators (Sener et al., 2005a, Sener et al., 2005b, Ypsilantis et al., 2009a) 
could have been mediated by the retrieved Mesna in the liver. Similarly, a 
compelling body of evidence suggests that renal tubular epithelium can 
efficiently reuptake dimesna from the circulation and reduce it back to Mesna via 
cytosolic thiol transferase and GSH reductase to be finally excreted in the urine 
(Ormstad et al., 1983, Shaw et al., 1986). The capacity could arguably elucidate 
the urothelial protection elicited by Mesna against renal ischaemia/reperfusion 
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injury (Mashiach et al., 2001, Sener et al., 2004, Kabasakal et al., 2004). Oral 
dose of either Mesna or dimesna can be absorbed by the intestine epithelium 
where dimesna can be reduced and enter the blood as Mesna in similar manner 
to the renal reuptake. Accordingly, the availability of free sulfhydryl form of 
Mesna in the intestine could possibly be responsible for the observed antioxidant 
activity of Mesna therapy in different forms of intestinal ischaemia/reperfusion 
injury (Ypsilantis et al., 2006, Ypsilantis et al., 2008, Ypsilantis et al., 2009b). It 
should also be mentioned here that this capacity of intestinal endothelium to 
retrieve Mesna from dimesna can explain the reduction in intestinal inflammation 
with intrarectal injections of Mesna in the study of (Shusterman et al., 2003). 
Conceivably, this could also be the case with Elsey’s work in Langendorff 
perfused heart model of myocardial infarction. In that model, the heart was 
perfused with Krebs-Henseleit buffer containing Mesna (50 µM). Therefore, it 
seems very plausible that cardioprotection established by Mesna ex vivo was 
elicited by the active form of Mesna as it is stable in diluted solutions and only 
oxidises to dimesna in negligible quantity over a long period of time (Goren et 
al., 1991). Arguably, this could explain the reason why Mesna did not show a 
comparable cardioprotection in the in vivo model as it might be oxidised to its 
inactive dimesna and lost its efficacy when injected directly into the circulation. 
In line with these results, it is plausible to suggest that the observed anti-
inflammatory effect of locally applied Mesna solution against experimental colitis 
reported by Shusterman et al. (2003) is also conferred by the active form of 
Mesna. Intriguingly, Yilmaz et al. (2013) reported that Mensa treatment given 
intraperitoneally at the time of traumatic brain injury did not effectively either 
mitigate oxidative stress or attenuate cell injury. Whether this failure was due to 
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the inactivation of Mesna in the blood which limited its antioxidant activity needs 
further investigation.     
4.5 Study limitations 
The main focus of this study was to characterise the potential cardioprotection 
of Mesna using an in vivo rat model of ischaemia/reperfusion injury. Since there 
was no significant effect of Mesna on myocardial infarction, a number of aspects 
have not been addressed here and need further investigation in future studies. 
The concentrations of Mesna and its disulfide form have not been measured in 
this study. The lack of sensitive probes or assay to selectively detect and 
differentiate between exogenous and endogenous thiol-containing compounds 
still represents a major challenge in measuring the plasma concentration of 
Mesna following administration and to estimate the rate of its conversion to 
Dimesna. Therefore, the pharmacokinetic profile of Mesna is yet to be fully 
elucidated.  
4.6 Conclusion 
In summary, Mesna represented a potential drug to be re-purposed clinically as 
adjunct to PPCI because it is a licenced, effective, well-tolerated and 
inexpensive drug. Previous studies by our group showed an infarct-limiting effect 
of Mesna in isolated rat heart that was, at least in part, related to triggering the 
RISK pathway at early reperfusion. We could not show cardioprotection with 
Mesna in vivo in term of infarct size reduction. We speculate that this could be 
due to its pharmacokinetic profile and its rapid auto-conversion to an inactive 
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disulfide form (i.e. dimesna) which limited its ability to enter most cells and 
enhance its clearance from body. 
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5.1 Introduction 
Hydrogen sulfide (H2S) has attracted considerable interest as a cardiovascular 
autacoid (see Chapter 1, section 1.6). Although produced endogenously within the 
myocardium and coronary vasculature (Liu et al., 2012, Hackfort and Mishra, 2016), 
in coronary artery disease, there may be reduced H2S production (Yong et al., 2008, 
Han et al., 2015, Islam et al., 2015). The administration of exogenous H2S donor 
compounds or increasing endogenous production of H2S has been well documented 
to reduce ischaemia/reperfusion injury in experimental models (Elrod et al., 2007, 
Calvert et al., 2009, King et al., 2014). There is also evidence that H2S is a mediator 
of IPost (Bian et al., 2006, Yong et al., 2008, Huang et al., 2012, Das et al., 2015). 
However, potential therapeutic extrapolation of this knowledge has been hindered by 
the limitations of H2S donor compounds. Much of the experimental literature has 
reported studies with inorganic sulfide salts (Na2S and NaHS) which are impure in 
commercial form and unstable. Despite them being water soluble and inexpensive, a 
particular issue is that the H2S release is largely uncontrollable as the salts dissociate 
in aqueous medium instantly to generate H2S at high concentration in a short-lasting 
burst (Papapetropoulos et al., 2015). However, these salts have helped in exploring 
the biological activities of H2S.  
5.1.1 GYY4137: a slow-releasing hydrogen sulfide (H2S) donor 
There have been a number of attempts to develop new thiol-containing compounds 
capable of acting as H2S donors, to overcome the drawbacks of sulfide salts, aiming 
to deliver a stable and controllable level of H2S to the cellular targets. GYY4137 
(morpholin-4-ium 4-methoxyphenyl-morpholino-phosphinodithioate, Figure 5.1) was 
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the first water soluble H2S donor reported to release H2S at a slow steady rate at 
physiological pH and temperature that was characterised in vitro and in vivo (Li et al., 
2008). Before that, GYY4137 was initially developed as an accelerator in the 
vulcanisation of natural rubber late in the 1950s (Rose et al., 2015). The H2S release 
profile of GYY4137 has been characterised using different methods including 
fluorescence HPLC (Shen et al., 2012), H2S selective polargraphic electrode (Kolluru 
et al., 2013) and using fluorescence probe 2,6-dansyl azide and 5,5’-dithiobis(2-
nitrobenzoic acid) (Qabazard et al., 2014).  
 
Figure 5.1 GYY4137 chemical structure (morpholin-4-ium 4-methoxyphenyl-morpholino-
phosphinodithioate). 
5.1.2 The biological activity of GYY4137 
Among the number of newly introduced and developed donors of H2S, GYY4137 is 
the best characterised and studied compound hitherto in term of the mode of H2S 
generation and biological activity (summarised in Table 5.1). The release of H2S from 
GYY4137 occurs through a hydrolysis pathway of two-steps; first with a direct sulfur-
oxygen exchange to produce a molecule of H2S and arylphosphonamidothioate. The 
second step, which is relatively slower, involves another exchange to produce H2S 
and arylphosphonate (Alexander et al., 2015). Li et al. (2008) first investigated the 
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vasodilatory effect of GYY4137 in rat aortic ring. They demonstrated a long-lasting 
vasodilatory response to GYY4137 which was mediated through opening of KATP 
channels. Using the same model, subsequent work by Bucci et al. (2012) showed that 
GYY4137-induced vasodilatation of aortic ring in a PKG-independent manner. 
Similarly, Chitnis et al. (2013) found that relaxant effect of GYY4137 mediated 
independently on eNOS signalling in bovine posterior ciliary artery. However, it has 
been suggested that GYY4137-released H2S possibly interacts with NO to generate 
thiol-sensitive compound which exerts positive inotropic effect in rat cardiomyocytes 
(Yong et al., 2011). Interestingly, chronic treatment with GYY4137 reduced the blood 
pressure in normotensive rats and to a greater extent in SHRs (Li et al., 2008). A part 
from its actions on vascular smooth muscle, it has also been shown that GYY4137 
mediates muscle relaxation on other nonvascular smooth muscles including human 
myometrium (Robinson and Wray, 2012) and primary human airway (Fitzgerald et al., 
2014) through the opening of ATP-sensitive K+ channels. Other beneficial effects of 
GYY4137 on the cardiovascular system have been demonstrated including 
antithrombotic activity by inhibiting platelet activation in mouse (Grambow et al., 2014); 
anti-atherosclerotic action in apolipoprotein knockout mice fed with high fat diet (Li et 
al., 2013); and mitigated fibrosis progression in myocardial pathologies (Meng et al., 
2015b, Lin et al., 2016).  
The activity of GYY4137 therapy in cardiac pathologies has also been tested. It has 
recently been reported that GYY4137 therapy for 7 days following permanent ligation 
of the left descending coronary artery preserved cardiac contractility and attenuated 
remodelling via increased natriuretic peptide (ANP and BNP) release in rat 
myocardium (Lilyanna et al., 2015). Moreover, pre-ischaemia GYY4137 treatment for 
seven days elicited infarct limitation against myocardial ischaemia/reperfusion in vivo 
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by enhancing the expression of Bcl-2 and inhibiting the activity of MAPK, caspase-3 
and Bax (Meng et al., 2015a). However, the therapeutically relevant time window for 
acute myocardial infarction implies administration as a postconditioning mimetic i.e. 
immediately prior to reperfusion since this is the time at which clinical therapeutic 
intervention can feasibly be made.  
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Table 5.1 Summary of the experimental studies using the slow-releasing hydrogen sulfide donor, GYY4137, listed in chronological order 
Reference Experimental model(s) Main observed effect(s) Mechanism(s) 
Li et al. (2008) Rat aortic ring, perfused rat kidney 
and anaesthetised rat 
- Vasodilator and 
antihypertensive  
- Opened the vascular smooth muscle KATP 
channels 
Li et al. (2009) Lipopolysaccharide (LPS)-induced 
endotoxic shock in rat 
- Anti-inflammatory - Inhibited LPS-induced TNF-α production 
and increased IL-10 in rat blood 
- Decreased the LPS-evoked rise in lung 
myeloperoxidase activity and upregulation 
liver transcription factors (NF-КB and 
STAT-3) 
Lee et al. (2011) Human cancer cell lines and 
Xenograft study in mouse 
- Pro-apoptotic and cell 
cycle arrest 
- Enhanced the generation of cleaved PARP 
and cleaved caspase 9. 
- Partial G2/M arrest 
Yong et al. 
(2011) 
Rat cardiomyocytes - Positive inotropic 
effect 
- Interaction with nitric oxide to generate 
thiol-sensitive compound  
Bucci et al. 
(2012) 
Phenylephrine-contracted mouse 
aortic ring 
- Vascular smooth 
muscle relaxation 
- PKG-independent mechanism 
Robinson and 
Wray (2012) 
Human and rat myometrium - Smooth muscle 
relalxation 
- opening of KATP-channels  
Fox et al. (2012) Primary human articular chondrocyte 
and mesenchymal progenitor cells 
- Cytoprotection - Unknown 
Chitnis et al. 
(2013) 
Phenylephrine-contracted bovine 
posterior ciliary artery 
- Vascular smooth 
muscle relaxation 
- The activity was dependent on endogenous 
production of both prostanoids and H2S 
and mediated by KATP channels with no role 
of either CBS or eNOS.   
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Li et al. (2013) Human synoviocytes and articular 
chondrocytes and Complete Freund’s 
adjuvant (CFA) model of acute joint 
inflammation in mouse 
- Pro-inflammatory 
when given before 
CFA 
- Anti-inflammatory 
when administrated 
after CFA 
- Inhibited TNF-α, IL-1β, IL-6 and IL-8. 
Lencesova et al. 
(2013) 
HeLa cell - Pro-apoptotic - Upregulated the expression of IP3R1 and 
IP3R2 on both mRNA and protein levels 
- Increased cytosolic Ca2+ and depleted 
reticular Ca2+ in concentration dependent 
manner 
- Increased endoplasmic reticulum stress 
markers, such as X-box, CHOP and ATF4  
Liu et al. (2013b) High fat fed apolipoprotein (ApoE-/-) 
mice 
- Anti-atherosclerotic - Abrogated TNF-α, ICAM-1and IL-6 
expression and activated aortic Akt and 
eNOS  
Grambow et al. 
(2014) 
Platelets activation and venular 
thrombus formation 
- Anti-thrombotic - Increased S-sulfhydration of platelet 
proteins 
- Reducted TRAP-induced adhesion molecule 
expression 
Fitzgerald et al. 
(2014) 
Primary human airway smooth 
muscle 
- Smooth muscle 
relaxant 
- Opened sarcolemmal KATP channels 
Wei et al. (2014) Diabetic cardiomyopathy in H9c2 
cells 
- Cytoprotection - Activated AMPK/mTOR signalling pathway 
Burguera et al. 
(2014) 
Human chondrocytes - Anti-inflammatory 
and anti-catabolic 
- Reduced the activation of NF-КB by 
inhibiting IL-1β signal 
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Lu et al. (2014) Human hepatocellular carcinoma cell 
line and subcutaneous HepG2 
xenograft model 
- Anti-cancer - Inhibited STAT3 phosphorylation and 
altered its downstream proteins including 
Bcl-2, Mcl-2, VEGF, surviving, HIF1-α and 
cyclin D1  
Lee et al. (2014) Human cancer cell and normal cell - Selective anti-cancer - Increased lactate accumulation and impair 
cellular pH regulation mechanisms, leading 
to metabolic acidosis 
Wang et al. 
(2015) 
Neck model of itch in mice - No scratching 
behaviour induced 
compare to NaHS  
- Unknown 
Meng et al. 
(2015b) 
Spontaneous hypertensive rat  - Anti-fibrotic - Inhibited oxidative stress, TGF-β1/Smad2 
pathway and α–SMA expression 
Lilyanna et al. 
(2015) 
Acute myocardial infarction model in 
rat 
- Cardioprotection 
when GYY4137 was 
given pre-ischaemia 
- Activated endogenous natriuretic peptide 
(ANP and BNP) at early post-ischaemic 
phase 
Meng et al. 
(2015a) 
Acute myocardial infarction model in 
rat 
- antioxidant and anti-
apoptosis when 
GYY4137 was given 
pre-ischaemia 
- Suppressed MAPK phosphorylation, 
activity of caspase-3 and expression of Bax, 
while increased the expression of Bcl-2 in 
the myocardium 
Wu et al. (2015) Coxsackie virus B3-induced 
myocarditis in rat-derived 
cardiomyocytes 
- Anti-inflammatory - Suppressed NF-КB and MAPK signalling 
pathway 
Kubickova et al. 
(2016) 
Cholinergic neuronal cell line - Differentiating factor - Unknown  
Lin et al. (2016) Unilateral ureteral obstruction model 
in rat 
- Anti-fibrotic  - Attenuated TGF-β1 and ANGII mediated 
mechanism of fibrosis  
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Chen et al. 
(2016b) 
Patients with spinal cord 
ischaemia/reperfusion injury and 
TNF-α-stimulated neural human cell 
lines (AGE1.HN and SY-SH5Y) 
- Anti-apoptotic - Reduced serum TNF-α and, consequently, 
suppressed the activity of miR-485-
5p/TRADD axis 
Chen et al. 
(2016a) 
Mouse model of endotoxemia - Cytoprotective - Inhibited the elevated levels of TNF-α/IFN-
γ in the plasma 
Salvi et al. (2016) Isolated superfused bovine iris-ciliary 
bodies 
- Inhibited sympathetic 
neurotransmission  
- Opening of KATP channels 
Ivanciuc et al. 
(2016) 
Respiratory syncytial virus-induced 
lung disease in wild and CSE 
knockout mice 
- Antiviral and anti-
inflammatory effects 
- Attenuated inflammatory mediators and 
cells infiltration  
Meng et al. 
(2016) 
SHR, human hypertrophic 
myocardium and neonatal rat 
cardiomyocytes 
- Mitigated cardiac 
hypertrophy 
- Abrogated KLF5-induced cardiac 
hypertrophy by S-sulfhydrating its 
transcriptional factor SP1 at Cys664 
Xie et al. (2016) STD-induced LDLr-/- mice,  
LDLr-/-Nrf2-/- mice and HG/ox-LDL-
treated endothelial cells 
- Attenuated diabetes-
accelerated 
atherosclerosis 
- Enhanced Nrf2 activity via S-sulfhydration 
of Keap1 at Cys151 and attenuated oxidative 
stress  
van den Born et 
al. (2016) 
HCA plaque and HMEC-1 CSE-/- cell - Destabilised 
atherosclerotic plaque 
- Stimulated micro-angiogenesis to create 
intraplaque microvessels 
Coavoy-Sanchez 
et al. (2016) 
Murine model of pruritus  - Alleviated itching - NO/cGMP-independent inhibition of PAR-2 
through opening KATP channel  
Grambow et al. 
(2016) 
Human whole blood - Antithrombotic - Enhanced endogenous thrombolysis by 
disturbing platelet-leukocyte aggregation 
Rodrigues et al. 
(2016) 
Dorsal skin pruritus and 
inflammation in BALB/c mice 
- No effect on either 
inflammation or 
pruritus 
- No effect on histamine release from rat 
peritoneal mast cell  
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Lobb et al. 
(2016) 
Renal I/R injury in mice and NRK-52E - Anti-apoptotic - Decreased mito-ROS generation and 
improved mitochondrial membrane 
potential 
VEGF vascular endothelial growth factor; HIF1-α hypoxia-inducible factor-1α, MAPK mitogen activated protein kinases; TNF-α tumor 
necrosis factor-alpha; SHR spontaneous hypertensive rat; KLF5 Krüppel‐Like Factor 5; SP1 specificity factor 1; STD Streptozotocin; LDLr 
low-density lipoprotein receptor; Nrf2 nuclear factor erythroid 2-related factor; HG high glucose; ox-LDL oxidised LDL; Keap1 Kelch-like 
ECH-associated protein 1; HCA Human carotid atherosclerotic; HMEC-1 human dermal microvascular endothelial cell, NO nitric oxide; 
cGMP cyclic guanosine monophosphate; PAR-2 proteinase-activated receptor-2. 
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5.1.3 Aim 
The aims of this study were to: 
1- Investigate for the first time the injury-limiting effects of GYY4137 at early 
reperfusion when given specifically as an adjunct to reperfusion in a rat 
model of acute myocardial infarction.  
2- Characterise whether GYY4137 triggers the RISK pathway at early 
reperfusion to limit infarct size. 
5.1.4 Hypotheses 
We hypothesised the following: 
1- GYY4137 will limit reperfusion injury when given just prior to reperfusion, 
thereby limiting ultimate infarct size.  
2- The protective action of GYY4137 is due to H2S-releasing capacity. 
3- GYY4137 replies on activation of key components of the RISK signalling 
cascade, namely PI3K/Akt and eNOS, at the first minutes of reperfusion to elicit 
its postconditioning effect. 
5.1.5 Objectives 
The aforementioned hypotheses were tested through the following specific 
experimental objectives: 
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1- Perform a dose-response study to determine the optimum cardioprotective 
dose of GYY4137 using an in vivo rat model of myocardial regional 
ischaemia/reperfusion injury. 
2- Apply depleted (D-GYY4137), as a negative control, at reperfusion to 
investigate whether the parent structure of GYY4137 retains any 
cardioprotection. 
3- Investigate the activity of the key kinases and effector proteins of the RISK 
pathway at the first minutes of reperfusion using Western blot analysis. 
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5.2 Materials and Methods 
5.2.1 Animals 
Male Sprague Dawley rats, 300-350 g (9-11 weeks old), were purchased from Harlan, 
UK and used to characterise the cardioprotection of GYY4137. Rats handling, housing 
and reporting are all explained in Chapter 2, section 2.2.  
5.2.2 Acute myocardial infarction model 
The potential infarct-limiting effect of GYY4137 was characterised using an in vivo rat 
model of myocardial ischaemia/reperfusion injury as was described in Chapter 2, 
section 2.3. Infarct quantification was carried out using TTC staining technique as 
described in Chapter 2, section 2.4.  
5.2.3 Treatment protocols 
5.2.3.1 Dose-response study of GYY4137 
The first series of experiments examined the dose-dependent effects of GYY4137 on 
infarct size and the involvement of H2S in mediating any responses. GYY4137 
(morpholino salt) is a water-soluble compound (up to 100 mM) and was the gift of 
Professor Matt Whiteman from University of Exeter/Medical School. It was 
synthesised as reported previously (Li et al., 2008) and the purity of GYY4137 was 
determined by NMR spectroscopy (1H, 31P and 13C). It was identical to a commercial 
sample from SigmaAldrich, UK. The dose range employed in this study was derived 
from previous studies in the rat heart ex vivo by our group (Suveren et al., 2012) and 
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in vivo studies conducted by others (Li et al., 2008, Meng et al., 2015a). Based on its 
H2S-releasing profile, GYY4137 was given 10 minutes before reperfusion to allow 
enough time for GYY4137 to significantly increase H2S level in the blood at the time 
of reperfusion. Animals underwent 30 minutes myocardial ischaemia and 2 hours of 
reperfusion and randomly assigned to one of five groups (Figure 5.2): 
 Group 1: Control (n=9). Animals were subjected to 30 minutes coronary artery 
occlusion and 120 minutes reperfusion with saline given as a slow i.v. bolus 
(500 µL min-1) 10 minutes before reperfusion. 
 Group 2-4: Each group (n=8) received GYY4137 at 26.6, 133 or 266 µmol kg-
1, respectively) as a slow i.v. bolus (500 µL min-1) 10 minutes before 
reperfusion. 
 Group 5: Depleted GYY4137 (n=6). GYY4137 solution (100 mg mL-1) was 
prepared in saline and left uncovered for 72 hours at room temperature to 
dissipate all H2S as described in (Alexander et al., 2015), then administered at 
a dose of 266 µmol kg-1 as a slow i.v. bolus (500 µL min-1) 10 minutes before 
reperfusion.  
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Figure 5.2 Treatment protocol for dose optimization study of GYY4137. After surgical 
preparation, rats were stabilised for 20 minutes then subjected to 30 minutes of left coronary 
artery occlusion (CAO)  followed by 120 minutes of reperfusion. Control rats received saline, 
while treatment groups received one of three GYY4137 doses or depleted GYY4137 (D-
GYY4137) 10 minutes before reperfusion. Hearts were excised at the end of reperfusion for 
infarct size determination, n = 6-10. Arrows indicate the time of pharmacological 
interventions. 
 
5.2.3.2 Mechanistic study with the pharmacological inhibitors 
The second series of experiments explored the involvement of the key elements of 
the RISK pathway in the cardioprotective effect of GYY4137. The optimum dose, 
within the applied dosing range, of GYY4137 (266 µmol kg-1) was selected from the 
first series and animals were randomised into six treatment groups (Figure 5.3). 
 Group 1: Control (n=7). Animals were subjected to coronary occlusion and 
reperfusion with saline or DMSO 5% (v/v) given as a slow i.v. bolus (500 µL 
min-1) 15 minutes before reperfusion. DMSO was used as vehicle for 
LY294002. Since DMSO exerted no effect on either cardiodynamics or infarct 
size, saline- and DMSO-treated animals are reported collectively. 
-20’ 0’
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30’ 150’20’
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 Group 2: GYY4137 (n=7). A slow bolus dose of GYY4137 (266 µmol kg-1, 500 
µL min-1) was administered at 10 minutes before reperfusion. 
 Group 3: GYY4137 + L-NAME (n=7). An intravenous bolus dose of L-NAME 
(20 mg kg-1) was administered 15 minutes before reperfusion followed by 
GYY4137 (266 µmol kg-1, 500 µL min-1) 10 minutes before reperfusion. 
 Group 4: L-NAME (n=6). An intravenous bolus dose of L-NAME (20 mg kg-1) 
was administered 15 minutes before reperfusion. 
 Group 5: GYY4137 + LY294002 (n=6). An intravenous bolus dose of LY294002 
(0.1 mg kg-1 in 5% DMSO) was given 15 minutes before reperfusion followed 
by GYY4137 (266 µmol kg-1, 500 µL min-1) 10 minutes before reperfusion. 
 Group 6: LY294002 (n=6). A bolus dose of LY294002 (0.1 mg kg-1 in 5% (v/v) 
DMSO) was administered intravenously 15 minutes before reperfusion. 
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Figure 5.3 Treatment protocol for the mechanistic study of GYY4137. Following stabilisation, 
rats were subjected to 30 minutes of left coronary artery occlusion and 120 minutes of 
reperfusion. Animals were randomised into six groups. GYY4137 was administered 10 
minutes before reperfusion.  LY294002 and L-NAME were administered 15 minutes before 
reperfusion. Hearts were excised at the end of reperfusion for infarct size determination, n = 
6-7. Arrows indicate the time of pharmacological interventions. 
 
5.2.3.3 Preparation of myocardial samples for protein analysis  
In a parallel series of experiments, rats were subjected to the same interventions as 
illustrated in section 5.2.3.2, to prepare myocardium samples for biochemical 
analysis. After 5 minutes of reperfusion, the experiment was terminated and 
myocardial biopsies were harvested from the left ventricle, rapidly frozen in liquid 
nitrogen then kept at −80 ºC for Western blotting of Akt, eNOS, GSK-3β and ERK1/2 
(Figure 5.4). 
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Figure 5.4 Experimental protocol of tissue sampling following GYY4137 treatment in the 
presence and absence of LY294002 and L-NAME. Animals were stabilised for 20 minutes and 
randomised into six groups. LY294002 and L-NAME were given at 15 minutes of ischaemia 
either alone or concomitantly with GYY4137. All rats underwent 30 minutes myocardial 
ischaemia and 5 minutes reperfusion followed by harvesting myocardial samples from the left 
ventricle. The tissue samples were snap frozen and kept under 80 ºC for analysis by 
immunoblotting. Arrows indicate the time of pharmacological interventions. n=4. 
5.2.3.4 Western blotting analysis 
Protein immunoblotting was carried out to analyse protein phosphorylation of the 
RISK pathway kinases, namely Akt, eNOS, GSK-3β and ERK1/2, following GYY4137 
treatment in the presence and absence of LY294002 and L-NAME. Myocardial 
samples were harvested from the left ventricle at 5 minutes of reperfusion as 
described in Chapter 2, section 2.6.1. Protein extraction was carried out as described 
in Chapter 2, section 2.6.2, and the protein level for the left ventricle biopsies was 
determined using bicinchoninic acid (BCA) assay as described in Chapter 2, section 
2.6.3. Immunoblotting of the proteins of interest was performed as reported in Chapter 
2, section 2.6.4.  
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5.3 Results 
5.3.1 Inclusion/exclusion criteria 
In dose-response study, 42 rats were used, of which two were excluded from final 
analysis, one due to failure of TTC staining and one rat which did not survive the 
ischaemia-reperfusion protocol. Thus data for 40 successfully completed experiments 
are reported. In the mechanistic study, 66 rats were employed, of which three did not 
complete the ischaemia-reperfusion protocol. Thus, data from a total of 63 completed 
experiments are reported in series 2: these comprised 39 completed infarct size 
experiments and 24 preparations for Western blot analysis (no exclusion). It is worth 
mentioning here that the number animals excluded is fewer than the previous series 
of experiments as the operator became more competent in conducting the surgery 
and developed the skills to carry out the intubation and cannulation. 
5.3.2 Dose-response study of GYY4137 
5.3.2.1 Hemodynamic parameters 
Baseline hemodynamics for dose-response study are summarised in Table 5.2. There 
was no significant difference in any of the baseline parameters among the 
experimental groups. Cardiodynamics (MAP and RPP) measurements before 
ischaemia, during ischaemia and at the end of reperfusion are also presented in Table 
5.2. GYY4137 had no detectable effect on cardiodynamics during the 
ischaemia/reperfusion protocol. 
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Table 5.2 Summary of Baselines and cardiodynamics for GYY4137 dose-effect study during ischaemia/reperfusion protocol. 
Experimental Protocol 
n BW (g) Baseline 20 min Ischaemia 120 min Reperfusion 
  RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
Control 10 355 ± 6 37.5 ± 2.0 88 ± 4 27.9 ± 1.8 68 ± 4 24.0 ± 1.4 53 ± 3 
GYY4137 26.6 µmol kg-1 8 360 ± 9 40.3 ± 3.0 90 ± 6 29.1 ± 2.1 71 ± 5 26.3 ± 2.0 59 ± 4 
GYY4137 133 µmol kg-1 8 346 ± 7 41.4 ± 1.8 94 ± 6 29.5 ± 2.2 70 ± 6 24.3 ± 1.5 53 ± 4 
GYY4137 266 µmol kg-1 8 368 ± 6 39.1 ± 1.7 83 ± 4 28.6 ± 2.0 65 ± 5 20.9 ± 1.6 45 ± 3 
D-GYY4137 6 368 ± 6 38.4 ± 2.3 85 ± 5 26.3 ± 2.1 69 ± 4 22.7 ± 1.3 48 ± 4 
n number of animals per group; BW body weight; RPP rate pressure product; MAP mean arterial pressure. Data are reported as mean ± 
SEM. There was no significant difference in any of the baselines between the experimental groups (repeated measures ANOVA followed 
by Bonferroni post hoc test). 
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5.3.2.2 Infarct size following GYY4137 postconditioning 
Series 1 examined the response to three doses of GYY4137 on infarct size (Figure 
5.5). AAR constituted approximately 40-60% of the total ventricular volume with no 
significant differences among the treatment groups (Figure 5.5A). Control infarct size 
(I/AAR%) was 52.5 ± 4.7% (Figure 5.5B). GYY4137 (266 µmol kg-1) produced 
significant infarct limitation when given 10 minutes before reperfusion compared to 
control hearts (27.9 ± 3.8% vs 52.5 ± 4.7%, p<0.01). This represents a 47% relative 
reduction in infarct size. In contrast, depleted-GYY4137, produced as described in 
section 5.2.3.1, which lacked H2S donating potential but was otherwise structurally 
identical had no effect on infarct size at the same dose (51.9 ± 3.1%). These result 
confirm the dependency of GYY4137’s infarct-limiting action on H2S-releasing 
capacity. 
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Figure 5.5 Infarct size data of GYY4137’s dose-response study. Area at risk was determined Evans’ blue exclusion and infarction was assessed 
by TTC staining. GYY4137 was administered at 26.6, 133, or 266 µmol kg-1 10 minutes before reperfusion. A. area at risk as a percentage of the 
total ventricular volume.  B. myocardial infarction expressed as a percentage of the area at risk. The mean of infarct size is reported by a filled 
circle (with error bars) along with the individual values. **p<0.01 versus Control; † p<0.05 versus GYY4137 266 µmol kg-1 (one way ANOVA 
with Newman Keuls post hoc test). 
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5.3.3 Mechanistic study: involvement of PI3K/Akt and eNOS 
5.3.3.1 Haemodynamic parameters 
Baselines and cardiodynamics measurements throughout ischaemia/reperfusion 
protocol are presented in Table 5.3. There was no significant difference in the baseline 
parameters among the experimental groups. Similar to the first series, GYY4137 did 
not have any effect on either RPP or MAP. Blocking either PI3K with LY294002 or 
endogenous nitric oxide synthesis with L-NAME resulted in no change in either RPP 
or MAP in the presence or absence of GYY4137. 
5.3.3.2 Infarct size data 
The second series of experiments was undertaken to examine the role of components 
of the RISK signalling pathway in the protective effect of GYY4137 (Figure 5.6). There 
was no significant difference in the area at risk among the experimental groups 
(Figure 5.6A). GYY4137 (266 µmol kg-1) elicited a significant reduction in %I/AAR 
compared to control (27.6 ± 2.0% vs 56.8 ± 3.5%, respectively, p<0.001, Figure 5.6B). 
Pharmacological inhibition of eNOS with L-NAME prior to GYY4137 almost halved the 
cardioprotective effect of GYY4137 (41.1 ± 6.3% vs 27.6 ± 2.0%, respectively, 
p<0.05), but did not abolish it (41.1 ± 6.3% vs 56.8 ± 3.5%, respectively, p<0.01, 
Figure 5.6B). Concomitant administration of LY294002 to inhibit PI3K activity 
completely abrogated the cardioprotective effect of GYY4137 (49.8 ± 4.2% vs 56.8 ± 
3.5%, respectively, p>0.05). Neither L-NAME nor LY294002 had any effect on infarct 
size when given alone (55.7 ±3.3% and 51.2 ± 2.7% respectively, both p>0.05 vs 
control). 
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Table 5.3 Summary of baseline parameters and haemodynamics throughout acute myocardial infarction protocol for the mechanistic study of 
GYY4137 with the pharmacological inhibitors 
Experimental Protocol 
n BW (g) Baseline 20 min Ischaemia 120 min Reperfusion 
  RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
Control 7 384 ± 7 36.3 ± 2.2 85 ± 5 24.8 ± 2.2 61 ± 6 21.2 ± 2.0 48 ± 4 
GYY4137 7 379 ± 8 41.3 ± 3.0 96 ± 6 26.8 ± 1.6 66 ± 6 21.6 ± 1.1 47 ± 2 
GYY4137 + L-NAME 7 387 ± 7 39.3 ± 2.5 88 ± 5 29.5 ± 2.4 69 ± 5 19.4 ± 2.4 50 ± 6 
L-NAME 6 381 ± 9 39.3 ± 1.6 97 ± 3 30.4 ± 2.1 76 ± 7 22.4 ± 5.1 57 ± 9 
GYY4137 + LY294002 6 362 ± 8 39.3 ± 1.8 88 ± 4 30.2 ± 1.8 71 ± 5 24.2 ± 0.6 53 ± 1 
LY294002 6 367 ± 11 44.5 ± 2.8 98 ± 4 29.6 ± 1.2 72 ± 4 25.0 ± 0.7 54 ± 2 
n number of animals per group; BW body weight; RPP rate pressure product; MAP mean arterial pressure. Data are expressed as mean 
± SEM. There was no significant difference in any of the baselines between the experimental groups (repeated measures ANOVA with 
Bonferroni post hoc test). 
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Figure 5.6 Infarct data of GYY4137 with pharmacological inhibitors. Infarct size quantification was carried out using dual staining with Evans’ 
blue and TTC. GYY4137 was administered at 266 µmol kg-1 10 minutes before reperfusion. LY294002 or L-NAME were given 15 minutes before 
reperfusion. A. area at risk expressed as a percentage of the total ventricular volume. B. infarct size expressed as a percentage of the area at risk. 
The mean of infarction presented by a filled circle (with error bars) next to the individual value of each group (open circles).  ** p<0.01 versus 
Control; *** p<0.001 versus control; † p<0.01 versus GYY4137 (one way ANOVA with Newman Keuls post hoc test).  
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5.3.4 Protein phosphorylation following postconditioning with GYY4137 
The extent of phosphorylation of Akt, eNOS, GSK-3β and ERK1/2 in early reperfusion 
was investigated with phospho-specific antibodies to determine the possible roles in 
cardioprotection by GYY4137. Hearts were postconditioned with GYY4137 at 10 
minutes before reperfusion in the presence and absence of PI3K inhibitor (LY294402) 
or constitutive nitric oxide synthase inhibitor (L-NAME). Immunoreactivity 
measurements of the RISK pathway components, namely Akt, eNOS, GSK-3β and 
ERK1/2, were performed using myocardial tissue sampled from the left ventricle 5 
minutes after reperfusion. There was no significant difference in protein expression to 
GAPDH of Akt, eNOS, GSK-3β or ERK1/2 among any of the experimental groups. 
There was a significant 2.8-fold increase (p<0.05 vs. control) in phospho-ser473Akt at 
reperfusion following GYY4137 treatment (Figure 5.7A). Prior administration of L-
NAME did not limit this increase in Akt phosphorylation. Both GYY4137 and L-NAME 
did not have an effect in the total Akt expression in the myocardium (Figure 5.7B). 
However, administration of LY294002 prior to GYY4137 abolished Akt 
phosphorylation (Figure 5.7A) with no effect on total Akt (Figure 5.7B). 
Postconditioning with GYY4137 also increased eNOS phosphorylation at the 
activating ser1177 site by 2.2-fold in early reperfusion (p<0.05 vs. control; Figure 5.8A). 
This activation was abrogated by concomitant administration of L-NAME which 
interestingly showed a trend of increase in the total eNOS expression in the tissue in 
the presence and absence of GYY4137 (Figure 5.8B). However, this trend did not 
reach the significance threshold. Activation of eNOS with GYY4137 was also 
abolished by co-administration of LY294002 with no significant effect on the total 
eNOS expression in the myocardium (Figure 5.8B). Ser9 phosphorylation of GSK-3β 
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was also increased 2.2-fold by GYY4137 (Figure 5.9A). This phosphorylation, leading 
to inactivation of GSK-3β, was not affected L-NAME. However, pre-treatment with 
LY294002 prior to GYY4137 abrogated GSK-3β phosphorylation. GYY4137 had no 
significant effect on the phosphorylation of ERK1/2 at early reperfusion (Figure 
5.10A). 
 
Figure 5.7 Representative blots and Western blot analysis of the phosphorylation of Akt in left 
ventricular myocardium, harvested from the area at risk 5 minutes after reperfusion, following 
GYY4137’s postconditioning. Histograms show densitometric ratios of (A) phosphorylated 
Akt to total Akt (B) total Akt to GAPDH. GAPDH was used as loading control for all 
determinations. Data were analysed using Kruskal-Wallis followed by Dunn’s post hoc test 
and reported as mean ± SEM. * p<0.05 versus control. In all groups, n = 4 hearts from 4 
independent experiments. 
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Figure 5.8 Representative blots and Western blot analysis of the phosphorylation of eNOS in 
left ventricular myocardium, harvested from the area at risk 5 minutes after reperfusion, 
following GYY4137’s postconditioning. Histograms show densitometric ratios of (A) 
phosphorylated eNOS to total eNOS (B) total eNOS to GAPDH. GAPDH was used as 
loading control for all determinations. Data were analysed using Kruskal-Wallis followed by 
Dunn’s post hoc test and reported as mean ± SEM. * p<0.05 versus control. In all groups, 
n=4 hearts from 4 independent experiments. 
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Figure 5.9 Representative blots and Western blot analysis of the phosphorylation of GSK-3β 
in left ventricular myocardium, harvested from the area at risk 5 minutes after reperfusion, 
following GYY4137’s postconditioning. Histograms show densitometric ratios of (A) 
phosphorylated GSK-3β to total GSK-3β (B) total GSK-3β to GAPDH. GAPDH was used as 
loading control for all determinations. Data were analysed using Kruskal-Wallis followed by 
Dunn’s post hoc test and reported as mean ± SEM. * p<0.05 versus control. In all groups, 
n=4 hearts from 4 independent experiments. 
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Figure 5.10 Representative blots and Western blot analysis of the phosphorylation of ERK1/2 
in left ventricular myocardium, harvested from the area at risk 5 minutes after reperfusion, 
following GYY4137’s postconditioning. Histograms show densitometric ratios of (A) 
phosphorylated ERK1/2 to total ERK1/2 (B) total ERK1/2 to GAPDH. GAPDH was used as 
loading control for all determinations. Data were analysed using Kruskal-Wallis and reported 
as mean ± SEM. For all groups, n= 4 hearts from 4 independent experiments. 
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5.4 Discussion 
The principal observations of this study can be summarised as follows: 
1- GYY4137 limited myocardial infarction in vivo when given specifically 
prior to reperfusion indicating potent attenuation of lethal reperfusion 
injury in a postconditioning-like manner. 
2- GYY4137 relied on its H2S-generating capacity to elicit its 
cardioprotection against acute myocardial infarction. 
3- The infarct-limiting effect of GYY4137 at early reperfusion was mediated 
through activation of the PI3K/Akt survival cascade. 
4- There was a partial dependency of GYY4137’s protective effect on 
increased eNOS phosphorylation. 
5- GYY4137 inhibited GSK-3β activity at early reperfusion by increasing the 
phosphorylation of its ser9 site downstream of PI3K/Akt signalling. 
These findings support the hypothesis that administration of GYY4137 at 
reperfusion can protect the heart against reperfusion injury by activating the key 
components of the RISK cascade (PI3K/Akt/NO) and inhibition of GSK-3β 
activity (Figure 5.11). 
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Figure 5.11 GYY4137, a donor of H2S, induces marked limitation of myocardial infarct 
size when given shortly before reperfusion. Based on the present experimental data, we 
present a mechanistic scheme by which GYY4137 mediates its cardioprotection against 
reperfusion injury. GYY4137 releases H2S which triggers a key component of the 
reperfusion injury salvage kinase cascade, namely PI3K/Akt activation at reperfusion. 
Downstream of activated Akt, phosphorylation of eNOS and GSK-3β are induced by 
GYY4137 treatment. Although not yet determined, it seems plausible that GYY4137 
eventually inhibits the opening of PTP at early reperfusion as a result of the increase in 
NO level and inhibition GSK-3β activity, resulting in reduced cardiomyocyte 
susceptibility to lethal reperfusion injury. 
 
5.4.1 Infarct limitation by GYY4137 
The results show for the first time the effect of GYY4137, as a slow-releasing 
H2S donor, on myocardial infarction in an in vivo model. Intracellular levels of 
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H2S are reported to be decreased during ischaemia-reperfusion as a result of 
overwhelming ROS generation which limits H2S synthesis and increases its 
degradation (Vandiver and Snyder, 2012). GYY4137 elicited significant infarct 
limitation when administered prior to reperfusion. Depleted GYY4137 
(Alexander et al., 2015) was employed as a control to ensure that any detectable 
effect was due to H2S released and not by the parent molecule or by-products 
formed from GYY4137 decomposition. Depleted GYY4137 had no effect on 
infarct size and this is consistent with previous studies where loss of H2S from 
GYY4137 was shown to be associated with loss of biological activity (Li et al., 
2009, Whiteman et al., 2010b, Fox et al., 2012, Jamroz-Wisniewska et al., 2014, 
Alexander et al., 2015). 
This is the first study of pharmacological postconditioning against reperfusion 
injury in vivo using GYY4137 as a stable H2S donor. Although inorganic H2S 
generators (NaHS and Na2S) have been used in different experimental species, 
the specific targeting of reperfusion injury by GYY4137 in this study is novel. 
Several studies have investigated the effect of H2S against myocardial 
ischaemia/reperfusion when commercially available sulfide salts were perfused 
or given pre-ischaemia. For example, Johansen et al. (2006) were the first to 
show that NaHS limited infarct size in a rat isolated heart preparation, while Pan 
et al. (2009), Sivarajah et al. (2009), Zhuo et al. (2009) and Yao et al. (2012) all 
showed that NaHS limited infarct size in an in vivo rat model through diverse 
mechanisms. Part of this variation is arguably due to the unstable nature of these 
H2S sources, in addition to the different experimental conditions and end-points 
of interest. Using garlic derivatives as organic sources of H2S, Zhang et al. 
(2001) and Chuah et al (2007) reported that allitridum and S-allylcysteine 
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respectively also elicited cardioprotection against myocardial infarction when 
given before ischaemia. Preconditioning the heart with the thiol derivative S-
diclofenac was also protective partially through the opening of mitochondrial 
KATP channels (Rossoni et al., 2008). Investigators have also examined the 
possibility of postconditioning the myocardium using NaHS and Na2S. For 
example, Elrod et al. (2007), Sodha et al. (2009) and Lambert et al. (2014) all 
reported that Na2S protected mouse heart against myocardial infarction in vivo 
when given at reperfusion. Bibli et al. (2015) showed that a bolus dose of NaHS 
10 minutes before reperfusion then continuous infusion of NaHS till the end of 
reperfusion was required to significantly exert cardioprotection in rabbit. In 
comparison with these results, in this study we showed that a single bolus dose 
of GYY4137 at reperfusion had a significant cardioprotective effect against 
myocardial infarction in the rat. To our knowledge, the only other long-lasting 
H2S donors that have been reported are the polysulfide diallyl trisulfide (DATS) 
and SG-1002, a thiol-activated H2S donor. Despite generating 10 times less H2S 
than Na2S, DATS was shown to improve mitochondrial respiration and stimulate 
eNOS at reperfusion in an in vivo mouse model of ischaemia/reperfusion injury. 
However, DATS is a polysulfide compound, and thus cannot be considered a 
pure H2S donor with the possibility of off-target effects. Moreover, H2S release 
from GYY4137 is reported to last longer compare to DATS (Li et al., 2008, 
Predmore et al., 2012). In the setting of pressure-overload-induced heart failure, 
SG-1002-treated hearts were protected during transverse aortic constriction via 
triggering VEGF/Akt/eNOS/NO/cGMP pathway. Recently, SG-1002 has 
successfully passed Phase I clinical study in patient with heart failure 
(ClinicalTrials.gov #NCT01989208 and #NCT02278276), by increasing blood 
H2S level and circulating NO bioavailability (Polhemus et al., 2015). However, 
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none of these studies have shown that the observed effects are due to H2S 
release due to the lack of negative control (like depleted GYY4137, for example). 
Therefore, there is persuasive experimental evidence that a stable level of H2S 
release confers effective cardioprotection against ischaemia/reperfusion injury. 
The present study confirms for the first time that administration of GYY4137 prior 
to reperfusion (postconditioning), rather than prior to coronary artery occlusion 
(preconditioning), exerts a marked cardioprotective effect due to H2S-releasing 
capacity. This cardioprotection by GYY4137 did not have an effect on 
cardiodynamics which, to some extent, shows a potential cardiac safety that 
needs further investigation. 
5.4.2 GYY4137 postconditioning activates PI3K/Akt signalling 
The second series of experiments aimed to explore the signalling mechanisms 
underpinning the protective effect of GYY4137. The involvement during early 
reperfusion of specific kinase mechanisms, notably activation of PI3K/Akt and/or 
ERK1/2, activation of eNOS and inhibition of GSK-3, has attracted 
considerable attention in relation to cardiac conditioning phenomena, especially 
postconditioning. Elucidation of the RISK pathway has confirmed that it is a key 
modulator of protection against reperfusion injury in many species, although not 
all. Here, we explored the effects of pharmacological inhibition of two key 
components, PI3K/Akt and eNOS, confirmed by assessment of the 
phosphorylation status of these proteins. We found that the PI3K inhibitor 
LY294002 abrogated the infarct-limiting effect of GYY4137 which indicated the 
involvement of PI3K/Akt survival pathway in cardioprotection established by 
GYY4137. This was supported by the observation that GYY4137 increased Akt 
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phosphorylation in left ventricular myocardium during early reperfusion, an effect 
abolished by LY294002. Li et al. (2015a) showed that NaHS at reperfusion 
limited cell death by activating PI3K/Akt pathway in aging rat heart and 
cardiomyocytes. However, Lambert et al. (2014) demonstrated that in diabetic 
rats NaHS-induced postconditioning might signal through the other arm of the 
RISK pathway, namely ERK1/2. LY294002 alone had no significant effect on 
either the infarct size or Akt phosphorylation compared to control which is 
consistent with the findings of other investigators (Wang et al., 2013, 
Barsukevich et al., 2015). This suggests that the PI3K/Akt pathway is almost 
inactive at basal physiological levels of H2S.  
We also investigated the involvement of ERK1/2 in cardioprotection established 
by GYY4137. In contrast to Akt phosphorylation, we observed no significant 
increase in ERK1/2 phosphorylation at early reperfusion following 
postconditioning with GYY4137. It has been reported by others that a bolus dose 
of Na2S at reperfusion could activate ERK1/2 and also inhibit GSK-3β (Lambert 
et al., 2014, Li et al., 2015b, Bibli et al., 2015). However, since in our hands 
GSK-3β phosphorylation (leading to enzyme inhibition) by GYY4137 was 
abrogated by LY294002, this suggests it is downstream of PI3K/Akt, rather than 
ERK1/2. It again emphasises the physiological differences between bolus sulfide 
(with NaHS or Na2S) and H2S generated in a more physiological manner (with 
GYY4137). 
5.4.3 Dependency of GYY4137-postconditioning on NO 
Inhibition of NO synthesis using L-NAME had no effect on the infarct size per se 
which is consistent with other investigators (Fradorf et al., 2010, Imani et al., 
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2011). This observation implies that NO does not afford any cardioprotection 
against myocardial infarction at basal physiological levels. GYY4137 treatment 
induced an increase in the phosphorylation of eNOS at its activating site, ser1177 
suggesting that NO bioavailability is increased following GYY4137 treatment. L-
NAME prior to GYY4137 administration limited the phosphorylation of eNOS and 
partially attenuated infarct limitation but did not completely abolish the protective 
effect. These data suggest that enhancing NO bioavailability synergises the 
cardioprotection of GYY4137 against reperfusion injury but blocking eNOS 
phosphorylation only partially limits the cardioprotection of GYY4137, 
suggesting the involvement of parallel NO-independent pathway(s). There has 
been considerable interest in cross-regulation of NO and H2S but the nature of 
their interactions is uncertain, at least in part because of the large variation in 
experimental conditions. 
SG-1002, H2S donor, was protective and increased NO bioavailability in an in 
vivo model of heart failure (Kondo et al., 2013). An increase in NO metabolites 
following DATS treatment was also observed by Lefer and co-workers 
(Predmore et al., 2012) in mouse heart. King et al. (2014) found that H2S did not 
limit infarction in eNOS phospho-mutant (ser1179A) or eNOS knockout mice. 
Considered together, these studies suggest that an increase in one of the 
gaseous mediators can eventually lead to an increase in the other but the picture 
is obscured by variations across species, pathological models and tissue types. 
The NO-dependency of H2S has recently been studied by Bibli et al. (2015) in 
an in vivo model of myocardial infarction using two species, rabbit and mouse. 
Pharmacologically limiting NO availability with L-NAME did not limit the 
protection of NaHS in rabbits, while genetic mutation or pharmacological 
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blockade of eNOS totally abolished H2S-induced protection in mice. 
Dependency of NaHS-induced cardioprotection on NO in mice was previously 
reported by Sojitra et al. (2012). Together and in line with our data, it seems 
plausible that NO involvement in the infarct-limiting effect of H2S could be tissue 
and/or species-dependent. Further detailed work needs to be carried out for 
better understanding of the molecular pharmacology of these molecules and to 
enhance the clinical implementation of H2S-delivering systems. 
5.4.4 GYY4137 postconditioning attenuates GSK-3β phosphorylation 
GSK-3β has been proposed as one of the key end effectors of some 
cardioprotective manoeuvres, particularly ischemic conditioning phenomena. It 
has been demonstrated that GSK-3β promotes the opening of mitochondrial 
permeability transition pore (PTP) during reperfusion, an event thought to be a 
major determinant of cell death (Cabrera-Fuentes et al., 2016). In isolated 
cardiomyocytes, Yao et al. (2010) and Li et al. (2015b) found that NaHS 
protected against hypoxia/reoxygenation induced cell death by inhibiting GSK-
3β-dependent opening of PTP. In line with these results, the present study 
demonstrated that GYY4137 increased the phosphorylation of GSK-3β at Ser9 
site at reperfusion. This was abolished by LY294002, but not by L-NAME, 
suggesting that GYY4137 induced inhibition of GSK-3β is downstream of 
PI3K/Akt. There is evidence that the increase in Akt phosphorylation (Hausenloy 
et al., 2009) and NO bioavailability (Burley et al., 2007) at early reperfusion may 
also inhibit the opening of PTP. Considering these data together, it seems 
plausible that postconditioning with GYY4137 is associated with a reduced 
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susceptibility of PTP opening, although this remains to be determined by specific 
measurements of PTP opening. 
5.5 Study limitations 
There are still questions which this study did not address and they could be 
interesting topics for further investigations. This study found that GYY4137 
activates the RISK pathway at early minutes of reperfusion to limit the infarct 
size where infarction was quantified after 2 hours of reperfusion. Nevertheless, 
whether GYY4137 could exert a comparable cardioprotection via similar or 
different mechanism(s) with longer reperfusion protocol, where there could be 
no-flow phenomena or late apoptosis, needs to be investigated. Although spent-
GYY4137 did not exert any cardioprotection, the direct effect of GYY4137 
administration on the level of H2S in the heart and circulation needs to be 
measured. Similarly, measuring the proposed elevation in NO bioavailability as 
a result of activating eNOS at reperfusion by GYY4137 administration could also 
underpin the conclusion. 
5.6 Conclusion 
In summary, we have demonstrated that the slow-releasing H2S donor 
GYY4137, but not its H2S-depleted control, protected the heart against lethal 
reperfusion injury when administered as an adjunct treatment prior to 
reperfusion. This cardioprotective action is dependent on activation of PI3K/Akt 
signalling pathway at early reperfusion, which in turn, increases NO 
bioavailability by increasing eNOS phosphorylation, and increases the 
phosphorylation of GSK-3β. Thus, stable slow-releasing H2S donor compounds 
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may be promising candidates for the development of adjunct therapies to 
reperfusion for the treatment of acute myocardial infarction. 
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6.1 Introduction  
As described in Chapter 1 (section 1.3.6), mitochondria play a pivotal role in cell 
survival, metabolism and proliferation (Murphy et al., 2016). In myocardial 
ischaemia/reperfusion injury, rapid pH normalisation, Ca2+ overload and overwhelming 
ROS and RNS generation disturb mitochondrial function and result in the opening of 
the PTP (Hausenloy and Yellon, 2007). PTP opening leads to collapse of 
mitochondrial membrane potential and swelling of the mitochondria, leading to loss of 
ATP-generating capacity and causing the release of cytochrome c into the cytoplasm 
which initiates apoptosis (Pell et al., 2016, Murphy et al., 2016). PTP opening at 
reperfusion is believed to be the no-return point of reperfusion injury (Hausenloy et al., 
2009). Therapeutic targeting of these processes during the first minutes of reperfusion 
has been investigated intensively in experimental settings as early reperfusion 
appears to afford a window of opportunity to prevent PTP opening and ultimately 
reduce lethal cell injury during reperfusion following acute myocardial ischaemic 
episodes such as occur in acute myocardial infarction (Ferdinandy et al., 2014). 
Hydrogen sulfide (H2S) is the simplest bioactive thiol (Abe and Kimura, 1996). The 
long-recognised toxic effects of environmental or exogenous H2S occur as a result of 
inhibition of cytochrome c oxidase, an essential enzyme for mitochondrial complex IV 
respiration, with perturbation of ATP production (Nicholls et al., 2013). However, the 
roles of endogenous H2S, in a wide range of physiological systems, have been 
extensively explored following the discovery that it is produced by several regulated 
biochemical pathways in mammalian species and can act as a freely diffusible and 
degradable signalling mediator (Kimura et al., 2011). In myocardium, enhanced levels 
of H2S, whether by H2S supplement or increased endogenous production, has been 
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shown to protect the heart against ischaemia/reperfusion injury (Elrod et al., 2007, 
Karwi et al., 2016). However, whether H2S directly interacts with mitochondria or 
triggers cytosolic salvage kinases arguably depends on the intracellular level of H2S, 
although the majority of these kinases have downstream end effectors at the 
mitochondrial level that converge on the mitochondria. Therefore, targeting the 
mitochondria with selective H2S donors is a plausible therapeutic approach to limit 
ischaemia/reperfusion injury.  
6.1.1 AP39: mitochondria-targeting H2S donor 
The lipophilic triphenylphosphonium (TPP+) scaffold is highly positively charged and 
has been shown to accumulate selectively (100-500 fold compared to the cytosol) in 
the mitochondrial matrix (Smith et al., 2003b, James et al., 2007). Therefore, the TPP+ 
scaffold has become an attractive moiety for investigation of mitochondrial function by 
specific delivery of bioactive molecules and probes (Murphy and Smith, 2007, Smith 
et al., 2011). In previous work, Prime et al. (2009) demonstrated infarct limitation using 
a mitochondria-targeted NO donor (MitoSNO), where an NO-releasing moiety linked 
to TPP+ was shown to be rapidly and exclusively taken up by mitochondria and 
increased the mitochondrial NO level. Krieg’s group (Methner et al., 2013) showed 
that MitoSNO works independently of cytosolic PKG, the mechanism which mediates 
the cardioprotective effect of non-mitochondrial-targeted NO donors. AP39 (10-oxo-
10-(4-(3-thioxo-3H-1, 2-dithiol-5-yl)phenoxy)decyl) triphenylphosphonium bromide) 
represented the first successful prototype to deliver H2S selectively and at a low 
concentration to the mitochondria (Figure 6.1A). By virtue of its highly cationic TTP+ 
moiety, AP39 accumulates in the mitochondria due to the mitochondrial membrane 
potential. It was first characterised by Le Trionnaire et al. (2014) and since then, 
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several studies have followed-up showing that AP39 could potentially have many 
therapeutic applications in various pathologies and in different tissues and organs 
(Table 6.1). Interestingly, this increase in mitochondrial H2S level following AP39 
application did not seem to upregulate or suppress any known endogenous H2S 
synthetic pathway, namely CSE, CBS and 3-MST (Ikeda et al., 2015). The rationale 
for targeted delivery of H2S to the mitochondria is based on the evidence that H2S 
could work as an inorganic fuel for ATP production (Fu et al., 2012), attenuate 
mitochondrial ROS (mito-ROS) generation (Jha et al., 2008) and preserves 
mitochondrial integrity (Elrod et al., 2007). There are recent observations that AP39 
can successfully deliver H2S into the mitochondria when given at reperfusion and that 
the agent reproducibly protects the mitochondria in particular and the cell in general 
against ischaemia/reperfusion injury in the brain and kidney (Ikeda et al., 2015, Ahmad 
et al., 2016). We sought to investigate the potential cardioprotection by AP39 against 
myocardial ischaemia/reperfusion injury when given at reperfusion in vivo using the 
rat model and to elucidate the underlying mechanisms. Moreover, we also employed 
the mitochondrial targeting scaffold of AP39 (AP219, Figure 6.1B) and H2S-generating 
moiety (ADT-OH, Figure 6.1C) individually as controls to characterise whether any of 
them possess any, cardioprotective effects. These controls are shown to lack any 
biological activity when used up to micromolar concentration range in vitro and in vivo 
(Le Trionnaire et al., 2014, Szczesny et al., 2014, Tomasova et al., 2015). Therefore, 
they offer the possibility to confirm whether the approach of selective delivery of H2S 
into the mitochondria could successfully protect the heart independently of triggering 
any cytosolic salvage pathway.   
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Table 6.1 Summary of experimental studies utilising the mitochondria-targeted H2S donor, AP39, listed in chronological order 
Reference Experimental model(s) Main observed effect(s) Mechanism(s) 
Le Trionnaire et 
al. (2014) 
HCMVEC/D3 and bEnd.3 
MMVEC 
- Antioxidant  - Enhanced the expression of Trx-1 
Szczesny et al. 
(2014) 
Glucose oxidase-induced 
oxidative stress in bEnd.3 
MMVEC  
- Antioxidant and 
cytoprotective 
- Improved cellular bioenergetics and limited 
mitochondrial DNA damage 
Tomasova et al. 
(2015) 
Anaesthetised Wistar rat, 
HEK293 cell and rat-derived 
SR 
- NO-independent 
Hypotensive effect 
- Reduced heart rate, blood pressure and pulse 
wave velocity by attenuating Ca2+ current, 
inhibited RyR2 channel activity and enhanced 
the conductance of Cl- channel  
(Ikeda et al. 
(2015) 
murine model of CA/CPR - Improved survival rate 
and neurological functions 
- Attenuated oxidative stress, preserve 
mitochondrial integrity by inhibiting PTP 
opening  
Ahmad et al. 
(2016) 
NRK-49F and rat model of 
renal I/RI 
- Antioxidant and anti-
inflammatory 
- Inhibition of neutrophil infiltration and 
TUNEL staining 
Gero et al. 
(2016) 
HG-induced oxidative stress in 
bEnd.3 MMVEC 
- Antioxidant and 
cytoprotective 
- Mitigated mitochondrial oxidants generation 
and promoted cellular metabolism   
Ahmad and 
Szabo (2016) 
Rat  model of burn injury  - Anti-inflammatory  - Decreased circulatory IL-6 and IL-10 
Lobb et al. 
(2016) 
Renal I/R injury in mice and 
NRK-52E 
- Anti-apoptotic - Decreased mito-ROS generation and improved 
mitochondrial membrane potential 
HCMVEC human cerebral microvascular endothelial cell; MMVEC mouse microvascular endothelial dell; SR sarcoplasmic reticulum; 
CA/CPR cardiac arrest and cardiopulmonary resuscitation; PTP permeability transition pore; I/RI ischaemia/reperfusion injury; HG high 
glucose; Trx-1 thirodoxin-1; NRK-52E rat kidney epithelial cells.   
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Figure 6.1 Chemical structures of (A) mitochondria-targeted H2S donor AP39 with the two control compounds (B) AP219 and (C) ADT-OH. 
AP39 consists of a mitochondria-targeting moiety (triphenylphosphonium; TPP+) and a H2S donor (anethole dithiolethione) attached via an ester 
to an aliphatic linker. 
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6.1.2 Aims 
The aims of this study were to  
1. Examine the potential cardioprotective effects of a novel mitochondria-targeting 
H2S donor (AP39) when administrated as adjunct to reperfusion in an in vivo 
rat model of myocardial ischaemia/reperfusion injury. 
2. Investigate whether the mitochondria-targeting scaffold (AP219, TPP+ moiety) 
or the H2S donor (ADT-OH, anethole dithiolethione moiety) exerts any 
cardioprotection against ischaemia/reperfusion injury. 
3. Identify the molecular pharmacology of AP39 and whether it acts directly on the 
mitochondria or within the cellular compartments to exert its cardioprotective 
effect. 
4. Investigate the direct effects of AP39 on the cardiomyocyte mitochondria, 
namely subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria, dynamics. 
6.1.3 Hypotheses 
1- Postconditioning with AP39 can protect the ischaemic myocardium against 
reperfusion injury when applied at reperfusion. 
2- AP39’s postconditioning effect is mediated independently of cardioprotective 
cytosolic signalling pathway at early reperfusion. 
3- AP39 can inhibit the opening of the mitochondrial permeability transition pore 
(PTP).  
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4- Selectively delivered H2S into the mitochondria via AP39 can improve 
mitochondrial respiration. 
5- Targeted delivery of H2S by AP39 can limit mito-ROS generation. 
6.1.4 Objectives 
The following experimental approaches have been used to test these hypotheses: 
1- Perform a dose-response study to identify the optimum cardioprotective dose 
of AP39 when given at reperfusion using an in vivo rat model of myocardial 
ischaemia/reperfusion injury in comparison with AP219 and ADT-OH. 
2- Investigate if AP39 limits infarct size through activating the RISK pathway, 
namely PI3K/Akt, eNOS and sGC, at reperfusion by concomitant administration 
of specific pharmacological inhibitors of these enzymes. 
3- Characterise whether AP39 alters the activity of constituents of the RISK 
pathway, namely Akt, eNOS, GSK-3β and ERK1/2, in the left ventricle at the 
first minutes of reperfusion using Western blotting. 
4- Determine whether AP39 inhibits Ca2+-sensitive PTP opening using isolated 
cardiomyocyte mitochondria, namely, subsarcolemmal (SSM) and interfibrillar 
(IFM) mitochondria, in vitro. 
5- Examine the effect of AP39 application on the mito-ROS generation in vitro 
using isolated SSM and IFM. 
6- Characterise the effect of AP39 on the mitochondrial respiration using isolated 
SSM and IFM in vitro.
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6.2 Materials and Methods 
6.2.1 Animals 
Male Sprague Dawley rats, 300-350 g (9-11 weeks), were obtained from Harlan, UK 
and used for infarct size and Western blotting studies. For mitochondrial functions and 
biochemistry undertaken in Giessen. Germany, male Wistar rats, 300-350 g (9-11 
weeks), were purchased from Harlan, France. Animals handling and reporting are 
described in more details in Chapter 2, section 2.2.  
6.2.2 Acute myocardial infarction model 
Rat model of myocardial ischaemia and reperfusion injury was employed to model the 
acute myocardial infarction as described in Chapter 2, section 2.3. Briefly, the rat was 
anaesthetised and underwent 30 minutes regional myocardial ischaemia, obtained by 
left coronary artery occlusion, and 120 minutes reperfusion following 20 minutes 
stabilisation period when inclusion/exclusion criteria were applied. Myocardial infarct 
size was quantified using Evans’ blue/TTC staining technique as described in Chapter 
2, section 2.4. 
6.2.3 Treatment protocols 
6.2.3.1 Dose-response study of AP39 
A series of infarct size experiments were carried out to characterise the dose-
dependent infarct-limiting effect of AP39. Along with these doses, AP219 
Chapter 6 
168 
 
(mitochondria-targeting moiety) and ADT-OH (H2S-releasing moiety) were also used 
individually to confirm the selective effect of H2S delivery into the mitochondria. AP39 
(MW = 722.2 g mol-1), AP219 (MW = 433.5 g mol-1) and ADT-OH (MW = 226.3 g mol-
1) were synthesised as previously reported (Tomasova et al., 2015, Szczesny et al., 
2014, Le Trionnaire et al., 2014). The purity of the compound was determined by NMR 
spectroscopy (1H, 31P and 13C). Doses of AP39, AP219 and ADT-OH used in these 
experiments derived from in vitro and in vivo studies undertaken by others (Szczesny 
et al., 2014, Ikeda et al., 2015, Ahmad et al., 2016). AP39 was given 10 minutes before 
reperfusion to allow enough time for AP39 to be accumulated in the mitochondria 
before reperfusion. 
Animals were randomised to receive one of six interventions (Figure 6.2): 
 Group 1: Control (n=10). Animals received a bolus dose of 0.05% DMSO (v/v), 
i.v. 10 min before reperfusion. DMSO was used as a vehicle for AP39, AP219 
and ADT-OH. 
 Group 2-4: Each group (n=8) received AP39 at 0.01, 0.1 or 1 µmol kg-1, 
respectively as an i.v. bolus contains 0.05% DMSO (v/v) 10 min before 
reperfusion. 
 Group 5: AP219 (n=8). Animals received AP219 (1 µmol kg-1) as an i.v. bolus 
contains 0.05% DMSO (v/v) 10 min before reperfusion. 
 Group 6: ADT-OH (n=8). Animals received ADT-OH (1 µmol kg-1) as an i.v. 
bolus contains 0.05% DMSO (v/v) 10 min before reperfusion.  
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Figure 6.2 Experimental protocol of dose-response study of AP39. Following 20 minutes 
stabilisation period, animals underwent 30 minutes myocardial regional ischaemia followed by 
120 minutes reperfusion. Arrows indicate the time of pharmacological interventions. n= 8-10. 
 
6.2.3.2 Mechanistic study of AP39 postconditioning 
The second series of infarct size experiments was undertaken to characterise whether 
AP39 replies on the RISK pathway to produce its cardioprotection. The optimum dose, 
within the applied dosing range, of AP39 (1 µmol kg-1), selected from the first series of 
experiments, was concomitantly administrated with specific pharmacological inhibitors 
for some of the RISK pathway components. Specific pharmacological inhibitors, 
namely the PI3K inhibitor LY294002 (Jiang et al., 2007), constitutive NOS inhibitor L-
NAME (Fradorf et al., 2010) and sGC inhibitor ODQ (Routhu et al., 2010) were used 
at doses that have previously been reported to abrogate the activity of their targets in 
in vivo models.  
Animals were randomly assigned to one of the following eight treatment groups (Figure 
6.3): 
-20’ 0’
Stabilisation Ischaemia (CAO)
30’ 150’20’
Control (0.05% DMSO)
AP39 (0.01, 0.1, 1 µmol kg-1)
Time
(mins)
Reperfusion
AP219 (1 µmol kg-1)
ADT-OH (1 µmol kg-1)
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 Group 1: Control (n=11). Animals received DMSO 0.05% (v/v) as an i.v. bolus 
15 min before reperfusion. DMSO was used as vehicle for AP39, LY294002 
and ODQ. 
 Group 2: AP39 (n=8). Animals received AP39 (1 µmol kg-1) as an i.v. bolus 10 
min before reperfusion. 
 Group 3: AP39 + L-NAME (n=8). L-NAME (20 mg kg-1) was administered 15 
min before reperfusion as an i.v. bolus followed by AP39 (1 µmol kg-1) 10 min 
before reperfusion. 
 Group 4: L-NAME (n=8). L-NAME (20 mg kg-1) was administered 15 min before 
reperfusion as an i.v. bolus. 
 Group 5: AP39 + LY294002 (n=8). LY294002 (0.1 mg kg-1) was given 15 min 
before reperfusion as an i.v. bolus followed by AP39 (1 µmol kg-1) 10 min before 
reperfusion. 
 Group 6: LY294002 (n=8). LY294002 (0.1 mg kg-1) was administered 15 min 
before reperfusion as an i.v. bolus. 
 Group 7: AP39 + ODQ (n=8). ODQ (1 mg kg-1) was given 15 min before 
reperfusion as an i.v. bolus followed by AP39 (1 µmol kg-1) 10 min before 
reperfusion. 
 Group 8: ODQ (n=8). ODQ (1 mg kg-1) was administered 15 min before 
reperfusion as an i.v. bolus. 
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Figure 6.3 Experimental protocol of the mechanistic study of AP39. Rats were subjected to 30 
left coronary occlusion and 120 minutes reperfusion. The pharmacological inhibitors were 
concomitantly administrated with AP39 to characterise the involvement of the RISK pathway 
in cardioprotection established by AP39. Arrows indicate the time of pharmacological 
interventions. n=8-11. 
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6.2.3.3 Myocardial tissue sampling for protein analysis 
The effect of AP39 on the phosphorylation of the RISK pathway components in the 
myocardium was further characterised in a parallel series prepared for biochemical 
analysis. Animals were randomised to receive either vehicle (0.05% DMSO) or AP39 
(1 µmol kg-1) 10 minutes before reperfusion (Figure 6.4). Animals were stabilised for 
20 minutes then subjected to 30 minutes of regional myocardial ischaemia. The heart 
was reperfused for 5 minutes then the tissue sampling was performed as described in 
Chapter 2, section 2.6.1. These samples were later used to investigate the effect of 
AP39 on the phosphorylation of Akt, eNOS, GSK-3β and ERK1/2 at the 
commencement of reperfusion using Western blotting as illustrated in Chapter 2, 
section 2.6.4. 
 
Figure 6.4 Experimental protocol of myocardial biopsies sampling following postconditioning 
with AP39. Animals were stabilised for 20 minutes with no further intervention following 
surgery then underwent 30 minutes of left coronary artery occlusion and 5 minutes 
reperfusion. Heart was then excised and myocardial samples from the left ventricle were snap 
frozen for later biochemical analysis. Rats received either vehicle of AP39 10 minutes before 
reperfusion. Arrows indicate the time of interventions.   
35’
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6.2.4 Isolation of cardiac mitochondria 
All work on isolated mitochondria was undertaken in the laboratory of Professor Rainer 
Schulz, Institute of Physiology, Justus-Liebig University, Giessen, Germany. The 
mitochondrial studies were conducted by me with the assistance of Dr Julia Bornbaum 
and Mrs Elvira Ungefug. The effect of specific delivery of H2S into the mitochondria by 
AP39 was investigated using freshly isolated rat cardiomyocyte mitochondria in vitro. 
Two subpopulations of cardiomyocyte mitochondria, namely subsarcolemmal (SSM) 
and interfibrillar mitochondria (IFM), were isolated to look at the direct effect of AP39 
on the mitochondria as they represent the most relevant mitochondria within the 
myocardium that is affected by the ischaemia and reperfusion insults. 
Isolation of the two mitochondrial subpopulations was carried out by differential 
centrifugation (Figure 6.5) using a modified protocol of Boengler et al. (2009). 
Differential centrifugation is a simple, rapid and most employed technique to 
fractionate different cell components based on the size, density and shape (Frezza et 
al., 2007). It involves applying different centrifugation cycles on the tissue homogenate 
at an increasing relative centrifugal forces. It is worth noting that isolated mitochondria 
which are fractionated by this method would be contaminated with other cell 
components (lysosomes and peroxisomes). Nevertheless, this method preserves 
mitochondria integrity and relatively less stressful for the mitochondria compared with 
density-gradient separation.  
All the procedures were undertaken at 4 ºC to maintain mitochondrial integrity. Each 
rat was anaesthetised with 4% v/v isoflurane and the heart was quickly excised and 
washed with Buffer A. The ventricles were isolated and weighed, then the right 
ventricle was snap frozen with liquid nitrogen and used as a negative control. The left 
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ventricles was transferred to Buffer B, finely chopped with scissors then gently minced 
with 6 strokes of a teflon pestle in a glass tube. Homogenate was centrifuged at 800 
g for 10 min. The supernatant was collected and centrifuged for 10 minutes at 8000 g 
to isolate the SSM. The sediment from the first centrifugation was re-suspended using 
Buffer B (10 mL 1 g-1 left ventricle weight) and incubated with protease nargase (8 U 
g-1) for 1 minute then gently minced with 5 strokes of teflon pestle and glass mortar. 
The homogenate was centrifuged at 800 g for 10 minutes then the supernatant was 
collected and centrifuged for 10 minutes at 8000 g to sediment the IFM. SSM and IFM 
were then washed twice with buffer A and final pellets were re-suspended in Buffer A 
with no ATP (i.e. incubation buffer). 
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Figure 6.5 Scheme illustrating the protocol for isolation of rat-derived cardiomyocyte 
mitochondria using differential centrifugation. 
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6.2.4.1 Protein quantification of the mitochondrial samples 
The total protein concentration in the mitochondrial samples was determined using 
Lowry assay (see Chapter Two, section 2.1.4). Lowry protein assay is based on the 
reaction of copper ion (Cu+), as an indicator of the protein concentration, with Folin 
phenol reagent in alkaline condition (Lowry et al., 1951). A serial dilution of bovine 
serum albumin (BSA) was prepared (0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.4 mg mL-1) and 
used as standard stocks to construct the standard curve. Samples from each 
subpopulation of mitochondria were taken and diluted 1:20 and 2:20 v/v with distilled 
water. Samples and standards were loaded onto 96-well plate in duplicate and 25 µL 
of a mixture of reagent A and reagent S in 1:20 v/v was added to each well. Reagent 
B (200 µL) was then added to each well and the absorbance was measured at 750 
nm using ELISA microplate reader model (Infornite M200, Tecan, Germany). 
6.2.5 Mitochondrial functions 
The concentration range of AP39 used for the mitochondrial studies was equivalent to 
the in vivo doses which were used in the infarct studies. Mitochondrial toxicity studies 
were also conducted to investigate the effect of these concentrations of AP39 on 
mitochondria integrity by measuring mitochondrial membrane potential and 
mitochondrial autofluorescence. 
6.2.5.1 Mitochondrial membrane potential  
The toxicity of AP39 on cardiomyocyte mitochondria integrity was characterised using 
mitochondrial membrane potential as an indicator. Fluorescence probes have been 
often used to study the cell biology in general and the biochemical functions of its 
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organelles in particular including the mitochondria. In these experiments, we employed 
Rhodamine 123 as a cell-permeant, cationic and fluorescence dye to assess the 
impact of AP39, within the chosen dosing range, on mitochondrial membrane 
potential. Rhodamine 123 can be sequestered into the mitochondria in the presence 
of the membrane potential. The leakage of Rhodamine 123, which could be due to the 
opening of PTP or membrane rupture, from the mitochondrial into the buffered solution 
will indicate the disruption of the membrane potential and will appear as an increase 
in the fluorescence magnitude. The fluorescence of Rhodamine 123 in the 
Glutamate/Malate buffer was measured for 1 minute then subsarcolemmal 
mitochondria (0.5 mL-1) were added to the solution in the cuvette. After five minutes 
stabilisation, mitochondria were randomly subjected to either 0.003% ethanol or AP39 
(0.3, 1, 3, 5 and 10 µM). The membrane potential was measured using Clary Eclipse 
spectrophotometer (Varian, Mulgrave, Australia) at 503/535 nm excitation/emission 
wavelength.  
6.2.5.2 Mitochondrial autofluorescence 
Autofluorescence of mitochondrial nicotinamide adenine dinucleotide (NADH) and 
flavin adenine dinucleotide (FADH) was used as another approach to evaluate the 
toxicity of AP39 on the mitochondria. NADH and FADH are electron carrier and they 
transfer the electrons from tricarboxylic acid cycle (TAC) to the mitochondrial electron 
transport chain (ECL). The level and the fluorescence of NADPH and the oxidised form 
of FADH (FAD) inside the mitochondria reflect the status of the ECL. Subsarcolemmal 
mitochondria were incubated with Glutamate/Malate buffer for 5 minutes with stirring 
at 25 °C when basal autofluorescence was measured. Mitochondria were then treated 
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with either vehicle (0.003% ethanol) or one of AP39’s concentrations (0.3, 1, 3, 5, 10 
µM). Mitochondrial autofluorescence was measured at 340/460 nm 
excitation/emission wavelength using Clary Eclipse spectrophotometer (Varian, 
Mulgrave, Australia). 
6.2.5.3 Ca2+ retention capacity (CRC) 
The opening of mitochondrial permeability transition pore (PTP) at the commencement 
of reperfusion represents the starting point of cell necrosis following myocardial 
ischaemia and reperfusion as a result of overwhelming ROS generation, pH 
normalisation and Ca2+ overload at early reperfusion. Therefore, we sought to examine 
if AP39 influences the mitochondrial calcium retention capacity, as an indicator of the 
susceptibility of PTP opening, in vitro using rat cardiomyocyte SSM and IFM. We used 
a modified protocol of Chen et al. (2012). The basis of CRC assay is that it measures 
mitochondrial tolerability toward Ca2+ which is considered as a major trigger of PTP 
opening. Mitochondria can retain calcium as calcium phosphate to buffer cytosolic 
level of calcium. However, when mitochondrial capacity to store calcium exceeded, 
this will lead to the opening of PTP and eventually releasing its calcium load back into 
the cytosol. 
Freshly isolated SSM and IFM (0.1 mg mL-1) were randomised to be incubated for 4 
minutes in 2 mL of Glutamate/Malate buffer. The suspension was supplemented with 
8 µL ADP (10 mM), 10 µL EGTA (1 mM), 6 µL CaCl2 (5 mM) and 1 µL calcium green-
5N (1 µM). Mitochondria fractions were then incubated with either vehicle (0.003% 
(v/v) ethanol) or AP39 (1 µM) in the presence and absence of cyclosporine A (CsA, 1 
µM). CsA was used as a positive control as it is a well-known inhibitor of the PTP 
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opening and increases mitochondrial tolerance to Ca2+ overload in a CypD-dependent 
mechanism in the experimental settings. Pulses of Ca2+ (5 µmol) were added at 3 
minutes intervals to the solution with stirring at 25 ºC and mitochondrial calcium 
tolerance was expressed as µmol of Ca2+ mg-1 of protein. Fluorescence was measured 
with excitation and emission wavelengths 500 and 530 nm, respectively. Data were 
coded using random number generator (https://www.random.org ) and the analysis 
was perform in a blind fashion to avoid possible bias. 
6.2.5.4 Mitochondrial ROS generation 
Measurement of mitochondrial ROS generation was carried out as previously 
descripted by Soetkamp et al. (2014). Freshly isolated SSM or IFM (50 µg) were 
separately gently suspended in Glutamate/Malate buffer and incubated randomly with 
either: (1) Glutamate/Malate buffer (1st Control); (2) vehicle (0.003% (v/v) ethanol) or 
(3) AP39 (0.3, 1, 3, 5 µM). Horseradish peroxidase (HRP, 0.1 U mL-1) and 50 µmol of 
Amplex UltraRed were added to the suspension directly before the measurement. 
Amplex Ultrared is a stable and sensitive fluorogenic substrate for peroxidase 
detection and extensively employed in cell culture and mitochondrial studies to detect 
the generation of H2O2. It reacts with activated HRP in 1:1 stoichiometric ratio to 
produce a brightly fluorescence product (Resorufin) which can be detected at 
excitation/emission wavelengths 565/581 nm. Amplex Ultrared offers a number of 
advantages over Amplex red as it is more sensitive to HRP on a per-mole basis and it 
is more resistant to oxidation by ROS. Moreover, it is stable over a wide pH range 
compared to Amplex red. 
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A second control group, form each subpopulation, with no intervention was employed 
at the end of the all measurements to ensure that any observed effects are due to 
AP39 and not because of the decline in the respiratory capacity (i.e. run-down of the 
mitochondria with the time). SSM and IFM were also incubated with rotenone (2 µM) 
to induce overproduction of mitochondrial ROS generation by uncoupling of complex 
I of the electron transport chain and used as a positive control for comparison. 
Mitochondrial ROS generation was measured for 4 minutes at room temperature using 
Cary Eclipse spectrophotometer (Agilent technologies, Santa Clara, Canada) at 
excitation/emission wavelengths 565/581 nm. Using random number generator 
(https://www.random.org), data were coded and slope of mito-ROS generation was 
calculated, as a mean fluorescence per time (a.u.), after subtracting the background 
fluorescence of the incubation buffer, in a blind fashion. 
6.2.5.5 Mitochondrial oxygen consumption 
The respiration of SSM and IFM was measured using a Mitocell Respiratory System 
(Strathkelvin, Glasgow, UK) at 25 ºC. Mitocell is a glass chamber surrounded by 
circulating water jacket to maintain temperature and has a Clark-type oxygen 
microelectrode which consists the base of the chamber. Microelectrode consists of 
cathode and anode where the oxygen is reduced by the cathode when both the anode 
and the cathode are polarised. Reduction of each oxygen molecule consumes four 
electrons which create the current that flows in the circuit.  
Basal mitochondrial oxygen consumption was measured in the presence and absence 
of either the vehicle (0.003% (v/v) ethanol) or AP39 (0.3, 1, 3, 5 µM). Mitochondria 
(0.1 mg ml-1) were randomly incubated in two chambers simultaneously, one with 
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complex I substrate (5 mM glutamate and 2.5 mM malate) or with complex II substrate 
(5 mM succinate plus 2 µM rotenone, to inhibit complex I activity). Respiration was 
stimulated by addition of 40 µM ADP and oxygen consumption was reported as nmol 
of O2 min-1 mg-1 of protein. Oxygraph charts were coded using random number 
generator (https://www.random.org) and data were analysed by a person who is blind 
to the treatments. 
6.2.5.6 Effect of AP39 on mitochondrial GSH production 
The levels of GSH and GSSG in the mitochondrial compartments following AP39 
application were assessed using a glutathione assay kit. Subsarcolemmal 
mitochondria (SSM) were isolated as described in section 6.2.4 with some 
modifications to measure the mitochondrial content of GSH and GSSG after AP39 
application (Figure 6.6). Left ventricle was isolated and finely chopped with scissors in 
Buffer A then ultrasonicated (3 X10 seconds cycle, with 5 seconds waiting interval) 
using an Ultra turrax homogeniser (IKA T-18, Cole Parmer, UK). Homogenate was 
centrifuged at 800 g for 10 minutes then the supernatant was recovered, which 
represents the SSM, and washed using isolation buffer 1 with centrifugation at 8000 g 
for 10 minutes. SSM pellet was then re-suspended in Glutamate/Malate buffer and 
incubation with either ultrapure water or AP39 (1 µmol) on thermomixer (BioShake, 
Jena, Germany) at 650 rpm for 10 minutes at 25 ºC. Stimulated mitochondria were 
centrifuged at 10300 g for 5 minutes, re-suspended in (200 µL) isolation buffer 2 and 
added gently on the top of 4 mL of 30% Percoll in 5 mL tube then centrifuged at 32000 
g for 30 minutes at 4 °C. Impurities ring was discarded and mitochondria was 
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recovered then washed twice with isolation buffer 2 with centrifugation at 12500 g for 
5 minutes.  
Purified mitochondria were re-suspended using 150 µL of 2-(N-morpholino) 
ethanesulfonic acid (MES) buffer with sonication. Mitochondria sample was then 
deproteinated by centrifugation at 10000 g for 15 minutes and the supernatant was 
collected. The supernatant was mixed with metaphosphoric acid (MPA, 1.25 M) with 
vortexing and left to set for 5 minutes. The supernatant was then carefully collected 
without disturbing the precipitation. 
A- To measure the total mitochondrial GSH content, the supernatant was mixed 
with 4 M triethanolamine (TEAM, 50 µL of TEAM for each 1 mL supernatant) 
with vortexing.  
B- To measure the mitochondrial GSSG content, GSSG was exclusively derived 
from GSH by treating the supernatant from step A with 1 M 2-vinylpyridine (10 
µL for each 1 mL of the supernatant) with vortexing and incubated for 1 hour 
before it was ready to assay. 
A series of GSSG standard aliquots (0, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0 µM GSSG) 
were prepared. Standard aliquots and the samples (50 µL from each) were loaded in 
duplicate onto a 96-well plate then, 150 µL of freshly prepared Assay Cocktail was 
added to each well. The plate was incubated on an orbital shaker in the dark for 25 
minutes then read using an ELISA microplate reader (Infonite M200, Tecan, Germany) 
at 405-414 nm. Absorbance values was corrected by subtracting the absorbance value 
of the diluting buffer (MES) and the corrected absorbance values were plotted as a 
functions of either GSSG or the total GSH concentration used to construct the 
Chapter 6 
183 
 
standard curve. The concentration of the total GSH or GSSG was calculated by the 
following equation: 
[𝑇𝑜𝑡𝑎𝑙 𝐺𝑆𝐻] 𝑜𝑟 [𝐺𝑆𝑆𝐺] =  [
(𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 405 − 414 𝑛𝑚) −  (𝑌 − 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡)
𝑆𝑙𝑜𝑝𝑒
]  × 2 × 𝑆𝑎𝑚𝑝𝑙𝑒 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
 
 
Figure 6.6 Protocol for isolation of subsarcolemmal mitochondria (SSM) and stimulation with 
AP39 for GSH experiments.  
Isolated rat heart Right ventricle
Left ventricle
- Washed with cold saline
- Finely chopped with scissors on ice
- Ultrasonicated in Buffer A on ice
- 800 g for 10 mins at 4  C
Supernatant Pellet
- 8000 g for 10 mins at 4  C
- Resuspended with Buffer A
- 8000 g for 10 mins at 4  C
Pellet
- Resuspended in iso. Buffer 1
- 8000 g for 10 mins at 4  C
Pellet
- Resuspended in Glu/Mal buffer
- Incubated with either AP39 or 
water for 10 mins at 25 C
- 10300 g for 5 mins at 4  C
Pellet
- Resuspended with iso. Buffer 2
- Added to 30% Percoll solution
- 32000 g for 30 mins at 4  C
Supernatant
Supernatant
Supernatant
Impurities layer
(top ring)
Mitochondrial layer
(bottom ring)
GSH assay
- Washed (2X) with iso. Buffer 2
- 12500 g for 5 mins at 4  C
Pellet Supernatant
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6.2.6 Effect of AP39 on S-nitrosylation of mitochondrial proteins 
6.2.6.1 Mitochondrial preparations 
Mitochondria fractions were isolated as previously described in section 6.2.6 with 
some modifications (Figure 6.7). Harvested rat heart was washed using ice-cold saline 
and the right ventricle was isolated and snap frozen with liquid nitrogen to use as a 
negative control then the left ventricle was weighed. Left ventricle was washed with 
Buffer A (3-4 times) until no blood clots were seen, then finely chopped using scissors. 
Cardiac tissue was further homogenised in ice-cold Buffer A (3 X 10 seconds cycle, 
with 5 seconds waiting after each cycle) using an Ultra turrax homogeniser (IKA T-18, 
Cole Parmer, UK). Mitochondria were then isolated by differential centrifugation. The 
homogenate was centrifuged at 800 g for 10 minutes and the supernatant, which 
contains the subsarcolemmal mitochondria (SSM), was transferred to 2 mL Eppendorf 
tubes. The pellet from the first centrifugation was then re-suspended with Buffer B and 
incubated with protease nargase (8 U 1 g-1 left ventricle weight) for 1 minute. The 
tissue suspension was homogenised by potter-teflon (5 strokes) and centrifuged at 
800 g for 10 minutes. Supernatant, which contained the interfibrillar mitochondria 
(IFM), was collected and transferred to 2 mL Eppendorf tubes. Both mitochondria 
pellets were centrifuged at 14300 g for 10 minutes and the produced pellets were 
washed twice using mitochondria isolation buffer 1 with centrifugation at 10300 g for 
5 minutes. The SSM and IFM pellets were finally re-suspended in isolation buffer 1. 
The total protein concentration in the final mitochondrial solutions was determined 
using Lowry assay as described in section 6.2.6.1. SSM and IFM (200 mg mL-1) 
solutions were diluted with Glutamate/Malate buffer and stimulated separately in 2 mL 
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amber Eppendorf tubes with one of the following treatments: (1) isolation buffer 1, (2) 
AP39 (0.3 µmol), (3) AP39 (1 µmol) and (4) 0.5 mmol SNAP, which is a NO donor and 
as a positive control. The incubation was carried out on thermomixer (BioShake, Jena, 
Germany) at 650 rpm for 10 minutes at 25 °C, then the tubes were centrifuged at 
10300 g for 5 minutes. Supernatant was discarded and the pellet was re-suspended 
with (200 µL) mitochondria isolation buffer 3. Mitochondria were purified using the 
Percoll gradient technique (Boengler et al., 2012). Re-suspended pellets were added 
on the top of 4 mL of 30% Percoll in 5 mL tube, then centrifuged at 32000 g for 30 
minutes. After centrifugation, impurities form a ring which is attached to the interior 
tube surface at the top of the tube while purified mitochondria form another ring near 
the bottom of the tube. The impurities ring was carefully discarded and purified 
mitochondria were recovered and diluted with mitochondria isolation buffer 2. 
Mitochondria were washed twice using isolation buffer 2 with centrifugation at 12500 
g for 5 minutes to remove any residue of Percoll. Purified mitochondrial proteins were 
then snap frozen using liquid nitrogen and kept at -80 °C.  
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Figure 6.7 Protocol for isolation of SSM and IFM and stimulation with AP39 and SNAP for 
S-nitrosylation Assay. 
  
Isolated rat heart Right ventricle
Left ventricle
- Washed with cold saline
- Finely chopped with scissors on ice
- Ultrasonicated in Buffer A on ice
- 800 g for 10 mins at 4  C
Supernatant 1 Pellet
- 14300 g for 10 mins at 4  C
- Resuspended with iso Buffer 1
- 10300 g for 5 mins at 4  C
Pellet
- Resuspended in Glu/Mal buffer
- Incubated with either AP39, SNAP 
or water for 10 mins at 25 C
- 10300 g for 5 mins at 4  C
- Resuspended with iso. Buffer 3
- Added to 30% Percoll solution
- 32000 g for 30 mins at 4  C
Supernatant
Impurities layer
(top ring)
Mitochondrial layer
(bottom ring)
S-nitrosylation
assay
- Washed (2X) with iso. Buffer 2
- 12500 g for 5 mins at 4  C
Pellet Supernatant
- Re-suspended in Buffer B on ice
- Incubated with  nargase for 1 min on ice
- Gently pottered (5X) on ice
- 800 g for 10 mins at 4 C
Pellet Supernatant 2
(It was treated similar to 
Supernatant 1 after this step)
SupernatantPellet (SSM)
Chapter 6 
187 
 
6.2.6.2 Detecting AP39-induced S-nitrosylation using Ponceau dye 
Mitochondrial proteins samples were heated at 95 °C for 5 minutes then loaded (30 
µg) to 10% w/v SDS-PAGE and separated electrophoretically at (120 mV). Separated 
proteins were then left overnight to transfer onto nitrocellulose membrane (Amersham, 
Germany) at 30V. The membrane was washed with distilled water before incubated 
with 0.2% TCA, Ponceau® S solution for 15 minutes. Ponceau® S is a rapid and 
reversible dye to detect and visualise the protein bands on polyvinylidene fluoride or 
nitrocellulose membranes without affecting the sequence of blotted proteins. The 
membrane was scanned using an imaging system (Quantum ST5, Vilber, Germany). 
6.2.6.3  Detecting AP39-induced S-nitrosylation using Pierce S-nitrosylation 
Western blot kit 
Detection of mitochondrial nitrosylated protein was carried out using Pierce S-
Nitrosylation Western blot kit according to the manufacturer’s instructions (Figure 6.8). 
Purified mitochondrial proteins were re-suspended with cell lysis HENS buffer (100 
mM HEPES (pH 7.8), 1 mM EDTA, 0.1 mM Neocuproine, and 1% SDS) to achieve 
final concentration of (100 µg 100 µL-1) for each protein sample. Free sulfhydryl groups 
were blocked using 4 µL of methyl methanethiosulfonate (MMTS, 1 M) with vortexing 
for 1 minute and incubation for 30 minutes at 25 °C. The proteins were then 
precipitated using 600 µL pre-chilled acetone and frozen at -20 °C for 1 hour to remove 
MMTS. Samples were centrifuged at 10000 g for 10 minutes and left to dry for 10 
minutes before re-suspending the pellet with 100 µL HENS buffer. Each sample was 
divided into two new Eppendorf tubes. Nitrosylated proteins were labelled using 1 µL 
of the 20 mM iodoTMTzeroTM Labelling reagent (iodoTMT reagent). To selectively 
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reduce the ntirosylated cysteine residues, 2 µL of 1 M sodium ascorbate was added 
to one of the tubes from each protein samples while 2 µL of ultrapure water was added 
to the other tube with brief vortexing. The reaction was proceeded for 2 hours at 25 
°C. Labelled sample (10 µL) were diluted with 5X reducing Laemmli buffer, heated at 
95 C for 5 minutes then separated by pre-cast 12-well SDS-PAGE gel (Mini-Protean® 
TGXTM Precast gel, BioRad, Germany) at 200 mV. Separated proteins were then 
transferred overnight onto nitrocellulose membrane and the immunoblot was blocked 
with blocking solution for 1 hour. The membrane was incubated with anti-TMT antibody 
solution (anti-TMT antibody in 5% NFDM in TBST) for 1 hour then washed three times 
for 15 minutes with 1% TBST. The probed membrane was incubated with the 
secondary antibody (anti-mouse IgG-HRP) for 1 hour then washed three times for 15 
minutes with TBST. The immunoblot was incubated with Supersignal West Pico 
Chemiluminescent Substrate for 5 minutes, then digitally scanned using automated 
imaging system (Quantum ST5, Vilber, Germany). 
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Figure 6.8 Scheme illustrating the detection of mitochondrial S-nitrosylated protein post-transilational modifications using Pierce S-Nitrosylation 
Western blot kit. SSM and IFM were isolated and stimulated with either AP39 or SNAP. Mitochondrial extract was treated with MMTS to block 
the free thiol groups. S-nitrosylated residues were then specifically reduced with ascorbate and labelled with TMT to be later detected with TMT 
antibody using Western blotting technique.     
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6.3 Results 
6.3.1 Inclusion/exclusion criteria 
A total of 164 rats were used for these studies. For the AP39 dose-response study, 52 
rats were employed, of which two were excluded: one did not have successful 
reperfusion and one rat did not survive ischaemia-induced ventricular fibrillation. 
Therefore, data from 50 successfully completed experiments are presented for series 
1. In the second series, 83 rats were used, of which four were excluded: two did not 
complete the ischaemia/reperfusion protocol, one did not have a successful TTC 
staining and one did not survive reperfusion-induced arrhythmia. Thus, data from 79 
rats (67 infarct size experiments which were successfully completed and 12 tissue 
sampling experiments) were reported for series 2. For mitochondria functional studies, 
data from 29 rats are reported with no exclusion. 
6.3.2 Pharmacological postconditioning with AP39 
6.3.2.1 Haemodynamic parameters 
Baseline parameters and haemodynamic measurements for the dose-response study 
are shown in Table 6.2. There was no significant difference among the six 
experimental groups in any of the baseline parameters. Postconditioning the heart with 
AP39 resulted in a dose-dependent improvement in the post-ischaemia functional 
recovery with maximum improvement (67.2 ± 3.8%) at (1 µmol kg-1) compared to the 
control hearts (46.2 ± 3.4%, Table 6.2). This functional recovery was represented by 
increased RPP at the end of reperfusion as a percentage of the pre-ischaemic RPP 
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(i.e. RPP recovery as a percentage of the baseline RPP). The control compounds 
(AP219 and ADT-OH) did not improve the functional recovery at the end of 
reperfusion. None of the interventions had any effect on the MAP. 
6.3.2.2 Infarct limitation with AP39 postconditioning 
Myocardial infarction was determined using the Evan’s blue/TTC staining protocol. 
Area at risk (ischaemic bed) is presented as a percentage of the total ventricular 
volume while, infarct size was reported as a percentage of the ischaemic bed. Risk 
zone was similar among the experimental groups (50-60% of the total ventricular 
volume, Figure 6.9A). Administration of AP39 10 minutes before reperfusion resulted 
in a dose-dependent infarct-sparing effect compared with vehicle-treated animals 
(Figure 6.9B), with maximum protection seen at 1 µmol kg-1 dose (infarct size 32.1 ± 
3.0% vs 52.8 ± 3.8%, p<0.001). This represents almost 40% reduction in infarct size. 
The control compounds, namely AP219 and ADT-OH, did not have a significant effect 
on infarct size. 
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Table 6.2 Summary of haemodynamic parameters for AP39 dose-response study during ischaemia/reperfusion protocol 
Experimental Protocol 
n BW (g) Baseline 20 min Ischaemia 120 min Reperfusion 
  RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
Control (0.05% DMSO) 10 342 ± 5 36.2 ± 2.1 90 ± 6 26.0 ± 1.9 70 ± 3 16.7 ± 2.2 55 ± 5 
AP39 0.01 µmol kg-1 8 347 ± 7 38.4 ± 2.8 92 ± 4 27.1 ± 2.4 70 ± 5 17.7 ± 1.8 58 ± 3 
AP39 0.1 µmol kg-1 8 339 ± 5 40.0 ± 2.0 89 ± 6 28.7 ± 1.2 68 ± 7 20.0 ± 1.3 54 ± 5 
AP39 1 µmol kg-1 8 355 ± 5 38.5 ± 1.5 85 ± 5 29.4 ± 2.3 67 ± 3 25.8 ± 1.2* 49 ± 4 
AP219 1 µmol kg-1 8 356 ± 7 37.8 ± 2.0 87 ± 7 27.6 ± 1.6 71 ± 5 16.2 ± 1.5 51 ± 6 
ADT-OH 1 µmol kg-1 8 342 ± 6 39.4 ± 2.5 90 ± 4 29.1 ± 2.3 68 ± 4 17.5 ± 1.8 54 ± 5 
n number of animals per group; BW body weight; RPP rate pressure product; MAP mean arterial pressure. Data are reported as mean ± SEM. 
(repeated measures ANOVA followed by Bonferroni post hoc test), * p < 0.05 vs control value at the same time point.  
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Figure 6.9 Area at risk and infarct size data for dose-response study of AP39. Infarct size was determined following 30 minutes left coronary 
artery occlusion and 120 minutes reperfusion using Evans’ blue/TTC staining technique. (A) Area at risk is expressed as a percentage of the total 
ventricular volume and (B) Infarct size is reported as a percentage of area at risk. All pharmacological interventions were given 10 minutes before 
reperfusion. Data were analysed using one-way ANOVA followed by Newman Keuls post hoc test and expressed as mean ± SEM, *p<0.05, 
***p<0.001 vs control; †p<0.05 vs AP39 (1 µmol kg-1). The mean of infarct size is presented as a filled circle (with error bars) next to the individual 
value for each group (open circles).   
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6.3.3 Mechanistic study of AP39: involvements of PI3K/Akt and NO 
6.3.3.1 Haemodynamic parameters 
Baselines and cardiodynamics are shown in Table 6.3. There was no significant 
difference among the experimental groups in any of the baseline parameters. Similar 
to the first series, postconditioning with AP39 significantly increased the RPP at the 
end of reperfusion compared to the control (28.2 ± 1.5 vs 15.2 ± 1.8, p<0.05). This 
represent an improvement in the post-ischaemic functional recovery (%RPP recovery) 
by 29% compared to the control group. Co-administration of any of the 
pharmacological inhibitors, namely LY294002, L-NAME and ODQ, did not alter the 
%RPP recovery induced by AP39 (24.5 ± 1.6, 27.4 ± 2.4 and 26.3 ± 1.9, respectively) 
compare to vehicle-treated group. Application of AP39 did not have an effect on the 
MAP. Administration of any of the inhibitors alone did not affect either RPP or MAP. 
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Table 6.3 Summary of haemodynamic parameters throughout ischaemia/reperfusion protocol for mechanistic study of AP39 with the 
pharmacological inhibitors 
Experimental Protocol 
n BW (g) Baseline 20 min Ischaemia 120 min Reperfusion 
  RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
RPP 
(mmHg min-1)*103 
MAP 
(mmHg) 
Control 11 361 ± 5 35.5 ± 2.0 87 ± 6 26.1 ± 1.7 65 ± 4 15.2 ± 1.8 53 ± 5 
AP39 8 356 ± 7 39.6 ± 3.1 92 ± 4 31.1 ± 2.0 68 ± 5 28.2 ± 1.5* 54 ± 6 
AP39 + L-NAME 8 365 ± 6 36.0 ± 1.9 90 ± 7 29.5 ± 1.8 67 ± 8 27.4 ± 2.4* 53 ± 5 
L-NAME 8 371 ± 9 39.3 ± 1.6 89 ± 5 28.6 ± 2.4 74 ± 5 14.4 ± 2.1 56 ± 4 
AP39 + LY294002 8 359 ± 10 37.4 ± 1.5 86 ± 6 32.0 ± 2.2 70 ± 6 24.5 ± 1.6* 52 ± 5 
LY294002 8 367 ± 9 42.3 ± 2.5 91 ± 4 30.2 ± 1.7 69 ± 6 16.4 ± 2.0 60 ± 7 
AP39 + ODQ 8 365 ± 7 39.6 ± 1.5 93 ± 5 31.5 ± 1.6 71 ± 4 26.3 ± 1.9* 55 ± 5 
ODQ  8 370 ± 8 40.3 ± 2.5 88 ± 7 28.6 ± 1.4 66 ± 5 15.6 ± 2.0 63 ± 4 
n number of animals per group; BW body weight; RPP rate pressure product; MAP mean arterial pressure. Data are reported as mean ± 
SEM. (repeated measures ANOVA followed by Bonferroni post hoc test), * p < 0.05 vs control value at the same time point. 
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6.3.3.2 Infarct size data 
We next investigated the dependency of AP39’s postconditioning protection on both 
PI3K/Akt and NO as a relevant protective cytosolic-signalling pathway using a “signal 
tracing” approach (i.e. sequential interrogation of each stage in the signal transduction 
cascade). There was no significant difference in the risk zone (ischaemic bed) among 
the groups (Figure 6.10A). None of the pharmacological inhibitors alone had a 
significant effect on infarct size when given alone 15 minutes before reperfusion 
compared to the control group (Fig. 6.10B). Pharmacological postconditioning using 
AP39 1 µmol kg-1 significantly limited the infarct size (30.1 ± 2.7% vs 53.0 ± 2.2%, 
p<0.001) when given at 10 minutes before reperfusion as seen in series 1. This 
represents a 43% reduction in the final infarct size following ischaemia/reperfusion 
protocol. Blockade of PI3K activity with LY294002 did not abolish the infarct limitation 
induced by applying AP39 alone (33.6 ± 2.4% vs 30.1 ± 2.7%). Similarly, neither 
blockade of NO synthesis by L-NAME nor selective inhibition of its downstream 
effector, sGC, with ODQ attenuated the protective effect of AP39 (38.3 ± 2.8% and 
32.9 ± 2.7%, respectively). 
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Figure 6.10 Area at risk and infarct size data for the mechanistic study of AP39 with the RISK pathway blockers. (A) Area at risk (risk zone) is 
expressed as a percentage of total ventricular volume and (B) myocardial infarction was reported as a percentage of the risk zone. Infarct size was 
determined using Evans’ blue/TTC staining protocol following 30 minutes myocardial ischaemia and 2 hours reperfusion. Data were analysed 
using one-way ANOVA with Newman Keuls post hoc test and reported as mean ± SEM. ***p<0.001 vs control. The mean infarction is shown as 
a filled circle (with error bars) next to the individual value for each group (open circles). 
0
10
20
30
40
50
60
70
80
A
re
a
 a
t 
R
is
k
(%
 o
f 
th
e
 t
o
ta
l 
v
e
n
tr
ic
u
la
r 
a
re
a
)
0
10
20
30
40
50
60
70
80
In
fa
rc
t 
S
iz
e
(%
 o
f 
th
e
 a
re
a
 a
t 
ri
sk
)
*
***
†
A B
Chapter 6 
198 
 
6.3.4 Protein phosphorylation following postconditioning with AP39 
The effect of AP39, used as an adjunct to reperfusion, on the phosphorylation of key 
cytosolic components of the RISK pathway was also evaluated in samples harvested 
from the left ventricle after 5 minutes of reperfusion. Immunoblotting was carried out 
using phospho-specific antibodies for Akt, eNOS, GSK-3β and ERK1/2 to outline their 
role in the cardioprotection. In line with the infarct size data, Western blot analysis 
showed that administration of AP39 at reperfusion had no significant effect on the 
phosphorylation of either Akt, eNOS, GSK-3β or ERK1/2 (Figures 6.11 and 6.12). 
Together with the infarct data described in 6.3.3.2, these data support the hypothesis 
that AP39 mediated its cardioprotection in a manner independently of the activation of 
cytosolic RISK pathway components. 
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Figure 6.11 Effect of postconditioning with AP39 on the phosphorylation of Akt and eNOS at 
early reperfusion. Representative western blots and densitometry analysis of (A) p-
Aktser473/total Akt, (B) total Akt/ GAPDH, (C) p-eNOSser1177/total eNOS and (D) total 
eNOS/GAPDH. Specific antibodies were used to assess the effect AP39 on the phosphorylation 
of Akt and eNOS in myocardial biopsies harvested from the left ventricle after 5 minutes of 
reperfusion. Histograms show the relative ratio of phosphorylated protein to the total level of 
protein. GAPDH was used as an internal standard for all quantifications. Data were analysed 
using unpaired student’s t-test and presented as mean ± SEM. There was no significant 
difference between AP39 and control. For all groups, n= 6 hearts from 6 independent 
experiments. 
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Figure 6.12 Effect of postconditioning with AP39 on the phosphorylation of GSK-3B and 
ERK1/2 at early reperfusion. Representative western blots and densitometry analysis of (A) p-
GSK-3βser9/total GSK-3β, (B) total GSK-3β/ GAPDH, (C) p-ERK1/2Thr202/Try204/total ERK1/2 
and (D) total ERK1/2/GAPDH. Specific antibodies were used to assess the effect AP39 on the 
phosphorylation of GSK-3β and ERK1/2 in myocardial biopsies harvested from the left 
ventricle after 5 minutes of reperfusion. Histograms show the relative ratio of phosphorylated 
protein to the total level of protein. GAPDH was used as an internal standard for all 
quantifications. Data were analysed using unpaired student’s t-test and presented as mean ± 
SEM. No significant difference between AP39 and control. For all groups, n= 6 hearts from 6 
independent experiments. 
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6.3.5 Direct mitochondrial effects of AP39 
6.3.5.1 Toxicity study of AP39 on the mitochondria 
The first series of mitochondria experiments involved evaluation of the toxicity of AP39 
on the mitochondria using two approaches, namely mitochondrial membrane potential 
and autofluorescence. Mitochondria were treated with a concentration range of AP39 
(0.3, 1, 3, 5, 10 µM) which was equivalent to the dosing range used in vivo. At the 
highest concentration of AP39 (10 µM), AP39 started to disturb the mitochondria 
integrity as an evidence of increase in Rhodamine 123 leak (Figure 6.13A) and 
decrease in mitochondrial autofluorescence (Figure 6.13B). None of the other 
concentration induced detectable effect on either mitochondrial membrane potential 
or autofluorescence. Accordingly, the concentration range (0.3, 1, 3 and 5 µM) of AP39 
was used in the consequent mitochondrial studies. 
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Figure 6.13 Toxicity study of AP39 on subsarcolemmal rat mitochondria in vitro. (A) Mitochondrial membrane potential and (B) autofluorescence 
were measured when mitochondria were treated with vehicle (0.003% ethanol) or with AP39 (0.3, 1, 3, 5 and 10 µM). AP39 started to disturb 
mitochondria integrity at 10 µM concentration. Accordingly, the concentration range (0.3-5 µM) was considered safe and used in subsequent 
mitochondrial studies. a.u., arbitrary unit. Arrows indicate when mitochondria were introduced and when treatments were added into the solution.    
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6.3.5.2 AP39’s impact on Ca2+overload-induced PTP opening 
We examined the effect of specific-delivery of H2S into the mitochondria on the 
susceptibility of PTP opening as a result of Ca2+ overload. We used freshly isolated 
rat-derived SSM and IFM and treated them with either vehicle or AP39 (1 µM). SSM 
and IFM were then exposed to pulses of Ca2+ in the presence and absence of CsA as 
a positive control (Figure 6.14). Untreated IFM showed a 30% higher calcium tolerance 
than untreated SSM (in µmol of Ca2+ mg-1: 171 ± 9 vs 121 ± 8, p<0.001). AP39 elicited 
a significant inhibitory effect on PTP opening in both SSM and IFM compared to 
vehicle-treated mitochondria (in µmol of Ca2+ mg-1:163 ± 6 and 240 ± 15, respectively, 
p<0.001). The inhibitory effect of AP39 on PTP opening was comparable to that 
observed after CsA in both mitochondria fractions, which represents almost 30% 
increase in mitochondrial Ca2+ tolerance. Interestingly, AP39 showed an additive effect 
to CsA-induced inhibition of PTP opening. There was a further 25% increase in 
mitochondrial Ca2+ retention capacity when mitochondria were incubated with both 
AP39 and CSA before the exposure to Ca2+ pulses, compared to CsA alone (in µmol 
of Ca2+ mg-1: SSM: 240 ± 9 vs 180 ± 7, p<0.001; IFM: 351 ± 19 vs 261 ± 14, p<0.001). 
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Figure 6.14 Effect of AP39 on the opening of the mitochondria permeability transition pore 
(PTP). Subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria were individually 
incubated with either vehicle (0.003% ethanol) or AP39 (1 µM). Mitochondria were then 
subjected to series of 5 µM of CaCl2 per 3 minutes at 25 ºC until the opening of the PTP. CsA 
was used as a positive control to inhibit the opening of PTP. Data were analysed using two-
way ANOVA followed by Bonferroni post hoc test and presented as mean ± SEM, ***p<0.001 
vs SSM + vehicle, ###p<0.001 vs SSM + vehicle + CsA, ††p<0.01 vs IFM + vehicle, †††p<0.001 
vs IFM + vehicle. $$$p<0.001 vs IFM + vehicle + CsA. n=10 per group. 
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6.3.5.3 The effect of AP39 on mito-ROS generation 
Overwhelming mitochondrial ROS generation at early reperfusion is one of the main 
determinants of cellular injury. Therefore, we performed in vitro experiments to look at 
the direct effect of AP39 on H2O2 generation in the rat isolated cardiomyocyte 
mitochondria (Figure 6.15). SSM and IFM were incubated with: 1) no intervention, (2) 
vehicle (0.003% ethanol), (3) AP39 (0.3, 1, 3 and 5 µM). In the control groups, ROS 
generation was significantly lower, by 20%, in IFM than SSM (0.67 ± 0.06 a.u. vs 0.84 
± 0.04 a.u., p<0.05). There was no significant difference in mito-ROS generation 
between the first control and the second control in either mitochondria fraction. AP39 
showed a dose-dependent inhibition of ROS generation in both subpopulations where 
AP39 (1 µM) exerted the maximum inhibitory effect (38% in SSM and 61% in IFM) 
compared to control, vehicle-treated and the second control mitochondria. The 
maximum inhibitory effect of AP39 was significantly greater in IFM than in SSM (0.28 
± 0.03 a.u. vs 0.52 ± 0.08 a.u., p<0.05). Interestingly, the inhibitory effect of AP39 on 
mitochondrial ROS generation was gradually reduced as the concentration was 
increased. Rotenone, as a positive control, resulted in overproduction of ROS to 
almost the same extent in both SSM and IFM (2.4 ± 0.4 a.u. and 2.7 ± 0.2 a.u., 
respectively). Rotenone, used as a positive control, resulted in overproduction of ROS 
in both SSM and IFM by 3.2 and 3.6 folds, respectively, compare to the basal ROS 
generation level.  
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Figure 6.15 Effect of AP39 on mitochondrial-ROS generation. Mitochondria subpopulations 
(SSM and IFM) were incubated with either vehicle (0.05% DMSO) or different concentrations 
of AP39. Rotenone 123 was used as a positive control to overproduce ROS through inhibition 
of complex I. Second control was measured at the end of each series of experiments to avoid any 
false positive results due to the run-down of mitochondria fitness with the time. (A) and (B) 
are representative charts for the ROS generation of SSM and IFM, respectively, and error bars 
were removed for clarity. The slope of ROS generation was measured continuously for 4 
minutes with the fluorescence indicator Amplex Ultrared both in (C) subsarcolemmal (SSM) 
and (D) interfibrillar (IFM) mitochondria. Data are expressed as mean ± SEM and analysed 
using two-way ANOVA followed by Bonferroni post hoc test. **p<0.01, ***p<0.001 vs 1st 
control; #p<0.05, ###p<0.001 vs 2nd control. n=10 per group.  
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6.3.5.4 The effect of AP39 on mitochondrial oxygen consumption 
Mitochondrial respiration was measured for both SSM and IFM using substrates for 
complex I (glutamate and malate) and complex II (succinate, in the presence of 
rotenone to inhibit complex I). There was no difference in the basal respiration of the 
two subpopulations of mitochondria (in nmol O2 min-1 mg-1: complex I - SSM: 32 ± 10, 
IFM: 40 ± 16, complex II – SSM: 56 ± 14, IFM: 68 ± 16, Figures 6.16 and 6.17). For 
the IFM, ADP-stimulated respiration was higher in IFM compared to SSM for both 
complexes I and II (in nmol O2 min-1 mg-1: complex I – SSM: 76 ± 18, IFM 101 ± 17, 
complex II – SSM: 134 ± 30, IFM: 193 ± 23). Different concentrations of AP39 (0.3, 1, 
3, 5 µM) were tested on SSM or IFM; however, none of the concentrations examined 
significantly influenced mitochondrial oxygen consumption. 
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Figure 6.16 Effect of AP39 on mitochondrial oxygen consumption in subsarcolemmal (SSM) 
mitochondria. Mitochondrial oxygen consumption of complexes I and II of the respiratory 
chain was measured at the basal level and after stimulation with ADP. SSM were incubated 
with either vehicle (0.003% ethanol) or different concentrations of AP39 for 3 minutes before 
stimulating the respiration by ADP. Data were analysed via repeated measures ANOVA with 
Bonferroni post hoc test and reported as mean ± SEM. ***p<0.001 vs basal level. n=10 per 
group.  
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Figure 6.17 Effect of AP39 on mitochondrial oxygen consumption in interfibrillar (IFM) 
mitochondria. Mitochondrial oxygen consumption of complexes I and II of the respiratory 
chain was measured at the basal level and after stimulation with ADP. IFM were incubated 
with either vehicle (0.003% ethanol) or different concentrations of AP39 for 3 minutes before 
stimulating the respiration by ADP. Data were analysed via repeated measures ANOVA with 
Bonferroni post hoc test and reported as mean ± SEM. ***p<0.001 vs basal level. n=10 per 
group. 
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6.3.5.5 Mitochondrial GSH and GSSG levels after AP39 application 
The influence of mitochondrial application of H2S, using AP39, on the production 
of mitochondrial GSH, as a possible mechanism for the limitation of mito-ROS 
generation observed with AP39, was evaluated in vitro. Incubation of SSM with 
AP39 did not show a significant change in the level of either GSH or GSSG 
compared to the control (Figure 6.18A and B). Similarly, AP39 had no effect on 
GSH/GSSG ratio in the SSM (Figure 6.18C). 
 
 
Figure 6.18 GSH and GSSG contents in the mitochondria following AP39 application. 
Mitochondria were incubated with either vehicle (0.003% ethanol) or AP39 (1 µM) then 
purified and absorbance of both total GSH and GSSG were measured. Data were 
analysed using unpaired student’s t-test and reported as mean ± SEM. There was no 
significant different between AP39 and control. For each groups, n= 3 hearts from 3 
independent experiments. 
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6.3.5.6 The pattern of S-nitrosylation following AP39 application in vitro 
The effect of AP39 on the S-nitrosylation of mitochondrial proteins in 
cardiomyocyte mitochondria both SSM and IFM, was assessed in vitro. The 
effect of AP39 (0.3 and 1 µM) was compared with SNAP (for Ponceau S staining) 
and with GSNO (for Pierce S-nitrosylation western blot kit) as positive controls. 
Analysis of Ponceau S stained membrane did not show a significant change in 
the general pattern of protein expression following AP39 application in either 
subpopulation (Figure 6.19 and 6.20). Interestingly, incubation of either 
mitochondrial fraction with SNAP also did not have a significant effect on the 
general expression of mitochondrial proteins. 
S-nitrosylation of mitochondrial proteins was also examined following AP39 
application using Pierce S-nitrosylation Western blot kit. None of AP39 
concentrations used in these experiments significantly altered the pattern of 
mitochondrial protein expression in either subpopulation of mitochondria (Figure 
6.21 and 6.22). However, the positive control (GSNO) which was used in this 
series also did not show any significant effect on the general mitochondrial 
proteins expression compare to the control group in both SSM and IFM. 
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Figure 6.19 Overall SSM proteins stained with Ponceau S following treatment with 
AP39. SSM were stimulated with AP39 (0.3 µM and 1 µM) and SNAP (0.5 mM), as 
a positive control. The representative blot demonstrated that there was no significant 
difference in banding pattern between AP39-treated mitochondria and the control 
group. SNAP, as a positive control, also did not show a significant effect on the banding 
pattern compare to the control group. RV, right ventricle; MM, Master Mix; SB, sample 
buffer.    
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Figure 6.20 Overall IFM proteins stained with Ponceau S following treatment with 
AP39. IFM were stimulated with AP39 (0.3 µM and 1 µM) and SNAP as a positive 
control. The representative blot demonstrated that there was no significant difference in 
banding pattern between AP39-treated mitochondria and the control group. It also 
shows no significant difference in the positive control mitochondria which were treated 
with SNAP. RV, right ventricle; MM, Master Mix. 
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Figure 6.21 Immunoidentification of the S-nitrosylated protein in subsarcolemmal 
mitochondria following AP39 application. Representative blot demonstrates that none 
of AP39 concentrations used in this series exerted a significant effect on the S-
nitrosylation pattern, neither did the positive control GSNO. The membrane was 
stripped and probed with a specific antibody to mitochondrial import receptor subunit 
(TOM20), which demonstrated that there was no significant difference in the protein 
loading. RV, right ventricle; +C, positive control; -C, negative control; MM, Master 
Mix; SB, sample buffer; TOM20, mitochondrial import receptor subunit homolog. 
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Figure 6.22 Immunoidentification of the mitochondrial S-nitrosylated protein in 
interfibrillar mitochondria following AP39 application. Representative blot 
demonstrates that none of AP39 concentrations used in this series exerted a significant 
effect on the S-nitrosylation pattern, neither did the positive control GSNO. The 
membrane was stripped and probed with a specific antibody to mitochondrial import 
receptor subunit (TOM20), which demonstrated that there was no significant difference 
in the protein loading. RV, right ventricle; +C, positive control; -C, negative control; 
MM, Master Mix; SB, sample buffer; TOM20, mitochondrial import receptor subunit 
homolog. 
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6.4 Discussion 
The main findings of this study are: 
1- AP39 had an infarct-limiting effect and improved post-ischaemic cardiac 
contractility in a postconditioning mimetic manner when given specifically 
at reperfusion. 
2- Neither the mitochondria-targeting scaffold (AP219) nor the H2S donor 
moiety (ADT-OH) had any detectable effect on either infarct size or RPP 
recovery. 
3-  Postconditioning with AP39 was attributed to directly targeting the 
mitochondria and in a cytosol-independent manner. 
4- AP39 inhibited the opening of PTP in cardiomyocyte mitochondria, 
namely SSM and IFM, subjected to Ca2+ overload. 
5- Application of AP39 limited mito-ROS generation in SSM and IFM 
fractions. 
6- AP39 did not have an effect on mitochondrial oxygen consumption by 
complexes I and II in both SSM and IFM. 
7- The levels of mitochondrial GSH and GSSG were not affected by AP39 
application in SSM and IFM mitochondrial populations. 
These results demonstrate that AP39 can protect the heart against 
ischaemia/reperfusion injury when given as an adjunct to reperfusion in a 
cytosolic-independent manner by limiting mito-ROS generation and inhibiting 
the opening of PTP.  
Chapter 6 
217 
 
6.4.1 Postconditioning the heart with AP39 
Postconditioning the heart by H2S (PostC-H2S) has been reported to be 
cardioprotective by us and others who used either bolus dose of H2S at 
reperfusion (King et al., 2014, Bibli et al., 2015, Karwi et al., 2016) or 
overexpression of CSE to increase endogenous H2S production (Elrod et al., 
2007, Calvert et al., 2010). Several mechanisms have been proposed for the 
cardioprotective effect of H2S including: 1) triggering the RISK pathway 
(PI3K/Akt and/or ERK1/2 signalling pathway (Li et al., 2015a); 2) influencing 
antioxidant gene expression (Calvert et al., 2009); 3) direct effects on the 
mitochondria (Yao et al., 2010). However, the exact mechanism is not yet clearly 
identified. Part of this uncertainty is due to the nature of the commercially-
available pharmacological tools which have been extensively utilised to deliver 
H2S, namely NaHS and Na2S (Whiteman et al., 2011). The purity of these salts 
is often questionable and their aqueous solutions cause a rapid peak in plasma 
H2S level, followed by rapid clearance from the circulation (Bos et al., 2015). 
There have also been doubts surrounding the actual dose/concentration used in 
these studies that render them unreliable and uncontrollable sources of H2S. 
The new slow-release series of H2S donors, such as GYY4137 (Li et al., 2008), 
ATB-346 (Wallace et al., 2012) and SG-1002 (Kondo et al., 2013), have shown 
better pharmacokinetic profiles and more reproducible biological activities. 
However, the potential for translation is still hindered by the cardioprotective 
dose of these donors (generally >200 µM) (Le Trionnaire et al., 2014). Therefore, 
enhancing the activity of the existing H2S donors or developing a new series of 
H2S donors which can target particular tissues or cellular compartments has 
been a focus of recent research in the field of H2S biology. 
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In the present study, AP39 significantly limited infarct size and improved the 
post-ischaemic functional recovery, both in a dose-dependent manner, when 
administered prior to reperfusion. Consistent with these data, Ahmed et al. 
(2016) recently reported that AP39 also exerted a dose-dependent attenuation 
in the renal damage, oxidative stress and renal inflammation when applied at 
reperfusion in an in vivo model of renal ischaemia/reperfusion injury. We 
observed that TPP+ scaffold molecule (AP219) and H2S-generating moiety 
(ADT-OH), which were used as controls, had no detectable effect on either 
myocardial infarction or hemodynamic recovery. This is in agreement with other 
reports where these controls lacked biological activity when used at nanomolar 
or micromolar concentrations (Le Trionnaire et al., 2014, Szczesny et al., 2014). 
Recent work by Papapetropoulos’s group (Chatzianastasiou et al., 2016) 
reported a “head-to-head” comparison of infarct limitation by different H2S 
donors (Na2S, GYY4137, thiovaline and AP39), and elucidation of the role of NO 
in mediating protection. Intriguingly, all donors had the same infarct-limiting 
effect in a mouse model of ischaemia/reperfusion injury. It is noteworthy that the 
optimum cardioprotective doses of GYY4137 and AP39 used were 26.6 µmol 
kg-1 and 0.25 µmol kg-1, respectively. Very recently, we reported that 26.6 µmole 
kg-1 GYY4137 was not cardioprotective in an in vivo rat model of 
ischaemia/reperfusion injury with the optimum cardioprotective dose being 10-
fold higher (Karwi et al., 2016). Similarly, in the present study we demonstrated 
that AP39 exerts an infarct-sparing effect with an optimum cardioprotective dose 
of 1 µmol kg-1, 4-fold higher than the effective dose in mouse reported by 
Chatzianastasiou et al. (2016). No haemodynamic data are available to compare 
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AP39-induced dose-dependent improvement in post-ischaemic functional 
recovery in Chatzianastasiou’s paper. 
6.4.2 Cytosol independent cardioprotection by AP39 
This study provides important mechanistic insight into AP39’s cardioprotective 
action in vivo. We found that selective blockade of PI3K, which is known to 
mediate the cardioprotective effect of non-mitochondrial H2S donors (Andreadou 
et al., 2015, Karwi et al., 2016), did not abolish the cardioprotection of AP39. 
Cross-talk between H2S and NO has been suggested to be responsible for the 
H2S-induced cardioprotection. King et al. (2014) and Bibli et al. (2015) have 
shown that H2S-induced cardioprotection against ischaemia/reperfusion injury 
was not observed when eNOS was genetically silenced or pharmacologically 
inhibited in mice. Intriguingly, the same study by Bibli et al. (2015) reported that 
H2S supplement at reperfusion was cardioprotective in rabbit through a NO-
independent mechanism. Moreover, we recently reported that cardioprotection 
by GYY4137, a slow-releasing H2S donor, was partially attenuated but was not 
abolished by L-NAME in vivo in a rat model of myocardial ischaemia/reperfusion 
injury (Karwi et al., 2016). However, the nature of this crosstalk seems to have 
different patterns in different organs/tissues and in various experimental 
conditions across species (Hancock and Whiteman, 2016). To test whether 
AP39 is signalling through the NO/sGC pathway, we blocked the endogenous 
synthesis pathway of NO and also inhibited the activity of its end effector (sGC) 
using L-NAME and ODQ, respectively. We found that cardioprotection by AP39 
was still present when either L-NAME or ODQ were given with AP39. 
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These results were supported by analysis of protein phosphorylation state during 
early reperfusion. We observed that AP39 did not induce the phosphorylation of 
either Akt ser473 or eNOS ser1177 at 5 min reperfusion. Chatzianastasiou et al. 
(2016) reported that AP39 did not phosphorylate either eNOS ser1176 or VASP 
ser239 after 10 minutes of reperfusion and its cardioprotection was not abolished 
by either L-NAME or DT2, indicating a cGMP/PKG-independent mechanism in 
the murine model. Their data are complementary to the fuller characterisation of 
the potential cytosolic signalling targets of AP39 that we present here. To further 
characterise the cardioprotective mechanism of AP39, we also investigated the 
effect of AP39 on the phosphorylation of GSK-3β, a downstream effector of the 
RISK pathway, and ERK1/2, a parallel arm of the RISK pathway. We observed 
no significant change in the phosphorylation of either GSK-3β or ERK1/2 at early 
reperfusion. Viewed together, our data and those of Chatzianastasiou et al. 
(2016) provide persuasive evidence that, unlike other H2S donors, AP39 
mediates its cardioprotection by a mechanism that is independent of activation 
of the cytosolic components of the RISK signalling cascade. 
6.4.3 Inhibition of PTP opening by AP39  
We then investigated the potential mitochondrial mechanism involved in the 
cardioprotection of AP39. We first tested the hypothesis that postconditioning 
with AP39 protects the heart against acute myocardial infarction by inhibiting the 
PTP opening at early reperfusion. To do so, we have characterised for the first 
time the direct effect of AP39 on the most relevant subpopulations of 
cardiomyocyte mitochondria, namely subsarcolemmal (SSM) and interfibrillar 
(IFM) mitochondria. Inhibition of PTP opening in the first minutes of reperfusion 
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has been extensively reported to protect against reperfusion injury (Halestrap, 
2010, Ong et al., 2015). It has been shown that many cardioprotective 
manoeuvres and interventions act to maintain PTP in a closed state at 
reperfusion (Hausenloy et al., 2009). With this in mind, we investigated the 
influence of AP39 on the opening of PTP, as a result of Ca2+ overload, in cardiac 
SSM and IFM in vitro, as a possible mechanism for the protective effects of 
AP39. We found that AP39 inhibited PTP opening in SSM and IFM with no 
significant difference from the inhibitory effect of CsA, which can protect the 
heart against ischaemia/reperfusion injury by inhibiting PTP opening at 
reperfusion (Hausenloy et al., 2012). We also showed that intervening with both 
AP39 and CsA increased mitochondrial tolerance to Ca2+ overload and resulted 
in an additive effect compared to CsA effect alone. CsA prevents the opening of 
PTP, multiprotein complex spanning both inner and outer mitochondrial 
membranes, by desensitising CypD, a proposed modulator of PTP located in the 
mitochondrial matrix (Bernardi and Di Lisa, 2015). Having an additive effect to 
the inhibitory effect of CsA suggests that AP39 may inhibit PTP opening via a 
CypD-independent mechanism. In line with these findings, Chatzianastasiou et 
al. (2016) reported that AP39 (0.3 µM versus 1 µM in our study), exerted an 
additive effect to CsA in mouse mitochondria isolated from the whole heart. 
However, isolating mitochondria from whole heart tissue is potentially a 
problematic approach as a number cell types contribute to the isolated 
mitochondrial fraction, for example endothelial cells, fibroblasts and other local 
resident cells. Even more importantly, cardiomyocyte mitochondria, namely 
SSM and IFM, themselves significantly differ in their main characteristics 
including oxygen consumption, mito-ROS generation and Ca2+ retention 
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capacity (Palmer et al., 1977, Palmer et al., 1986). Our present study 
characterised for the first time the effect of AP39 on the most relevant 
cardiomyocyte mitochondria in the context of ischaemia/reperfusion injury, 
namely SSM and IFM. 
6.4.4  Limitation of mito-ROS generation by AP39 
We investigated potential mechanisms underlying AP39-induced inhibition of 
PTP opening. We characterised the effect of AP39 on the mito-ROS generation 
in vitro using SSM and IFM. The detrimental effect of overwhelming mito-ROS 
generation, as a result of respiratory chain uncoupling and oxidation of 
anaerobic metabolism products, is one of the hallmarks of ischaemia/reperfusion 
injury (Venditti et al., 2001, Chouchani et al., 2014, Brown and Griendling, 2015). 
It is one of the main contributors to the opening of PTP, initiating cell apoptosis 
and accelerated necrosis during reperfusion (Hausenloy et al., 2009). Targeted 
delivery of H2S to the mitochondria with AP39 has been shown to preserve 
mitochondrial function and integrity by attenuating ROS in different experimental 
settings (Szczesny et al., 2014, Le Trionnaire et al., 2014, Ikeda et al., 2015, 
Ahmad et al., 2016). Since oxidative stress and the mitochondria play central 
roles in ischaemia/reperfusion injury, targeting the mitochondria with selective 
H2S donors is a plausible therapeutic approach to limit ischaemia/reperfusion 
injury. Ikeda et al. (2015) found that AP39 (10 nmol kg-1) given before cardiac 
arrest increased H2S level in the brain, decreased H2O2 level in the serum and 
inhibited PTP opening. In line with these studies, our data showed that AP39 
limited mitochondrial ROS level in both subpopulations of cardiac mitochondria. 
In the present study, AP39’s activity against ROS generation was attenuated as 
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the AP39 concentration was increased in a dose-dependent manner. This is 
consistent with the findings of others (Szczesny et al., 2014, Ahmad et al., 2016) 
who suggested that H2S, and AP39 in particular, has a bell-shaped dose-
response curve where it could be protective at low concentrations but toxic at 
high concentrations. 
6.4.5 Selective delivery of H2S into the mitochondria by AP39 does not 
affect respiratory complexes I and II  
We then wanted to look at the potential protective mechanisms by which 
selective delivery of H2S into the mitochondria by AP39 attenuates mito-ROS 
generation. There is growing evidence that H2S is an endogenous modulator of 
mitochondrial function in health and disease (Guo et al., 2012). The basal 
mitochondrial level of H2S is mainly generated by 3-mercaptopyruvate 
sulfurtransferase (3-MST) and it appears to be essential for normal function of 
the citric acid cycle (Modis et al., 2013b). There is a clear evidence that the intra-
mitochondrial H2S level is disturbed during oxidative stress due to the increase 
in H2S degradation and reduction in its production which might contribute to cell 
death (Geng et al., 2004, Doeller et al., 2005, Whiteman et al., 2011, Vandiver 
and Snyder, 2012). This is consistent with some observations that overwhelming 
ROS generation during ischaemia/reperfusion injury, which also results in 
mitochondrial dysfunction, causes a reduction in H2S availability (Predmore et 
al., 2012, Bos et al., 2015). This reduction is usually combined with translocation 
of the H2S generating enzymes CBS and CSE from the cytosol to the 
mitochondria as a cellular adaptation to compensate for the suppression in H2S 
production (Fu et al., 2012, Modis et al., 2013a, Szabo et al., 2013). Fox et al. 
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(2012) reported that the mitochondria of RNAi-mediated CSE knockdown in cells 
rendered them were more vulnerable to oxidative stress and mitochondrial 
toxicity. H2S replacement, either by H2S donors (such as the non-targeting 
compound GYY4137) or overexpression of endogenous synthetic enzymes, has 
been shown to protect against ischaemia/reperfusion injury by mitigating 
oxidative stress and preserving mitochondrial integrity (Andreadou et al., 2015). 
We also investigated whether AP39 could have an effect on the mitochondrial 
electron transport chain which is a major source of mito-ROS generation at early 
reperfusion. It has been reported that H2S at low concentration (nanomolar/low 
micromolar) can stimulate mitochondrial ATP production by acting as an 
“emergency fuel” for the electron transport chain inorganic electron donor 
(Szabo et al., 2014, Modis et al., 2014). It donates electrons at the level of 
coenzyme Q to the sulfide quinone reductase (SQR) where the electrons then 
transport to complex III, cytochrome c and complex IV which finally reduces 
molecular oxygen to water (Goubern et al., 2007). However, sulfide oxidation is 
an inefficient source of energy as it cost more oxygen (three mole of oxygen for 
each sulfide molecule) with low yield of electrons (two sulfide molecules 
produces two electrons) compared to other mitochondrial carbon-containing 
substrates, namely NADH, FADH, succinate, L-alpha-glycerophosphate (Szabo 
et al., 2014). Accordingly, we sought to characterise the influence of AP39 on 
mitochondrial respiration through complexes I and II in both SSM and IFM. We 
did not detect any significant effect of AP39 on the oxygen consumption of these 
complexes in either mitochondrial subpopulation. With these results, we can 
exclude the possibility that H2S delivered by AP39 improves mitochondrial 
respiration over the concentration range we employed. Moreover, these data 
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suggest the safety margin of the applied concentration range. However, 
arguably it is possible that AP39 might energise Complexes III and/or IV by 
electron donation without altering the activity of complexes I and II. It has been 
demonstrated that inhibition of complex I using rotenone did not affect sulfide 
oxidation, while inhibiting complex III or IV by antimycin or cyanide, respectively, 
impeded it (Volkel and Grieshaber, 1996, Yong and Searcy, 2001, Goubern et 
al., 2007). Nevertheless, this needs further investigation.  
6.4.6 Mitochondrial GSH/GSSG ratio is not altered by AP39 application 
We then measured the levels of both GSH and GSSG following AP39 application 
in vitro as another possible antioxidant mechanism for AP39-induced abrogation 
of mito-ROS generation. It has been reported that H2S can mitigate oxidative 
stress-induced mitochondrial damage via increasing GSH pool in the 
mitochondria by increased GSH production, activation of cysteine/cysteine 
transporters and enhanced GSH uptake (Tan et al., 2010, Kimura et al., 2010). 
H2S has also been demonstrated to upregulate the endogenous antioxidant 
defence mechanism against oxidative stress-induced mitochondrial dysfunction, 
namely superoxide dismutase (SOD) isoforms (Cu/Zn-SOD and Mn-SOD), 
catalase, glutathione S-transferase and glutathione peroxidase (Sun et al., 2012, 
Wen et al., 2013). Jha et al. (2008) also found that the H2S donor IKI1001 was 
protective against hepatic ischaemia/reperfusion injury by increasing the 
expression of Trx-1, HSP-90 and Bcl-2. In the present study, there was no 
significant effect of AP39 on the mitochondrial level of either GSH or GSSG after 
10 minutes of exposure. However, antioxidant activity established by AP39 could 
possibly be due to the fact that H2S is a potent reducing agent and directly 
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scavenge ROS and RNS as has been shown by other investigators in different 
experimental models (Geng et al., 2004, Whiteman et al., 2004, Tang et al., 
2010). 
6.4.7 The effect of AP39 on posttranslational modifications (PTMs) 
We also wanted to explore the potential PTMs following mitochondrial 
stimulation with AP39. The interest in H2S-induced PTMS has tremendously 
increased over the least five years demonstrating an array of its biological 
activities could be in fact mediated through these modifications. For instant, it 
has been demonstrated that endogenous H2S mediates an indispensable 
smooth muscle relaxation through S-sulfhydration of KATP channel facilitating the 
binding of (PIP2) to open the channel (Mustafa et al., 2011). Moreover, Murphy’s 
group (Sun et al., 2016) found that NaHS could exert an infarct-limiting effect 
additive to SNAP in Langendorff perfused mouse heart potentially by protein S-
sulfhydration (also known as S-persulfidation) and to a greater extent by 
increase in S-nitrosylation. Interestingly, proteomic analysis revealed that the 
majority of S-nitrosylated proteins were mitochondrial proteins. Modis et al. 
(2016) also very recently demonstrated that endogenous H2S plays a supportive 
role for mitochondrial respiration through S-sulfhydration of the α-subunit 
mitochondrial inner membrane protein ATP synthase (F1F0 ATP 
synthase/Complex V) at Cys244 and Cys294. Furthermore, Meng et al. (2016) 
demonstrated that GYY4137 mitigated myocardial hypertrophy by 
downregulated KLF5 expression through S-sulfhydrating of SP-1, impairing its 
transcriptional activity. Conversely, S-sulfhydration of Keap1 by GYY4137 
enhanced its transcriptional activity and enhanced the expression of Nrf2 
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attenuating the diabetes-induced atherosclerosis (Xie et al., 2016). A previous 
study by Kai et al. (2012) found that NaHS-induced protection was abolished in 
mitochondria-free cells. Taken together, these studies provide persuasive 
evidence for H2S-induced PTMS and that the primary target of H2S in 
cardioprotection is the mitochondrion. Ponceau S solution was used as a simple 
and quick method to identify any significant modification in the general protein 
expression in mitochondrial samples. We could not detect a considerable effect 
of AP39 on the general protein expression in both subpopulations of 
mitochondria. Interestingly, the effect of SNAP, which was used as a positive 
control, on the general protein expression was not reproducible which made it 
difficult to draw any conclusion. It is highly likely that the extent of protein 
modification (whether by protein S-nitrosylation and/or S-sulfhydration) 
mediated by both AP39 and SNAP might not be clearly distinguishable using 
Ponceau S staining. Therefore, we then used modified biotin switch assay to 
selectively measure S-nitrosylated cysteine occupancy by iodoTMTzeroTM label 
reagent and detect this by Western blot. However, the results of these 
experiments also were not conclusive as no detectable change was observed in 
the pattern of mitochondrial proteins S-nitrosylation following stimulation with 
AP39 in both mitochondria fractions. Interestingly, GSNO, the positive control in 
this series, also did not show any detectible effect on the general S-nitrosylation 
pattern in both subpopulations detected with the modified biotin switch method. 
It is plausible that H2S-induced PMTS are rather selective/specific modifications 
to certain cellular targets and are unlikely to be detected by blotting the whole 
spectrum of mitochondrial proteins. More importantly, the concentration of H2S 
which is delivered by AP39 is remarkably low (50 to 300 fold lower) compared 
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to the previous reports that showed significant change in the general proteins 
expression following exposure to H2S (Sun et al., 2016, Modis et al., 2016). 
Therefore, more selective and sensitive approach to detect H2S-induced PTMS 
might be using proteomic analysis to characterise the cellular and mitochondria 
targets of AP39 such as iodoTMT sixplex label reagent set and proteomic 
analysis. 
6.5 Study limitations 
The exact mechanisms whereby AP39 limits ROS generation and inhibits PTP 
opening remains to be determined. Ikeda et al. (2015b) reported that AP39 did 
not influence the expression of CSE, CBS or 3-MST in the brain. That means 
that AP39 probably elevates mitochondrial H2S level without interfering with the 
endogenous synthesis of H2S. A convincing body of evidence supports that H2S 
mediates a wide range of its physiological roles through inducing its PTMS, 
namely S-nitrosylation and S-sulfhydration. Intriguingly, it has been 
demonstrated that the activities of CypD and F0F1 ATP synthase, the potential 
triggers/modulators of the PTP opening, could be manipulated through S-
nitrosylation or S-sulfhydration and that could be cardioprotective against 
ischaemia/reperfusion injury. Accordingly, it is tempting to suggest that AP39 
possibly modulate the activity of either CypD or F0F1 ATP synthase to inhibit the 
opening of PTP. However, this still needs further investigation. The molecular 
mechanism of mito-ROS suppression by AP39 also still unclear. In addition, it is 
still unclear how AP39 attenuated mito-ROS generation in cardiomyocyte 
mitochondria. Whether this antioxidant effect is mediated by direct quenching of 
ROS by H2S or by enhancing endogenous antioxidant system (Trx-1, SOD, 
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catalase, GPx, for example) still needs to be characterised. Moreover, the 
possibility that AP39-induced S-sulfhydration could influence the antioxidant 
gene transcription of certain transcription factors such as Nrf2, as shown by 
others, should not be discounted and awaits clarification. Furthermore, 
understanding whether mitochondrial protection is the only mechanism of infarct 
limitation or if there are other possible mechanisms involved in AP39’s 
cardioprotection, such as triggering the SAFE pathway, still needs further 
investigation. The metabolism of AP39 as well as the concentration of the 
released H2S by AP39 inside the mitochondria needs clarification. 
6.6 Conclusion 
We have presented evidence that selectively targeting the mitochondria with 
AP39 at reperfusion can significantly limit infarct size and improve post-
ischaemic haemodynamic recovery in an in vivo model of myocardial 
ischaemia/reperfusion injury. Moreover, AP39’s ability to selectively deliver low 
concentration of H2S to the mitochondria can minimise off-target effects and 
toxicity associated with the less reliable inorganic H2S donors. The 
cardioprotective effect of AP39 is not mediated by the RISK pathway, which 
appears to be a pivotal cardioprotective mechanism activated by other H2S 
donors. In isolated SSM and IFM, targeted-delivery of H2S inhibits mito-ROS 
generation in both subpopulations in a dose-dependent manner without affecting 
mitochondrial respiration. AP39 also inhibits the opening of PTP in a CypD-
independent mechanism, and provides an inhibitory effect on the PTP opening 
which is additive to CsA. Taken together, these findings provide proof-of-concept 
that direct delivery of H2S to mitochondria by mitochondria-targeting H2S donors, 
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of which AP39 is a prototype, represents a novel and effective intervention to 
mitigate the irreversible myocardial injury associated with reperfusion. Although 
the clinical use of H2S donors still needs further investigation, future translation 
of this concept using AP39 or derivatives as adjunctive therapy to reperfusion 
would be expected to improve clinical outcome after acute myocardial infarction. 
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7.1 General discussion 
7.1.1 Principal findings 
The most important findings of the studies included in this thesis can be 
summarised as follows. 
Slow and stable elevation of the level of exogenous H2S applied as an adjunct 
to reperfusion is a cardioprotective approach in an in vivo rat model of 
myocardial ischaemia/reperfusion injury. This was demonstrated in Chapter 4 
using GYY4137 a slow-releasing H2S donor which significantly limited 
myocardial infarction when administrated specifically at reperfusion compare to 
control hearts. The cardioprotective effect of GYY4137 was also confirmed to be 
mediated by its payload of H2S and not due to the parent structure of GYY4137 
as depleted GYY4137 lacked any infarct-limiting effect. The lack of activity with 
depleted-GYY4137 is consistent with other reports (Li et al., 2009, Whiteman et 
al., 2010b, Fox et al., 2012, Jamroz-Wisniewska et al., 2014). Co-administration 
of PI3K inhibitor LY294002 completely abolished GYY4137’s cardioprotection 
through inhibiting GYY4137-enhanced phosphorylation of Akt and GSK-3β. This 
suggested the essential role of PI3K/Akt/GSK-3β signalling pathway for 
GYY4137-induced infarct limitation. Blocking endogenous NO synthesis using 
L-NAME reduced the infarct-limiting effect of GYY4137, but did not abrogate it, 
by inhibiting GYY4137-induced eNOS phosphorylation. This demonstrated a 
partial dependency of the cardioprotective effect of GYY4137 on the 
bioavailability of NO at reperfusion. 
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In Chapter 6, it was shown that augmenting the mitochondrial H2S level with 
selective mitochondrial delivery of H2S at reperfusion protects the heart against 
ischaemia/reperfusion injury in vivo. This was interpreted as acute supplement 
of AP39, a mitochondria-targeting H2S donor, specifically given at reperfusion 
limited the infarct size and improved post-ischaemic functional recovery in the 
rat model of myocardial ischaemia/reperfusion injury. We also showed in 
Chapter 6 that blocking the activity of PI3K with LY294002 at reperfusion does 
not attenuate the protective effects of AP39. The involvement of NO and its end 
effector sGC in the cardioprotection of AP39 were also explored. Inhibition of 
endogenous NO synthesis with L-NAME at reperfusion showed no significant 
effect on AP39-induced cardioprotection. Similarly, selective oxidation of the 
haem site of sGC, leading to its inhibition, did not abrogate the infarct limitation 
by AP39. In line with that, we also demonstrated that postconditioning the heart 
with AP39 does not alter the levels of p-Akt, p-eNOS, p-GSK-3β and p-ERK1/2 
in the ischaemic myocardium at early reperfusion. These data supported the 
hypothesis that AP39 directly targets the mitochondrion and does not trigger 
cytosolic salvage kinases to mediate its cardioprotection. We also explored the 
direct effects of AP39 on isolated cardiomyocyte mitochondria, namely SSM and 
IFM. We showed that AP39 inhibits the opening of PTP in both subpopulations 
of mitochondria. Interestingly, AP39 also elicited an additive effect to CsA-
evoked desensitisation of PTP which suggests CypD independent mechanism. 
This is consistent with a previous study by Ikeda et al. (2015a) which reported 
AP39-induced inhibition of PTP opening in cortical cells 6 hours after cardiac 
arrest/cardiopulmonary resuscitation in mouse model. We also demonstrated 
that AP39 limited mito-ROS generation in both SSM and IFM in a concentration-
dependent manner. 
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7.1.2 Context validation of the work 
The studies presented in this thesis focused on exploring the potential 
cardioprotection of different thiol-containing compounds as potential H2S 
donors, when given in clinically relevant way at reperfusion using preclinical rat 
model of acute myocardial infarction. These studies provided further evidence 
to support that exogenous supplementation of H2S via stable and targeted H2S 
donors at the time of reperfusion is a feasible and applicable cardioprotective 
approach against ischaemia/reperfusion injury. There is a general consensus in 
the field of cardioprotection that postconditioning is a reliable and relevant time 
point of intervention due to the unpredictable nature of myocardial ischaemia. 
Targeting the reperfusion phase has unveiled some of the cellular salvage 
kinases which can mitigate cardiac injury when specifically triggered at early 
reperfusion. These pathways include the RISK and the SAFE pathways. 
Interestingly, inhibition of the RISK pathway kinases at reperfusion does not 
appear to exacerbate infarct size. This emphasises the non-linearity of the RISK 
cascade and that these kinases are normally inactive at reperfusion. Data 
presented in Chapters 4 and 5 fully concur with this concept. Specific blockade 
of PI3K, eNOS using LY294002 and L-NAME, respectively, did not produce 
greater infarction compared with the control hearts.  
The cardioprotective effects of exogenous thiol-containing compounds such as 
inorganic sulfide salts (i.e. NaHS and Na2S) have been linked to recruitment of 
some components of the RISK pathway when applied before ischaemia or at 
reperfusion. However, the reproducibility of the generated data using these salts 
has been questioned due to the considerable technical difficulties associated 
with these salts. Sulfide salts instantly release their payload of H2S once they 
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are dissolved, potentially causing a massive release of H2S and triggering cell 
stress/toxicity. Neither the concentration nor the releasing pattern of H2S by 
these salts relate to the physiological concentration or roles of H2S. Therefore, 
there was an urgent need for developing a new generation of pharmacological 
tools to explore the biology of H2S. Accordingly, this will not only improve the 
consistency of data but also facilitate the clinical translation of the beneficial 
effects of H2S research. The development of GYY4137 is of great clinical 
relevance and has advanced the field of H2S. It has been demonstrated that 
GYY4137 is a stable H2S donor which releases H2S at a slow rate which mimics 
the endogenous rate of H2S production. The findings in Chapter 4 demonstrated 
that postconditioning the heart with GYY4137 protected against myocardial 
infarction via triggering PI3K/Akt/eNOS and abrogating the activity of GSK-3β at 
early reperfusion. These results are of considerable clinical relevance and 
warrant further investigation for the possible use of GYY4137 in other disease 
states where impaired endogenous H2S level contributes to the pathology of the 
disease. It is worth mentioning here that SG1002, a long-acting H2S prodrug, 
has recently successfully passed Phase I clinical trial in patients with heart 
failure. This study demonstrated the ability of SG1002 to augment circulating 
H2S and NO levels in both healthy subjects and heart failure patients (Polhemus 
et al., 2015). This trial holds a great promise considering that enhanced level of 
either gas has already shown cardioprotective effects in preclinical studies.  
Despite the multifactorial aetiology of acute myocardial infarction, there is a large 
consensus that mitochondrial dysfunction at reperfusion has a central role in this 
pathology and is a fundamental determinant of clinical outcome. There is a 
compelling body of evidence demonstrating that the initial burst of mito-ROS at 
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the first minutes of reperfusion is the main mediator of PTP opening which 
initiates cell death. Application of antioxidants at early reperfusion has been 
reported as a promising cardioprotective intervention in experimental settings 
but failed to exert clinically-appreciable benefits. In part, this failure could be due 
to the application of a blanket approach to scavenge generated ROS with poor 
identification of the sources and mechanisms of mito-ROS generation during 
ischaemia/reperfusion injury and inability of most antioxidants to enter the 
mitochondria. We have demonstrated that postconditioning the heart with a 
mitochondria-targeted donor of H2S (AP39) protects against injurious 
reperfusion. Unlike GYY4137, AP39-induced protection did not trigger any 
cytosolic component of the RISK pathway at early reperfusion, demonstrating 
that AP39 acts specifically on the mitochondrion. Cardiomyocyte mitochondria 
are the most relevant population of mitochondria in the myocardium which would 
be affected by ischaemia/reperfusion injury. Taking this into consideration, two 
subpopulations of cardiomyocyte mitochondria, namely subsarcolemmal (SSM) 
and interfibrillar (IFM) mitochondria, were specifically isolated from the left 
ventricle using differential centrifugation. We investigated the direct 
mitochondrial-effects of AP39 on mitochondrial function. We also demonstrated 
that AP39 increased mitochondrial Ca2+ tolerance thereby inhibiting Ca2+ 
overload-stimulated PTP opening. AP39 also had an additive effect to CsA-
induced desensitisation of PTP. These data supported the notion that AP39 
inhibits the activation of PTP via a CypD-independent mechanism. We found 
that AP39 limited mito-ROS generation in a concentration dependent manner. 
This limitation was not mediated through enhancing GSH production, a 
mitochondrial antioxidant system.  
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7.1.3 Limitations and future perspectives 
All the studies in this thesis have been complimentary to each other and show a 
logical order of progression to investigate the cardioprotection of thiol-containing 
compounds. Nevertheless, there are a number of further studies which could 
broaden the scope of investigation and be interesting topics for further 
characterisation of thiol-induced cardioprotection. 
The detection of H2S level in the plasma and tissue has been a challenge despite 
having a crucial role in many pathologies such as ischaemia/reperfusion injury. 
In part this is because the majority of available H2S probes cannot be used in 
vivo as they are fluorescent. However, Murphy’s laboratory (Arndt et al., 2015) 
recently developed a mitochondria-targeted H2S probe (MitoA) which 
preferentially accumulates in the mitochondria due to the virtue of a TTP+ 
scaffold. This probe selectively reacts with endogenous H2S in vitro and in vivo, 
generating MitoN that can sensitively be detected using mass spectrometer. 
Although this technique is still under development and need further optimisation, 
its application could advance our understanding of the biological roles of 
endogenous H2S. It could also guide the manipulation of H2S level using newly 
developed H2S donors in many disease states. 
In Chapters 4 and 5, H2S donors exerted a significant limitation in infarct size 
when they were given at reperfusion. Two hours of reperfusion was chosen in 
this work as it was sufficient to washout dehydrogenases from the infarcted 
tissue, avoiding false positive results. However, it is still unclear whether these 
donors will exert a comparable cardioprotection through similar mechanisms 
following longer period of reperfusion where there could be no-flow phenomena 
and late apoptosis. A suitable model to investigate that could be an in situ model 
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of myocardial ischaemia/reperfusion injury where the animal is allowed to 
recover for longer reperfusion following LAD ligation then sacrifice to look at 
potential late effects of cardioprotective H2S donors.  
There is a direct link between extent of ischaemia/reperfusion injury and 
arrhythmia severity (Wit and Duffy, 2008). Moreover, it has recently been shown 
that mitochondrial instability during regional ischaemia/reperfusion could 
underlie the arrhythmias (Solhjoo and O'Rourke, 2015). Accordingly, it might be 
of interest to characterise the antioxidant effect of AP39 on the occurrence and 
severity of ventricular arrhythmia during simulated ischaemia/reperfusion injury 
using monolayers of cardiomyocyte and measuring the membrane potential and 
oxidative stress. 
The role of the SAFE pathway in mediating the cardioprotection of H2S still 
needs further investigation. This signal transduction pathway has been shown 
to work independently of the RISK pathway (Lecour et al., 2005), although its 
exact cardioprotective mechanism is still unclear. Experimentally, it has been 
demonstrated that JAK/STAT-3 signalling mediates, at least in part, the 
cardioprotection of IPC (Lecour et al., 2005) and IPost (Boengler et al., 2008a). 
Interestingly, Huffman et al. (2008) reported a transferable infarct-limiting effect 
when a virgin heart was perfused with a coronary effluent from preconditioned 
heart which signalled through JAK/STAT-3 pathway. Intriguingly, STAT-5 was 
found to be the dominant isoform triggered in patients subjected to RIPC before 
coronary artery bypass grafting (Heusch et al., 2012). Previous reports 
demonstrated that NaHS could mediate a postconditioning-mimetic effect in 
aging cardiomyocytes (Li et al., 2016) and isolated rat heart (Luan et al, 2012) 
via triggering JAK/STAT-3 signalling. These data suggest that the SAFE 
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pathway might be implicated in the cardioprotection of the non-targeted H2S-
donors (GYY4137) which could be an interesting topic for future investigation. 
PTM produced by H2S in the mitochondria is also an uncharted area requiring 
further investigation. In Chapter 5, it was concluded that AP39 limited mito-ROS 
in both subpopulations of cardiomyocyte mitochondria via a mechanism which 
is independent of enhanced GSH production. The sources of ROS generated at 
the first moments of reperfusion are still under debate with complexes I and III 
being the most likely sites of ROS generation. However, seminal work by 
Murphy’s laboratory (Chouchani et al., 2014) recently suggested that rapid 
activation of complex I in the first minutes of reperfusion could be the most 
relevant site for detrimental mito-ROS generation. They also demonstrated that 
S-nitrosylation of the Cys39 residue in the ND3 subunit of complex I, using 
mitochondria-targeted NO donor (MitoSNO), can reversibly lock complex I in the 
“deactived state” at early reperfusion and prevent mito-ROS generation in 
murine heart. It has also been recently reported that NaHS mediated an additive 
effect to NO’s infarct limitation through synergising NO-induced S-nitrosylation 
of mitochondrial proteins in mouse heart (Sun et al., 2016). Taken together, it 
seems tempting to suggest that AP39 could limit mito-ROS generation through 
S-nitrosylation of Cys39 of complex I at reperfusion, although these experiments 
need to be performed before drawing any conclusion. 
In Chapter 6, we also found that AP39-desensitised the PTP against Ca2+ 
overload possibly independently of CypD desensitisation. This conclusion was 
derived from the observation that AP39 had an additive effect to CsA-evoked 
desensitisation of PTP component in both cardiomyocyte mitochondria fractions 
(i.e. SSM and IFM). However, the exact mechanism of AP39-induced PTP 
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deactivation was not unveiled in this thesis. The ability of H2S to trigger/induce 
S-nitrosylation and S-sulfhydration to shield critical mitochondrial proteins, 
especially when selectively delivered to mitochondria, should not be discounted. 
Unfortunately, the detection of mitochondrial S-nitrosylated proteins following 
AP39 application was not successful using Pierce™ S-nitrosylation Kit. The 
results were not conclusive and the assay needs further troubleshooting. 
Nevertheless, other assay procedures could be utilised instead such as 
DyLight™ Sulfhydryl-Reactive Fluors which could identified S-nitrosylated and 
S-sulfhydrated proteins. Despite the considerable controversy regarding the 
main components of the PTP, it has been reported by Murphy and colleagues 
(Nguyen et al., 2011a) that Cys203 residue of CypD has a crucial role in the 
activation of PTP. Later work by the same group later showed that mutation of 
Cys203 to serine residue significantly modulated the activation of PTP in vitro 
(Nguyen et al., 2011b). Furthermore, an increasing body of evidence also 
suggests that F0F1-ATP synthase (complex V), could be a major component of 
the PTP. Wang’s laboratory have recently published data which showed the 
ability of H2S to stimulate mitochondrial bioenergetics via S-sulfhydration of α-
subunit of ATP synthase at Cys244 and Cys294 (Modis et al., 2016). Altogether, 
further studies investigating the influence of mitochondrially delivered H2S using 
AP39 on the potential components of PTP would provide extremely important 
mechanistic insight into the cardioprotection of H2S. The involvement of CypD in 
AP39’s cardioprotection could be investigated using wild type and CypD null 
(CypD-/-) mice. In addition, site-directed mutagenesis of Cys244 and Cys294 of 
ATP synthase could be used to explore the influence of AP39 on F0F1-ATP 
synthase in vitro using cell line. 
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7.1.4 Concluding remarks 
The research carried out in this thesis represents a detailed characterisation of 
thiol-induced cardioprotection against ischaemia/reperfusion injury in a 
preclinical rodent model. The data provide new insights into the underlying 
cardioprotective mechanisms of thiol-containing compounds at the cellular and 
mitochondrial levels. The results also raise many questions regarding the exact 
PTMs induced by H2S. The field of H2S biology has been in great need of new 
pharmacological approaches to overcome the systemic side effects of simple 
sulfide salts. The H2S donors used in this thesis are prototypes for potential 
therapeutic agent which offer a novel approach to mitigate irreversible 
myocardial infarction in the clinical setting. The work also explored the 
dependency of H2S cardioprotection on eNOS activity in the myocardium and 
emphasises how their interactions could differ depending on the 
pharmacological tools employed. The concept could also possibly be extended 
to other pathologies, such as endothelial dysfunction and erectile dysfunction, 
which could help to clarify the inconclusive relationship between NO and H2S in 
these pathologies.  
The studies in this thesis set out to address the following questions: 
1. Does Mesna at reperfusion protect the heart from ischaemia/reperfusion 
injury in vivo? 
2. Does administration of GYY4137 at reperfusion limit acute myocardial 
infarction in vivo? 
3. Does GYY4137 activate the RISK pathway components to mediate its 
infarct limitation? 
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4. Does GYY4137 reply on NO signalling to mediate its cardioprotection?  
5. Does mitochondrial delivery of H2S by AP39 protect against myocardial 
ischaemia/reperfusion in vivo? 
6. Does AP39 trigger any of the RISK pathway components to exert its 
protection against reperfusion injury? 
7. What effects does AP39 have on cardiomyocyte mitochondria in vitro? 
 
Data in this thesis demonstrate that stable and controlled H2S donors given at 
the time of reperfusion limits acute myocardial infarction in preclinical model. 
The cardioprotective mechanism of H2S could significantly vary depending on 
its tissue concentration and the pharmacokinetic of the H2S-releasing 
compound. Selectively delivering H2S to specific organelles, such as the 
mitochondria, opens a wide window of opportunity of therapeutic applications of 
H2S and facilitate its clinical translation. In this thesis, targeting the mitochondria 
with H2S donor attenuated mito-ROS generation and inhibited the opening of 
PTP, the two detrimental hallmarks of what is so-called reperfusion injury. With 
the bewildering possibility of targeting the mitochondrion, H2S-donating 
compounds represent promising therapeutic approaches to give in conjunction 
with PPCI to mitigate mitochondrial dysfunction and eventually improve the 
clinical outcome for patients who are admitted for the early reperfusion therapy.  
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BACKGROUND AND PURPOSE
H2S protects myocardium against ischaemia/reperfusion injury. This protection may involve the cytosolic reperfusion injury
salvage kinase (RISK) pathway, but direct effects on mitochondrial function are possible. Here, we investigated the potential
cardioprotective effect of a mitochondria-speciﬁc H2S donor, AP39, at reperfusion against ischaemia/reperfusion injury.
EXPERIMENTAL APPROACH
Anaesthetized rats underwent myocardial ischaemia (30 min)/reperfusion (120 min) with randomization to receive interventions
before reperfusion: vehicle, AP39 (0.01, 0.1, 1 μmol·kg1), or control compounds AP219 and ADT-OH (1 μmol·kg1). LY294002,
L-NAME or ODQ were used to investigate the involvement of the RISK pathway. Myocardial samples harvested 5 min after re-
perfusion were analysed for RISK protein phosphorylation and isolated cardiac mitochondria were used to examine the direct
mitochondrial effects of AP39.
KEY RESULTS
AP39, dose-dependently, reduced infarct size. Inhibition of either PI3K/Akt, eNOS or sGC did not affect this effect of AP39.
Western blot analysis conﬁrmed that AP39 did not induce phosphorylation of Akt, eNOS, GSK-3β or ERK1/2. In isolated
subsarcolemmal and interﬁbrillar mitochondria, AP39 signiﬁcantly attenuated mitochondrial ROS generation without affecting
respiratory complexes I or II. Furthermore, AP39 inhibited mitochondrial permeability transition pore (PTP) opening and co-
incubation of mitochondria with AP39 and cyclosporine A induced an additive inhibitory effect on the PTP.
CONCLUSION AND IMPLICATIONS
AP39 protects against reperfusion injury independently of the cytosolic RISK pathway. This cardioprotective effect could be
mediated by inhibiting PTP via a cyclophilin D-independent mechanism. Thus, selective delivery of H2S to mitochondria may be
therapeutically applicable for employing the cardioprotective utility of H2S.
Abbreviations
AAR, area at risk; ADT-OH, 5-(4-hydroxyphenyl)-3H-1, 2-dithiole-3-thione; AP219, mitochondria-targeting moiety; AP39,
10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5yl)phenoxy)decyl) triphenylphosphonium bromide, mitochondria-targeting H2S
donor; CsA, cyclosporine A; eNOS, endothelial NOS; GSK-3β, glycogen synthase kinase-3 β; IFM, interﬁbrillar mitochon-
dria; Mito-ROS, mitochondrial ROS; PTP, permeability transition pore; RISK, reperfusion injury salvage kinase (signalling
pathway); RNS, reactive nitrogen species; SSM, subsarcolemmal mitochondria; TPP+, triphenylphosphonium
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Introduction
In myocardial ischaemia/reperfusion injury, rapid pH nor-
malization, Ca2+ overload and overwhelming generation of
ROS and reactive nitrogen species (RNS) at reperfusion dis-
turb mitochondrial function and result in the opening of
the mitochondrial permeability transition pore (PTP)
(Hausenloy and Yellon, 2007). PTP opening leads to collapse
of mitochondrial membrane potential, swelling of the mito-
chondria and the leakage of cytochrome c into the cyto-
plasm. As a result, ATP production will be impaired,
initiating cell apoptosis/necrosis (Murphy et al., 2016; Pell
et al., 2016). PTP opening at reperfusion is believed to be the
no-return point of reperfusion injury (Hausenloy et al.,
2009). Therapeutic targeting of these processes during the
ﬁrst minutes of reperfusion has been investigated intensively
in experimental settings as early reperfusion appears to offer a
window of opportunity to prevent PTP opening and ulti-
mately reduce lethal cell injury (Ferdinandy et al., 2014).
The roles of endogenous H2S, in a wide range of physio-
logical systems, has been extensively explored following the
discovery that it is produced by several regulated biochemical
pathways in mammalian species (Kimura, 2011). In the myo-
cardium, enhanced levels of H2S, whether by H2S supplement
or increased endogenous production, have been shown to
protect the heart against ischaemia/reperfusion injury
(Johansen et al., 2006; Elrod et al., 2007; Karwi et al., 2016).
The exact cardioprotective mechanism of H2S has yet to be
clariﬁed, but a number of molecular targets have been identi-
ﬁed. These include activation of the reperfusion injury sal-
vage kinase (RISK) pathway (Hausenloy, 2013), enhanced
cellular and mitochondrial antioxidant defences, and preser-
vation of mitochondrial integrity (Bos et al., 2015). However,
these effects have been found to vary in many experimental
studies for several reasons including variations in animal
species and models, different experimental conditions and
inconsistencies in dosing with inorganic sulﬁde salts (Bos
et al., 2015). Inorganic sulﬁde salts (notably NaHS and Na2S)
have been extensively employed to explore the biological
activity of H2S. Nevertheless, these salts are impure and gen-
erate H2S instantaneously at high (i.e. supraphysiological)
concentrations, and there is increasing concern that they
are unreliable sources of H2S (Whiteman et al., 2011).
We have examined cardioprotection by a novel
mitochondria-targeting H2S donor, 10-oxo-10-(4-(3-thioxo-
3H-1,2-dithiol-5yl)phenoxy)decyl) triphenylphosphonium
bromide (AP39) (Le Trionnaire et al., 2014) when given as ad-
junct to reperfusion and its direct effect on cardiomyocyte
mitochondria, namely, subsarcolemmal (SSM) and interﬁbrillar
mitochondria (IFM). The rationale for targeted delivery of H2S
to the mitochondria is based on the evidence that H2S can at-
tenuate mitochondrial ROS (mito-ROS) generation and pre-
serves mitochondrial integrity. There are recent observations
that AP39 can successfully deliver H2S into the mitochondria
when given at reperfusion and that it reproducibly protects
the mitochondria in particular and the cell in general against
ischaemia/reperfusion insults in the brain and kidney (Ikeda
et al., 2015; Ahmad et al., 2016). We hypothesized that AP39
protects the heart against ischaemia/reperfusion injury when
administrated at reperfusion though a cytosolic-independent
mechanism. We also hypothesized that AP39 attenuates
mito-ROS generation and thereby inhibits PTP opening in the
SSM and IFM.
Methods
Animals and ethical statement
All animals care and procedures for in vivo studies complied
with UK Home Ofﬁce Guidelines on the Animals (Scientiﬁc
Procedures) Act 1986, (published by the Stationery Ofﬁce,
London, UK), project licence (PPL30/3032) and was approved
by the Animal Welfare and Ethical Review Body at Cardiff
University. Studies involved mitochondria isolation was ap-
proved by the Animal Welfare Ofﬁce of the Justus-Liebig Uni-
versity Giessen. Male Sprague Dawley rats, 300–350 g
(9–11 weeks), were obtained for in vivo studies from Harlan,
UK. For mitochondria isolation, male Wistar rats, 300–350 g
(9–11 weeks), were purchased fromHarlan, France. They were
housed in polypropylene cages (2–4 rats in each) on wood
shavings. Animals acclimatized in the institutional animal
house at constant temperature and humidity on a 12 h
light/dark cycle for at least 7 days prior to experimentation,
with free access to water and a small animal diet at all times.
Animals studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilly, 2015).
Tables of Links
TARGETS
PI3K GSK-3β
Akt (PKB) ERK1
eNOS ERK2
sGC
LIGANDS
LY294002
L-NAME
ODQ
Cyclosporine A
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise
Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015).
BJP Q G Karwi et al.
288 British Journal of Pharmacology (2017) 174 287–301
Acute myocardial infarction model
Myocardial infarction was induced as previously reported
(Karwi et al., 2016). Brieﬂy, rats were anaesthetized using
thiobutabarbital (Inactin® 200 mg·kg1, i.p), and anaesthe-
sia was maintained throughout the procedure by supple-
mental dosing (75 mg kg1, i.v.) as required. The left
jugular vein was cannulated for drug administration while
the right common carotid artery was cannulated and
connected to a pressure transducer (Powerlab data acquisi-
tion system, AD instruments, Abingdon, UK) to monitor
the heart rate and the blood pressure throughout the exper-
iment. The trachea was intubated and the animal ventilated
with room air using a small animal ventilator (Hugo Sachs
Elektronik, March, Germany) at a rate of 75 strokes min1
and tidal volume of 1.0 to 1.25 mL·100 g1. The chest was
opened by midline sternotomy and the heart exposed using
a retractor. The pericardium was incised and a 4/0 braided
silk suture (Mersilk, Ethicon Ltd, UK) was placed around
the left main coronary artery close to its origin to induce
regional ischaemia. ECG was monitored using standard lead
lI electrodes inserted s.c. into the limbs and connected to a
Powerlab data acquisition system. Rectal temperature was
maintained at 37  1°C using a thermal blanket (Harvard
Apparatus Ltd, Cambridge, UK). The following inclusion
criteria were employed during the stabilization period of
20 min: no ECG or visual signs of ischaemia, steady sinus
rhythm without arrhythmia, heart rate ≥250 beats min1,
and diastolic blood pressure ≥50 mmHg.
To induce regional ischaemia in the left ventricle, the left
coronary artery was transiently occluded for 30 min by
pulling the ligature taut through a plastic snare ﬁxed against
the epicardium. Ischaemia was conﬁrmed by colour change
of the left ventricle, a drop in the mean arterial pressure
(MAP), ST-segment elevation and arrhythmia developing be-
tween 5 and 13 min of ischaemia. The ligature was then re-
leased to start reperfusion for 120 min. Successful
reperfusion was conﬁrmed by blushing of the previously isch-
aemic area, reperfusion-induced arrhythmia and increase in
the MAP.
Infarct size determination
At the end of 120 min reperfusion, the heart was harvested
and retrogradely perfused with saline through the aorta on
a modiﬁed Langendorff apparatus. The ligature was re-
occluded and the heart perfused with 2% Evans’ blue dye
to delineate the ischaemic area at risk (AAR), then quickly
frozen at 20°C for 24 h. The heart was transversely
sectioned into 5–6 sections of 2 mm thickness and incu-
bated with 1% w.v-1TTC for 15 min. Sections were then
ﬁxed with 4% formalin in PBS for 24 h before being
scanned. Sections were scanned using a digital scanner and
coded using a random number generator (https://www.ran-
dom.org), then planimetry was carried out in a blind
fashion using the image analysis programme Image J
(version 1.47, NIH, Bethesda, USA). The analysis determined
the total ventricular area (Evans’ blue positive), AAR (TTC
positive) and the infarcted area (I, TTC negative), which
were converted to volumes by multiplying these areas by
2 mm section thickness. Infarct size was expressed as a
percentage of the AAR (% I/AAR).
Treatment protocols
The experimental protocols are summarized in Figure 1. Two
series of experiments were carried out. The ﬁrst series charac-
terized the dose-dependent infarct-limiting effect of AP39
along with the control compounds (AP219 and ADT-OH) to
conﬁrm the selective effect ofH2S delivery into themitochondria.
The doses of AP39, AP219 and ADT-OH used in these
experiments were derived from in vitro and in vivo studies
undertaken by others (Szczesny et al., 2014; Ikeda et al., 2015;
Ahmad et al., 2016).
Animals were randomised to receive one of six interven-
tions (Figure 1A):
• Group 1: Control (n = 10). Animals received a bolus dose of
(0.05% DMSO, i.v.) 10 min before reperfusion. DMSO was
used as a vehicle for AP39, AP219 and ADT-OH.
• Groups 2–4: Each group (n = 8) received AP39 at (0.01, 0.1
or 1 μmol·kg1 respectively) as an i.v. bolus 10 min before
reperfusion.
• Group 5: AP219 (n = 8). Animals received AP219
(1 μmol·kg1) as an i.v. bolus 10 min before reperfusion.
• Group 6: ADT-OH (n = 8). Animals received ADT-OH
(1 μmol·kg1) as an i.v. bolus 10 min before reperfusion.
The optimum dose of AP39 (1 μmol·kg1), selected from
the ﬁrst series of experiments, was used in a second series of
experiments that investigated the involvement of the RISK
pathway components using inhibitors of Akt phosphoryla-
tion (LY294002), eNOS (L-NAME) or sGC (ODQ). Animals
were randomly assigned to one of the following eight treat-
ment groups (Figure 1B).
• Group 1: Control (n = 11). Animals received DMSO 0.05%
given as an i.v. bolus 15 min before reperfusion. DMSO
was used as vehicle for AP39, LY294002 and ODQ.
• Group 2: AP39 (n = 8). Animals received AP39 (1 μmol·kg1)
as an i.v. bolus 10 min before reperfusion.
• Group 3: AP39 + L-NAME (n = 8). L-NAME (20mg·kg1) was
administered 15 min before reperfusion as an i.v. bolus
followed by AP39 (1 μmol·kg1) 10 min before reperfusion.
• Group 4: L-NAME (n = 8). L-NAME (20mg·kg1) was admin-
istered 15 min before reperfusion as an i.v. bolus.
• Group 5: AP39 + LY294002 (n = 8). LY294002 (0.3 mg·kg1)
was given 15 min before reperfusion as an i.v. bolus
followed by AP39 (1 μmol·kg1) 10 min before reperfusion.
• Group 6: LY294002 (n = 8). LY294002 (0.3 mg·kg1) was ad-
ministered 15 min before reperfusion as an i.v. bolus.
• Group 7: AP39 + ODQ (n = 8). ODQ (1 mg·kg1) was given
15 min before reperfusion as an i.v. bolus followed by
AP39 (1 μmol·kg1) 10 min before reperfusion.
• Group 8: ODQ (n = 8). ODQ (1 mg·kg1) was administered
15 min before reperfusion as an i.v. bolus.
In a parallel series prepared for biochemical analysis of
RISK pathway components, animals were randomised to re-
ceive either vehicle (0.05% DMSO) or AP39 (1 μmol·kg1)
10 min before reperfusion (Figure 1C). The heart was
excised after 5 min of reperfusion and washed with saline
to remove any blood residue. Tissue samples were rapidly
harvested from the left ventricle, snap frozen with liquid
nitrogen then kept at 80°C. These samples were used to
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investigate the effect of AP39 on the phosphorylation of
Akt, eNOS, GSK-3β and ERK1/2 at the commencement of
reperfusion using western blotting.
Isolation of cardiac mitochondria
Isolation of two mitochondrial subpopulations, subsarco-
lemmal mitochondria (SSM) and interﬁbrillar mitochondria
(IFM), was carried out using a modiﬁed protocol of that
described by Boengler et al. (2009). All the procedures were
undertaken at 4°C to maintain mitochondrial integrity.
Each rat was anaesthetized with 4% v.v-1 isoﬂurane, and
the heart was quickly excised and washed with buffer A
(100 mM KCl, 50 mM 3-[N-morpholino]-propanesulfonic
acid (MOPS), 5 mM MgSO4, 1 mM ATP and 1 mM EGTA,
pH 7.4). The ventricles were isolated and weighed. Ventri-
cles were transferred to buffer B (buffer A + 0.04% BSA),
ﬁnely chopped with scissors then gently minced with six
strokes of a teﬂon pestle in a glass tube. Homogenate was
centrifuged at 800 g for 10 min. The supernatant from
the ﬁrst centrifugation was collected and centrifuged for
10 min at 8000 g to isolate the SSM. The sediment of the
ﬁrst centrifugation was resuspended for 1 min in buffer B
Figure 1
Experimental protocols: Animals underwent 30min of ischaemia followed by 2 h of reperfusion. Infarct size was determined using Evans’ blue/TTC
staining technique. Infarction was reported as a percentage of the AAR (I/AAR %). (A) AP39 dose effect on infarct size: Animals were randomly
assigned to be treated with either vehicle or AP39 or the controls (AP219 or ADT-OH) at 10 min before reperfusion. (B) Mechanistic study: Rats
were randomised to receive the pharmacological inhibitors, namely LY294002, L-NAME and ODQ, at 15 min before reperfusion with or without
AP39 applied at 10 min before reperfusion. Control group only received the vehicle (0.05% DMSO) 10 min before reperfusion. (C) Myocardium
sampling protocol: Rats were randomised to receive either vehicle (0.05% DMSO) or AP39 10 minutes before reperfusion. Myocardial biopsies
were harvested at 5 minutes of reperfusion from the left ventricle. Arrows indicate the time of the pharmacological interventions.
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with protease nargase (8 U·g1) then gently minced with ﬁve
strokes of the teﬂon pestle and glass mortar. The homogenate
was centrifuged at 800 g for 10 min, then the supernatant was
collected and centrifuged for 10 min at 8000 g to sediment
the IFM. The SSM and IFM were washed with buffer A and ﬁ-
nal pellets were resuspended in buffer A with no ATP. Protein
concentration was determined using Lowry assay (BioRad,
Hercules, Canada).
Calcium retention capacity
Mitochondrial tolerance to calcium overload, a trigger to PTP
opening, was investigated in the presence and absence of
AP39 using a modiﬁed protocol of Chen et al. (2012). Freshly
isolated SSM and IFM (0.1 mg·mL1) were randomised to be
incubated for 4 min in 2 mL (in mM: KCl 125, Tris-MOPS
10, KH2PO4 1.2, MgCl2 1.2, glutamate 5, malate 2.5). The sus-
pension was supplemented with 8 μL ADP (10 mM), 10 μL
EGTA (1 mM), 6 μL CaCl2 (5 mM) and calcium green-5 N
(1 μM, Invitrogen, Carlsbad, Canada). Mitochondria were
treated with vehicle (0.003% ethanol) or AP39 (1 μM) during
the incubation period. Cyclosporine A (CsA) (1 μM) was used
as a positive control as it is a well-known inhibitor of the PTP
opening and increases mitochondrial tolerance to Ca2+
overload by a cyclophilin D-dependent mechanism. Pulses
of Ca2+ (5 μM) were added at 3 min intervals to the solution
with stirring at 25°C and mitochondrial calcium tolerance
was expressed as μM of Ca2+ mg1 of protein. Fluorescence
was measured with excitation and emission wavelengths
530/530 nm, respectively. Data were coded using a random
number generator (https://www.random.org) and blindly
analysed.
Mitochondrial oxygen consumption
The respiration of SSM and IFM was measured using a Clark-
type oxygen electrode (Strathkelvin, Glasgow, UK) at 25°C.
The concentrations range of AP39 used for the mitochondrial
studies were equivalent to the in vivo doses and after assessing
the direct effect of AP39 on themitochondria autoﬂouresence
and membrane potential (data not shown). Basal mitochon-
drial oxygen consumption was measured in the presence
and absence of either the vehicle (0.003% ethanol) or AP39
(0.3, 1, 3, 5 μM). Mitochondria (0.1 mg·mL1) were
randomised to receive one of the treatments and were incu-
bated in two chambers simultaneously, one with complex I
substrate (5 mM glutamate and 2.5mMmalate) and the other
with complex II substrate (5 mM succinate plus 2 μM of rote-
none, to inhibit complex I activity). Respiration was stimu-
lated by addition of 40 μM of ADP, and oxygen
consumption was reported as nmol of O2·min
1·mg 1 of pro-
tein. Oxygraph charts were randomly coded (https://www.
random.org) and blindly analysed.
Mito-ROS generation
Measurement of mito-ROS generation was carried out as pre-
viously descripted by Soetkamp et al. (2014). Freshly isolated
SSM or IFM (50 μg) were suspended in incubation buffer (in
mM: Tris-MOPS 10, EGTA 0.02, KCl 125, glutamate 5, malate
2.5, Pi-Tris 1.2, MgCl2 1.2, pH 7.4). Then 0.1 U·mL
1 HRP
(Roche Diagnostic, Grenzach, Germany) and 50 μmol
Amplex UltraRed (Invitogen, Eugene, OR) were added to the
suspension directly before the measurements were
performed. Cardiomyocyte mitochondria were randomly in-
cubated with: (i) no intervention; (ii) vehicle (0.003% etha-
nol); and (iii) AP39 (0.3, 1, 3 and 5 μM). A second control
group with no intervention was employed at the end of the
all measurements to ensure that any observed effects are due
to AP39 and not because of the decline in the respiratory ca-
pacity. SSM and IFM were also incubated with rotenone
(2 μM) to induce overproduction of mito-ROS generation
and used as a positive control. Mito-ROS generation was mea-
sured for 4 min at room temperature using Cary Eclipse spec-
trophotometer (Agilent technologies, Santa Clara, Canada) at
excitation/emission wavelengths 565/581 nm. Using a code
generator (https://www.random.org), data were coded and
the slope of mito-ROS generation was calculated, as a mean
ﬂuorescence per time (a.u.), by an operator blind to the treat-
ments after subtracting the background ﬂuorescence of the
incubation buffer.
Western blot analysis
Myocardial samples were homogenized and lysed using a
hard tissue lysing kit (Stretton Scientiﬁc Ltd, Stretton, UK).
Then 30 μg of protein was loaded into each well of a 10% w.
v-1 SDS-PAGE and separated electrophoretically at 120 mV.
Separated proteins were transferred onto nitrocellulose mem-
brane (Amersham, Germany), and the membrane was
blocked for non-speciﬁc binding with 5% skimmed milk for
2 h. The membrane was then probed with the primary anti-
body overnight at 4°C. The membrane was then incubated
with secondary antibody (goat anti-rabbit HRP, 1:15 000, Cell
Signalling, UK) for 1 h at room temperature. Super Signal
West Dura Extended Duration Substrate (Thermo Scientiﬁc,
UK) was added on the surface of the membrane to laminate
the bands and the bands were visualized on X-ray ﬁlm. Films
were scanned and coded, and densitometry was carried out in
blind fashion using Image J software (1.48v, National Insti-
tutes of Health USA). All protein bands were expressed as
the relative density of myocardium sample, harvested after
20 min of stabilization (baseline), and then normalised for
corresponding GAPDH bands, which served as an internal
standard.
Antibodies
The following antibodies were used for Western blotting: Akt
(1:1000), phospho- ser473Akt (1:1000), endothelial NOS
(eNOS 1:500), phospho- ser1177eNOS (1:500), GSK-3β
(1:1000), phospho- ser9GSK-3β (1:1000), ERK 1/2 (1:1000),
phospho- Thr202/Tyr204 ERK 1/2 (1:1000) and GAPDH
(1:50 000).
Statistical analysis
The data and statistical analysis comply with the recom-
mendations on experimental design and analysis in phar-
macology (Curtis et al., 2015). All data passed the
Kolmogorov–Smirnov normality test of distribution.
Statistical analysis was performed using GraphPad Prism®
software (2007, Version 5.01, USA), and data are presented
as mean  SEM. Infarct size data were analysed using one-
way ANOVA with Newman–Keuls post hoc test, and Western
blot analysis was performed using Student’s unpaired t-test.
Haemodynamic and mitochondrial data were statistically
analysed using repeated measures ANOVA supported by
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Bonferroni’s post hoc test. P < 0.05 was considered statisti-
cally signiﬁcant. Post tests were only carried out if
P < 0.05 was achieved in the ANOVA.
Materials
AP39 and the control compounds, the mitochondria-
targeting moiety, AP219, and the H2S-releasing moiety,
ADT-OH (5-(4-hydroxyphenyl)-3H-1, 2-dithiole-3-thione),
were synthesized by us as previously reported (Le Trionnaire
et al., 2014; Szczesny et al., 2014; Tomasova et al., 2014).
The purity of the compounds was determined by NMR
spectroscopy (1H, 31P and 13C). The irreversible haem-site
soluble GC (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]
quinoxalin-1-one (ODQ), the constitutive NOS inhibitor
L-nitroarginine methyl ester (L-NAME), the PI3K inhibitor
LY294002, thiobutabarbital sodium salt hydrate (Inactin®
hydrate), Evans blue dye, triphenyltetrazolium chloride
(TTC) and DMSO were all purchased from Sigma-Aldrich,
Gillingham, UK.Western blotting antibodies were all sourced
from Cell Signalling, UK.
Results
For the AP39 dose–response study, 52 rats were used, of
which two were excluded: one did not have successful
reperfusion, and one rat did not survive ischaemia-induced
ventricular ﬁbrillation. Therefore, data from 50 successfully
completed experiments are presented. In the second series,
83 rats were used, of which, four were excluded: two did
not complete the ischaemia–reperfusion protocol, one did
not have successful TTC staining and one did not survive
reperfusion-induced arrhythmia. Thus, data from 79 rats,
67 infarct size experiments that were successfully com-
pleted and 12 tissue sampling experiments were reported.
For mitochondria functional studies, data from 20 rats are
reported.
Pharmacological postconditioning with AP39
Baseline parameters for infarct size studies are shown in
(Table 1). There was no difference among the 14 experimen-
tal groups in any of the baseline parameters. Risk zone was
similar among the experimental groups (50–60% of the total
ventricular volume, Figure 2A). Administration of AP39
10 min before reperfusion resulted in a dose-dependent
infarct-sparing effect compared with vehicle-treated animals
(Figure 2B). The maximum cardioprotection was seen at 1-
μmol·kg1 dose with almost 40% reduction in infarct size
compared with vehicle-treated animals. Postconditioning
with AP39 (1 μmol·kg1) also dose-dependently increased in
the post-ischaemic functional recovery [% rate pressure prod-
uct (RPP) recovery as a percentage of pre-ischaemia RPP] mea-
sured at the end of reperfusion (67.2  3.8%) compared with
the control hearts (46.2  3.8%, Table 1). The control com-
pounds, namely AP219 and ADT-OH, did not have a signiﬁ-
cant effect on either RPP recovery or infarct size, conﬁrming
that selective delivery of H2S to the mitochondria mediates
AP39’s cardioprotection.
Cytosol-independent mechanism of
postconditioning with AP39
We next investigated the effect of AP39 on the RISK pathway
as a relevant protective cytosolic-signalling pathway using a
‘signal tracing’ technique. Speciﬁc pharmacological inhibi-
tors, namely the PI3K inhibitor LY294002 (Jiang et al.,
2007), constitutive NOS inhibitor L-NAME (Fradorf et al.,
2010) and sGC inhibitor ODQ (Routhu et al., 2010) were used
at doses that have previously been reported to abrogate the
activity of their targets in in vivo models.
There was no signiﬁcant difference in either the baseline
characteristics or the risk zone (ischaemic bed) among the
groups (Figure 3A). None of the pharmacological inhibitors
had a signiﬁcant effect on infarct size when given alone
15 min before reperfusion compared with the control group
(Figure 3B). Blockade of PI3K activity with LY294002 did
not abolish the infarct limitation by AP39. Similarly, neither
blockade of NO synthesis by L-NAME nor selective inhibition
of its downstream effector, sGC, with ODQ attenuated the
protective effect of AP39.
The effect of AP39, used as an adjunct to reperfusion,
on the key cytosolic components of the RISK pathway
was also evaluated in samples harvested from the left ven-
tricle after 5 min of reperfusion (Figure 4). Immunoblot-
ting was carried out using phospho-speciﬁc antibodies
for Akt, eNOS, GSK-3β and ERK1/2 to outline their role
in the cardioprotection. In line with the infarct size data,
Western blot analysis showed that administration of AP39
at reperfusion had no signiﬁcant effect on the phosphory-
lation of either Akt, eNOS, GSK-3β or ERK1/2. This
conﬁrms that AP39 mediated its cardioprotection indepen-
dently of these cytosolic components on the RISK
pathway.
Mitochondrial effects of AP39
We examined the effect of speciﬁc-delivery of H2S into the
mitochondria on the susceptibility to PTP opening. We used
freshly isolated SSM and IFM and treated them with vehicle
or AP39 (1 μM). SSM and IFM were exposed to pulses of
Ca2+ in the presence and absence of CsA as a positive control
(Figure 5). Untreated IFM showed 30% higher calcium toler-
ance than untreated SSM. AP39 elicited a signiﬁcant inhibi-
tory effect on the PTP opening in both SSM and IFM, which
represents 30% increase in Ca2+ overload tolerance, com-
pared with vehicle-treated mitochondria. The inhibitory
effect of AP39 on PTP opening was comparable with that ob-
served after CsA in SSM and IFM. Interestingly, AP39 showed
25% additive effect to CsA-induced inhibition of PTP open-
ing when either SSM or IFM were incubated with both AP39
and CsA before the exposure to Ca2+ pulses, compared with
CsA alone.
Mitochondrial respiration was measured for both SSM
and IFM using substrates for complex I (glutamate and ma-
late) and complex II (succinate, in the presence of rote-
none to inhibit complex I). There was no difference in
the basal respiration of the two subpopulations of mito-
chondria. ADP-stimulated respiration was higher in IFM
(by 25% and 31% for complex I and II respectively) com-
pared with SSM. Different concentrations of AP39 (0.3, 1,
3, 5 μM) were tested on SSM or IFM; however, none of
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the concentrations examined signiﬁcantly inﬂuenced
mitochondrial oxygen consumption.
Overwhelming mito-ROS generation at early reperfusion
is one of the main determinants of cellular injury. Therefore,
we performed in vitro experiments to look at the direct effect
of AP39 on H2O2 generation in the isolated rat left ventricle
mitochondria (Figure 7A–D). In the control groups, ROS gen-
eration was signiﬁcantly lower by 20% in IFM than SSM.
AP39 showed a dose-dependent inhibition of ROS generation
in both SSM and IFM. AP39 (1 μM) exerted the maximum
inhibitory effect (38% in SSM and 61% in IFM) compared
with control, vehicle-treated and the second control
mitochondria. Interestingly, the inhibitory effect of AP39 on
mito-ROS generation was gradually reduced as the concentra-
tion was increased. Rotenone, as a positive control, resulted
in overproduction of ROS in both SSM and IFM by 65% and
75%, respectively, compare the basal ROS generation level.
Discussion
The lipophilic triphenylphosphonium (TPP+) scaffold is an
attractive moiety for investigating mitochondrial function
as it selectively accumulates (100- to 500-fold vs. cytosol) in
Figure 2
Infarct-limiting effect of AP39 at reperfusion: (A) area at risk (AAR) reported as a percentage of the total ventricular volume. (B) Infarct size pre-
sented as a percentage of the AAR. Data were analysed using one-way ANOVA with Neuman Keuls post hoc test and presented as mean  SEM,
n = 8 for all groups except the control group (0.05% DMSO) where n = 10. The mean of the infarct size for each group is represented by a ﬁlled
circle (with error bars) next to the individual values (open circles). * P < 0.05 versus control, † P < 0.05 versus AP39 0.1 μmol·kg1.
Figure 3
Effect of pharmacological inhibitors of the RISK pathway on infarct-limitation by AP39: (A) risk zone measurements of experimental groups
expressed as a percentage of the total ventricular area. (B) Myocardial infarction data are expressed as a percentage of the risk zone. Individual
animal data in each group are represented by empty circles while the mean of infarct size is presented by a full circle. Data were analysed via
one-way ANOVA followed by Newman Keuls post hoc test and reported as mean  SEM, n = 8 for all groups except the control group where
n = 11. * P < 0.05 versus control.
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the mitochondrial matrix (Murphy and Smith, 2007; Smith
et al., 2011). Previous work (Prime et al., 2009) demonstrated
infarct limitation using a mitochondria-targeted NO donor
(MitoSNO) with an NO-releasing moiety linked to TPP+.
Work by Krieg’s group (Methner et al., 2013) showed that
MitoSNO works independently of cytosolic protein kinase G
that mediates the cardioprotective effect of non-mitochon-
drial-targeted NO donors. AP39 represents the ﬁrst successful
attempt to deliver H2S selectively and at low concentration to
the mitochondria (Le Trionnaire et al., 2014; Szczesny et al.,
2014; Tomasova et al., 2014; Ikeda et al., 2015; Ahmad et al.,
2016).
In the present study, AP39 signiﬁcantly limited infarct
size (Figure 2B) and improved the post-ischaemic functional
recovery (Table 1), both in a dose-dependent manner, when
administered prior to reperfusion. Consistent with these
data, Ahmad et al. (2016) reported that AP39 also exerted at-
tenuation in renal damage, oxidative stress and renal inﬂam-
mation when applied at reperfusion in an in vivo renal
ischaemia/reperfusion injury model. We observed that the
TPP+ scaffold molecule (AP219) and the H2S-generating moi-
ety (ADT-OH), which were used as controls, had no effect on
myocardial injury. This is in agreement with other reports
where these controls lacked biologically activity when used
at nanomolar or micromolar concentrations (Le Trionnaire
et al., 2014; Szczesny et al., 2014; Ahmad et al., 2016).
At the time of ﬁnalizing this manuscript, recent work with
AP39 by Papapetropoulos’s group (Chatzianastasiou et al.,
2016) has appeared. The main focus of Chatzianastasiou’s
work is ‘head-to-head’ comparison of infarct limitation by
different H2S donors (Na2S, GYY4137, thiovaline and AP39)
and elucidation of the role of NO inmediating protection. In-
triguingly, all donors had the same infarct-limiting effect in a
mouse model of ischaemia/reperfusion injury. It is notewor-
thy that the optimum cardioprotective doses of GYY4137
and AP39 used were 26.6 and 0.25 μmol·kg1 respectively.
Very recently, we reported that 26.6 μmol·kg1 GYY4137
was not cardioprotective in an in vivo rat model of
ischaemia/reperfusion injury with the optimum
cardioprotective dose being 10-fold higher (Karwi et al.,
2016). Similarly, in the present study, we demonstrated that
AP39 exerts an infarct-sparing effect with an optimum
cardioprotective dose of 1 μmol·kg1, fourfold higher than
the effective dose in mouse reported by Chatzianastasiou
et al. (2016). No haemodynamic data are available to compare
AP39-induced dose-dependent improvement in post-
ischaemic functional recovery with Chatzianastasiou’s paper.
Our present study provides important mechanistic in-
sight into AP39’s cardioprotective action in vivo. We found
that selective blockade of PI3K, which is known to mediate
the cardioprotective effect of non-mitochondrial H2S donors
(Andreadou et al., 2015; Karwi et al., 2016), did not abolish
Figure 4
Effect of AP39 on RISK pathway proteins at early reperfusion: representative western blots and densitometry analysis of (A) pAktS473, total Akt and
GAPDH; (B) p-eNOSS1177, total eNOS and GAPDH; (C) p-GSK-3βS9, GSK-3β and GAPDH; (D) p-ERK1/2Thr202/Tyr204, ERK1/2 and GAPDH. Speciﬁc
antibodies were used to assess the effect of AP39 on the phosphorylation of the RISK components in myocardial biopsies harvested from the left
ventricle at early reperfusion. Histograms show the relative ratio of phosphorylated protein to the total level of protein. GAPDH was used as an
internal standard for all quantiﬁcations. Data were analysed using Student’s t-test and presented as mean  SEM, n = 6 per group.
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cardioprotection (Figure 3B). Crosstalk/interaction between
H2S and NO has different patterns depending on
organs/tissues, experimental conditions and species (King
et al., 2014; Bibli et al., 2015; Karwi et al., 2016). To test if
NO/sGC pathway mediates the effect of AP39, we blocked
the endogenous NO synthesis pathway and also inhibited
the activity of its end effector (sGC) using L-NAME and
ODQ respectively. We found that cardioprotection by AP39
was still observed in the presence of L-NAME or ODQ, sup-
ported by analysis of protein phosphorylation during early
reperfusion. We observed that AP39 did not induce phos-
phorylation of Akt, eNOS, GSK-3β, a downstream effector of
the RISK pathway, or ERK1/2, a parallel arm of the RISK path-
way at 5 min reperfusion (Figure 4A–D). Chatzianastasiou
et al. (2016) reported that AP39 did not phosphorylate either
eNOS ser1176 or VASP ser239 after 10min of reperfusion and its
cardioprotection was not abolished by either L-NAME or
DT2, indicating a cGMP/PKG-independent mechanism in
themurine model. Their data are complementary to the fuller
characterization of the potential cytosolic signalling targets
of AP39 that we present here. Viewed together, our data and
those of Chatzianastasiou et al. (2016) provide persuasive ev-
idence that, unlike other H2S donors, AP39 mediates its
cardioprotection by a mechanism that is independent of acti-
vation of the cytosolic components of the RISK signalling
cascade.
Intra-mitochondrial H2S is essential for normal function
of the citric acid cycle. Levels are disturbed during oxidative
stress due to increased H2S degradation and reduced produc-
tion (Geng et al., 2004; Doeller et al., 2005; Whiteman et al.,
2011; Vandiver and Snyder, 2012). H2S supplements or
overexpression of endogenous synthetic enzymes have been
shown to protect against ischaemia/reperfusion injury by
mitigating oxidative stress and preserving mitochondrial in-
tegrity (Andreadou et al., 2015). Interestingly, Kai et al.
(2012) found that NaHS-induced protection was abolished
in mitochondria-free cells. Nevertheless, whether H2S di-
rectly interacts withmitochondria or triggers cytosolic signal-
ling pathways that converge on the mitochondria may
depend on the intracellular level of H2S. Therefore, we have
characterized for the ﬁrst time the direct effect of AP39 on
the most relevant subpopulations of cardiomyocyte mito-
chondria, namely SSM and IFM. Inhibition of the PTP open-
ing in the ﬁrst minutes of reperfusion has been extensively
reported to protect against reperfusion injury (Halestrap,
2010; Ong et al., 2014). It has been shown that many
cardioprotective interventions act to maintain PTP in a
closed state (Hausenloy et al., 2009). With this in mind, we
investigated the inﬂuence of AP39 on the opening of PTP,
as a result of Ca2+ overload, in cardiac SSM and IFM. We
found that AP39 inhibited PTP opening in SSM and IFM
(Figure 5) with no signiﬁcant difference from the inhibitory
effect of the positive control, CsA, which can protect myocar-
dium against ischaemia/reperfusion injury (Hausenloy et al.,
2012). We observed that AP39 and CsA in combination
increased mitochondrial tolerance to Ca2+ overload and
resulted in an additive effect compared with either
compound alone. CsA prevents the opening of PTP by
desensitizing cyclophilin-D, a component of the
multiprotein complex spanning the inner and outer
mitochondrial membranes, which is a modulator of PTP
located in the mitochondrial matrix (Bernardi and Di Lisa,
Figure 5
Effect of AP39 onmitochondrial PTP opening: SSM and IFMwere incubated individually with vehicle (0.003% ethanol) or different concentrations
of AP39 and subjected to pulses of 5 μMof CaCl2 per 3 min at 25°C until the opening of PTP in the presence and absence of CsA. Data expressed as
mean  SEM, n = 10, * P < 0.05 versus SSM + vehicle, # P < 0.05 versus SSM + vehicle + CsA, † P < 0.05 versus IFM + vehicle, $ P < 0.05 versus
IFM + vehicle + CsA (two-way ANOVA followed by Bonferroni post hoc test, n = 10).
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2015). Having an additive effect to CsA suggests that AP39
may inhibit PTP opening via a cyclophilin-D independent
mechanism. Chatzianastasiou et al. (2016) reported that
AP39 (0.3 vs. 1 μM in our study), exerted an additive effect
to CsA in mouse mitochondria isolated from the whole heart.
However, isolating mitochondria from whole heart tissue is
potentially problematic as a number of cell types contribute
to the isolated mitochondrial fraction, for example
endothelial cells, ﬁbroblasts and other local resident cells.
Even more important, cardiomyocyte mitochondria, namely
SSM and IFM, themselves signiﬁcantly differ in their main
characteristics including oxygen consumption, mito-ROS
generation and calcium retention capacity (Palmer et al.,
1977; Palmer et al., 1986). Our present study conﬁrms for
the ﬁrst time the effect of AP39 in both IFM and SSM
subpopulations.
It has been reported that H2S can stimulate mitochondrial
ATP production by acting as an electron donor for the elec-
tron transport chain (Modis et al., 2014; Szabo et al., 2014).
Accordingly, we explored the inﬂuence of AP39 onmitochon-
drial respiration through complexes I and II in both SSM and
IFM. The respiration control ratio (RCR), an index for the cou-
pling between mitochondrial respiration and oxidative phos-
phorylation, for isolated mitochondria fractions in this study
was around 2.5. Although this result is comparable with our
previously data (Boengler et al. 2009), others have reported
higher RCR ratios (Chen et al., 2008; Asemu et al., 2013; Gao
et al., 2013). This could be due to either measuring oxygen
consumption at 30°C instead of 25°C, using trypsin instead
of nargase to release the IFM or stimulating the mitochondria
with higher concentration of ADP than what was used in this
study. We did not detect any signiﬁcant effect of AP39 on the
oxygen consumption of these complexes in either mitochon-
drial subpopulation (Figure 6). These data suggest the safety
margin of the applied concentration range. More importantly
and in line with others, these results show that electron sup-
ply by H2S (at low concentration) to the electron transport
chain occurs at the level of coenzyme Q where sulﬁde qui-
none reductase activity is involved. Following that, electrons
will ﬂow forward toward Complex III and Complex IV with-
out affecting either Complexes I or II (Goubern et al., 2007;
Szabo et al., 2014). It has been demonstrated that inhibition
of Complex I using rotenone did not affect sulﬁde oxidation
while inhibition of Complex III or VI by antimycin or cya-
nide, respectively, impeded it (Volkel & Grieshaber, 1996;
Yong & Searcy, 2001; Goubern et al., 2007). Investigating
the effect of AP39 on mitochondrial respiration at 37°C also
needs further investigation in future work.
The detrimental effect of overwhelming mito-ROS gener-
ation, as a result of respiratory chain uncoupling, is one of
the hallmarks of ischaemia/reperfusion injury (Venditti
et al., 2001; Brown and Griendling, 2015). It is a major con-
tributor to the opening of PTP, initiating cell apoptosis and
accelerated necrosis during reperfusion (Hausenloy et al.,
2009). Since oxidative stress and the mitochondria play cen-
tral roles in ischaemia/reperfusion injury, targeting the mito-
chondria with selective H2S donors is a plausible therapeutic
approach to limit ischaemia/reperfusion injury. Here, we
Figure 6
Effect of AP39 on mitochondrial respiration: Respiration of complexes I and II were measured at basal level and after ADP-stimulation in the pres-
ence and absence of the vehicle or different concentrations of AP39 in SSM and IFM mitochondria. Data were analysed by two-way ANOVA with
Bonferroni post hoc test and reported as mean  SEM, n = 10, * P < 0.05 versus basal respiration.
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have investigated for the ﬁrst time the inﬂuence of AP39 on
mito-ROS generation in both SSM and IFM. We found that
AP39 limited mito-ROS level in both subpopulations
(Figure 7), which is in line with other studies of mito-ROS re-
duction with AP39 (Le Trionnaire et al., 2014; Szczesny et al.,
2014; Ikeda et al., 2015; Ahmad et al., 2016). We also observed
an attenuation in AP39’s activity as its concentration was in-
creased, consistent with the ﬁndings of others (Szczesny et al.,
2014; Ahmad et al., 2016).
Although we have provided novel mechanistic insights
into how AP39 could mediate cardioprotection, there are
several caveats and current limitations. Assessing the ex-
tent of mitochondrial H2S level increase following AP39
application remains a challenge due to the lack of sensitive
probes. Ikeda et al. (2015) reported that AP39 did not
inﬂuence the expression of cystathionine γ lyase (CSE),
cystathionine β synthase (CBS) or 3-mercaptopyruvate
sulphurtransferase (3-MST) in the brain. This suggests that
AP39 probably elevates mitochondrial H2S level without in-
terfering with the endogenous synthesis of H2S. The focus
of ongoing work is to investigate whether AP39 supresses
oxidative stress by increasing GSH production or by up-
regulating mito-ROS scavenging pathways or by directly
scavenging ROS. The exact mechanism/target whereby
AP39 inhibits PTP opening also remains to be determined.
It may be interesting to identify what happens to these
Figure 7
Effect of AP39 on mitochondrial-ROS generation: Mitochondria were incubated with either vehicle (0.05% DMSO) or different concentrations of
AP39. (A) and (B) are representative charts for the ROS generation of SSM and IFM, respectively, and error bars were removed for clarity. The slope
of ROS generation was measured continuously for 4 min with the ﬂuorescence indicator Amplex Ultrared both in (C) SSM and (D) IFM mitochon-
dria. Data are expressed as mean SEM, n = 10, * P< 0.05 versus ﬁrst control, # P< 0.05 versus second control (two-way ANOVA with Bonferroni
post hoc test, n = 10).
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subpopulations in the animal treated with AP39. Both sub-
populations play signiﬁcant roles in mediating
cardioprotection, although it is possible this includes
persulﬁdation (also called S-sulfhydration) of mitochon-
drial proteins such as ATP synthase (Modis et al., 2016;
Wedmann et al., 2016). Very recent work by Murphy’s
group (Sun et al., 2016) also proposed that
postconditioning with NaHS protected against myocardial
infarction via an increase in S-nitrosylation and most of
the S-nitrosylated proteins were mitochondrial proteins.
This further emphasizes the physiological importance of
post-translation modiﬁcations of H2S and its interaction
with NO in the mitochondria, a phenomenon that we are
now seeking to characterize.
In conclusion, our results conﬁrm that AP39 can protect
the heart against myocardial infarction when given at reper-
fusion in a manner that is independent of classical cytosolic
signalling mechanisms. We also report for the ﬁrst time that
AP39 inhibits mito-ROS generation and PTP opening in both
SSM and IFM, probably in a cyclophilin D-independent man-
ner without affecting mitochondrial respiration. These ﬁnd-
ings provide proof-of-concept that direct delivery of H2S to
mitochondria by mitochondria-targeting H2S donors, of
which AP39 is a prototype of several compounds in this class
under development, represents a novel and effective adjunc-
tive intervention to mitigate the irreversible myocardial in-
jury associated with reperfusion.
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a  b  s  t  r  a  c  t
Exogenous  hydrogen  sulﬁde  (H2S)  protects  against  myocardial  ischemia/reperfusion  injury  but  the  mech-
anism  of action  is  unclear.  The  present  study  investigated  the  effect  of  GYY4137,  a slow-releasing  H2S
donor,  on  myocardial  infarction  given  speciﬁcally  at reperfusion  and  the  signalling  pathway  involved.
Thiobutabarbital-anesthetised  rats  were  subjected  to 30 min  of  left coronary  artery  occlusion  and  2 h
reperfusion.  Infarct  size  was  assessed  by  tetrazolium  staining.  In  the  ﬁrst study,  animals  randomly
received  either  no  treatment  or GYY4137  (26.6,  133  or 266  mol  kg−1)  by intravenous  injection  10  min
before  reperfusion.  In  a second  series,  involvement  of  PI3K  and  NO signalling  were  interrogated  by
concomitant  administration  of LY294002  or  L-NAME  respectively  and  the  effects  on the  phosphory-
lation  of Akt,  eNOS,  GSK-3  and  ERK1/2  during  early  reperfusion  were  assessed  by  immunoblotting.
GYY4137  266  mol  kg−1 signiﬁcantly  limited  infarct  size  by  47%  compared  to control  hearts  (P < 0.01).
In  GYY4137-treated  hearts,  phosphorylation  of  Akt,  eNOS  and  GSK-3  was  increased  2.8, 2.2  and  2.2
fold  respectively  at early  reperfusion.  Co-administration  of  L-NAME  and  GYY4137  attenuated  the  cardio-
protection  afforded  by  GYY4137,  associated  with  attenuated  phosphorylation  of eNOS.  LY294002  totally
abrogated  the infarct-limiting  effect  of  GYY4137  and  inhibited  Akt, eNOS  and  GSK-3  phosphorylation.
These  data  are  the  ﬁrst  to demonstrate  that GYY4137  protects  the  heart  against  lethal  reperfusion  injury
through  activation  of  PI3K/Akt  signalling,  with  partial  dependency  on  NO  signalling  and  inhibition  of  GSK-
3 during  early  reperfusion.  H2S-based  therapeutic  approaches  may  have  value  as adjuncts  to reperfusion
in  the treatment  of acute  myocardial  infarction.
© 2016  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
In acute myocardial infarction, prompt restoration of coronary
blood ﬂow with appropriate reperfusion interventions is essential
to salvage ischemic myocardium. Paradoxically, sudden reperfu-
sion induces further irreversible cell injury and death beyond
Abbreviations: AAR, area at risk; Akt, protein kinase B; DATS, diallyltrisul-
ﬁde; eNOS, endothelial nitric oxide synthase; ERK1/2, extracellular signal-regulated
kinases 1/2 (p42/p44 mitogen activated protein kinase); GSK-3, glycogen syn-
thase kinase-3 Beta; GYY4137, morpholin-4-ium 4-methoxyphenyl-morpholino-
phosphinodithioate; H2S, hydrogen sulﬁde; IPost-C, ischemic postconditioning;
mPTP, mitochondrial permeability transition pore; NO, nitric oxide; PBS, phosphate
buffered saline; PI3K, phosphatidylinositol-3-kinase; RISK, reperfusion injury sal-
vage kinase (signalling pathway).
∗ Corresponding author at: School of Pharmacy and Pharmaceutical Sciences,
Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, UK.
E-mail address: baxtergf@cardiff.ac.uk (G.F. Baxter).
that caused by ischemia. Therefore, reperfusion injury contributes
to overall clinical outcome since ultimate infarct size will be
determined by both ischemic and reperfusion injuries [12]. Reper-
fusion injury is a challenging but important therapeutic target.
The molecular pathology of reperfusion injury is complex and is
likely to involve overwhelming oxidative/nitrosative stress, sud-
den intracellular pH normalisation and cytosolic Ca2+ oscillation,
precipitating opening of the mitochondrial permeability transition
pore (mPTP) during the early moments of reperfusion which initi-
ates necrosis [47,7].
Ischemic postconditioning (IPost-C) is an experimental
manoeuvre in which very brief intermittent periods of ischemia
are introduced immediately after reperfusion [58]. This inter-
vention has been shown to limit infarct size signiﬁcantly, most
likely through the activation of survival signalling mechanisms
that reduce opening of the mPTP [19]. The so-called “reperfusion
injury salvage kinase” (RISK) pathway includes as key components
http://dx.doi.org/10.1016/j.phrs.2016.06.028
1043-6618/© 2016 Elsevier Ltd. All rights reserved.
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Table  1
Baseline and cardiodynamics for series 1 and 2 at the end of stabilisation period, after 20 min  of ischaemia and at the end of reperfusion.
Experimental Protocol n BW (g) Baseline 20 min  Ischaemia 120 min Reperfusion
RPP (mmHg  min−1*103) MAP  (mmHg) RPP (mmHg  min−1*103) MAP (mmHg) RPP (mmHg min−1*103) MAP  (mmHg)
Series 1
Control 10 355 ± 6 37.5 ± 2.0 88 ± 4 27.9 ± 1.8 68 ± 4 24.0 ± 1.4 53 ± 3
GYY4137 26.6 mol kg−1 8 360 ± 9 40.3 ± 3.0 90 ± 6 29.1 ± 2.1 71 ± 5 26.3 ± 2.0 59 ± 4
GYY4137 133 mol kg−1 8 346 ± 7 41.4 ± 1.8 94 ± 6 29.5 ± 2.2 70 ± 6 24.3 ± 1.5 53 ± 4
GYY4137 266 mol kg−1 8 368 ± 6 39.1 ± 1.7 83 ± 4 28.6 ± 2.0 65 ± 5 20.9 ± 1.6 45 ± 3
D-GYY4137 6 368 ± 6 38.4 ± 2.3 85 ± 5 26.3 ± 2.1 69 ± 4 22.7 ± 1.3 48 ± 4
Series  2
Control 7 384 ± 7 36.3 ± 2.2 85 ± 5 24.8 ± 2.2 61 ± 6 21.2 ± 2.0 48 ± 4
GYY4137 7 379 ± 8 41.3 ± 3.0 96 ± 6 26.8 ± 1.6 66 ± 6 21.6 ± 1.1 47 ± 2
GYY4137 + L-NAME 7 387 ± 7 39.3 ± 2.5 88 ± 5 29.5 ± 2.4 69 ± 5 19.4 ± 2.4 50 ± 6
L-NAME 6 381 ± 9 39.3 ± 1.6 97 ± 3 30.4 ± 2.1 76 ± 7 22.4 ± 5.1 57 ± 9
GYY4137 + LY294002 6 362 ± 8 39.3 ± 1.8 88 ± 4 30.2 ± 1.8 71 ± 5 24.2 ± 0.6 53 ± 1
LY294002 6 367 ± 11 44.5 ± 2.8 98 ± 4 29.6 ± 1.2 72 ± 4 25.0 ± 0.7 54 ± 2
RPP = Rate pressure product, MAP  = mean arterial pressure. Data are reported as Mean ± SEM. There was no signiﬁcant difference among the experimental groups (One way
ANOVA  + Newman Keuls post-hoc), p > 0.05.
phosphatidylinositol-3-kinase (PI3K)/Akt, and endothelial nitric
oxide synthase (eNOS). Other kinases have been described as
part of the RISK pathway including extracellular regulated kinase
(ERK1/2; p42/p44 mitogen activated protein kinase) and glycogen
synthase-3 (GSK-3). Although IPost-C is of limited clinical
applicability, a number of pharmacological approaches that mimic
IPost-C have been described, including the administration of
autacoids and other mediators thought to activate the kinases of
the RISK cascade [5].
Hydrogen sulﬁde (H2S) has attracted considerable interest as a
cardiovascular autacoid. Although produced endogenously within
the myocardium and coronary vasculature [35,16], in coronary
artery disease, there may  be reduced H2S production [56,17,22].
The administration of exogenous H2S donor compounds or increas-
ing endogenous production of H2S has been well documented
to reduce ischemia-reperfusion injury in experimental models
[11,8,26]. There is also evidence that H2S is a mediator of IPost-C
[3,56,20,10]. However, potential therapeutic extrapolation of this
knowledge has been hindered by the limitations of H2S donor com-
pounds. Much of the experimental literature has reported studies
with inorganic sulﬁde salts (Na2S and NaSH) which are impure
in commercial form and unstable. Despite them being water sol-
uble and inexpensive, a particular issue is that the H2S release
is largely uncontrollable as they dissociate in aqueous medium
instantly to generate H2S at high concentration in a short-lasting
burst [41]. In contrast to Na2S and NaSH, GYY4137 (morpholin-
4-ium 4-methoxyphenyl-morpholino-phosphinodithioate) is a
donor compound which releases H2S at a slow steady rate at phys-
iological pH and temperature [33]. Several studies have suggested
that GYY4137 effectively delivers H2S in various physiological
systems [32,34,29,44,36,15,39]. Recent work by Meng et al. [38]
showed that GYY4137 given prior to myocardial ischemia protected
against injury development and improved post-ischemic recovery
of function. However, the therapeutically relevant time window for
acute myocardial infarction implies administration as a postcondi-
tioning mimetic i.e. immediately prior to reperfusion since this is
the time at which clinical therapeutic intervention can feasibly be
made.
The aim of the present study was to investigate for the ﬁrst time
the injury limiting effects of GYY4137 at early reperfusion when
given speciﬁcally as an adjunct to reperfusion in a rat model of acute
myocardial infarction. We  hypothesised that GYY4137 was able
to limit reperfusion injury when given just prior to reperfusion,
thereby limiting ultimate infarct size. We  further hypothesised that
the protective action was due to H2S release and the activation of
key components of the RISK signalling cascade at the ﬁrst minutes
of reperfusion associated with postconditioning, namely PI3K/Akt
and eNOS.
2. Materials and methods
2.1. Animals
Male Sprague Dawley rats, 300–350 g, were purchased from
Harlan, UK. They were acclimatised in the institutional animal
house at constant temperature and humidity on a 12 h light/dark
cycle for at least seven days prior to experimentation, with free
access to water and a small animal diet (Teklad global 14% protein
rodent maintenance diet) at all times. All handling and procedures
were carried out in accordance with UK Home Ofﬁce Guidelines
on the Animals (Scientiﬁc Procedures) Act 1986, (published by the
Stationery Ofﬁce, London, UK). The reporting of animal studies was
in accordance with ARRIVE guidelines [25,37].
2.2. Materials
GYY4137 and ’depleted’ GYY4137 were synthesised in-house
as described [1,33] and purity determined by by NMR  spectroscopy
(1H, 31P and 13C). The purity of GYY4137 was identical to a com-
mercial sample from SigmaAldrich. The constitutive nitric oxide
synthase (NOS) inhibitor L-nitroarginine methyl ester (L-NAME),
the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002,
thiobutabarbital sodium salt hydrate (Inactin® hydrate), Evans blue
dye, triphenyltetrazolium chloride (TTC) and dimethylsulfoxide
(DMSO) were all purchased from Sigma-Aldrich, Gillingham, UK.
Western blotting antibodies were all sourced from Cell Signalling,
UK.
2.3. Acute myocardial infarction model
Rats were anesthetised by intraperitoneal injection of
thiobutabarbital sodium (200 mg  kg−1) and maintained by intra-
venous supplemental dosing (75 mg  kg−1) as required to maintain
surgical anesthesia throughout the procedure. Body temperature
was maintained at 37 ± 1 ◦C via rectal thermometer attached to a
thermo-regulated blanket unit (Harvard Apparatus Ltd, Cambridge,
UK). The right common carotid artery was  cannulated and con-
nected to a pressure transducer to measure heart rate and blood
pressure throughout the procedure (Powerlab data acquisition
system, AD instruments, Abingdon, UK). The left jugular vein was
cannulated for drug administration. The trachea was  cannulated
via tracheotomy and the animal ventilated with room air by a
444 Q.G. Karwi et al. / Pharmacological Research 111 (2016) 442–451
-20’ 0’
Stabilisation
30’ 150 ’20’
Control
GYY4137
Time
(mi ns)
Reperfusion
D-GYY4137
GYY4137 
D-GYY4137
Control
GYY 4137
L-NAME
GYY4 137 + L-NAME
LY2 94002
GYY4 137 + LY294002
-20’ 0’
Stabilisat ion CAO 
30’ 150’20’15’
Time
(mins)
Reperfusion
L-NA ME
GYY4137
LY294 002
A
B
Fig. 1. Treatment protocols. (A) Series 1 infarct studies. After surgical preparation, rats were stabilised for 20 min then subjected to 30 min of left coronary artery occlusion
(CAO) followed by 120 min  of reperfusion. Control rats did not receive any further intervention, while treatment groups received one of three GYY4137 doses or depleted
GYY4137 (D-GYY4137) 10 min  before reperfusion. Hearts were excised at the end of reperfusion for infarct size determination, n = 6–10. Arrows indicate the time of
pharmacological interventions. (B) Series 2 infarct studies. Following stabilisation, rats were subjected to 30 min  of left coronary artery occlusion and 120 min  of reperfusion.
Animals were randomised into six groups. Control heart did not receive any further intervention. GYY4137 was administered 10 min  before reperfusion. LY294002 and
L-NAME were administered 15 min  before reperfusion. Hearts were excised at the end of reperfusion for infarct size determination, n = 6–7. Parallel groups, n = 4, were
prepared identically but hearts were excised 5 min  after reperfusion for analysis by immunoblotting. Arrows indicate the time of pharmacological interventions.
small animal volume controlled ventilator (Hugo Sachs Elektronik,
March, Germany) at a rate of 75 strokes min−1 and tidal volume
of 1.0–1.25 mL  100 g−1. The electrocardiogram was recorded using
standard lead lI electrodes inserted subcutaneously into the limbs
and connected to a Powerlab data acquisition system. A midline
sternotomy was performed and the chest opened using a metal
retractor to expose the heart. After pericardiotomy, a 4/0 braided
silk suture (Mersilk, Ethicon Ltd, UK) was placed around the left
main coronary artery close to its origin from the left border of
the pulmonary conus. The animal was left to stabilise for 20 min
during which the two ends of the silk ligature remained loose.
For each animal to be included it had to achieve the following
hemodynamic parameters during the stabilisation period: heart
rate ≥ 250 beats per minute, diastolic blood pressure ≥ 50 mmHg,
steady sinus rhythm, no signs of ischemia or arrhythmia during
the stabilisation period.
After stabilisation, the ligature was pulled taut through a plas-
tic snare and fastened against the epicardium to induce regional
ischemia for 30 min. Ischemia was conﬁrmed by a drop in the mean
arterial pressure (MAP), a colour change of the left ventricle (from
red to pale), and ECG changes (ST-segment elevation). After 30 min,
the snare was released to allow reperfusion for 120 min. Success-
ful reperfusion was conﬁrmed by hyperemic colour change of the
ischemic tissue bed, occurrence of reperfusion-induced arrhyth-
mia  during the ﬁrst minute after reperfusion, and an increase in
the MAP.
2.4. Infarct size determination
After 120 min  reperfusion, the heart was  excised and perfused
via the aorta with saline on a modiﬁed Langendorff apparatus. After
re-occluding the coronary ligature, the heart was perfused with 2%
Evans’ blue dye to identify the ischemic zone (area at risk, AAR).
The heart was  then frozen at −20 ◦C for 5–24 h. The frozen heart
was transversely sliced at 2 mm  thickness into 5–6 sections from
apex to base and the sections incubated with triphenyltetrazoilum
chloride (TTC) 1% w/v in phosphate buffered saline (PBS; pH 7.4)
at 37 ◦C for 15 min. TTC is reduced to a red formazan pigment in
viable tissue while necrotic tissue is unstained. Stained sections
were ﬁxed in 4% formalin in PBS for 24 h before being scanned.
Planimetry was  conducted using the image analysis program Image
J (version 1.47, NIH, Bethesda, USA). Sections were coded so that
image analysis was  undertaken in a blinded fashion to obviate bias.
Planimetric analysis determined the total ventricular area, the AAR
(Evans blue negative), and the infarcted area (TTC negative). These
areas were then converted into volumes by multiplying each total
area by 2 mm section thickness and the infarct size was reported
as a percentage of the area at risk volume (% I/AAR).
2.5. Treatment protocols
Treatment protocols are illustrated in Fig. 1. Two separate series
of experiments were undertaken. The ﬁrst series examined the
dose-dependent effects of GYY4137 on infarct size and the involve-
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Fig. 2. Infarct size data: GYY4137 dose-response study (Series 1). Area at risk was determined Evans’ blue exclusion and infarction was assessed by TTC staining. GYY4137
was  administered at 26.6, 133, or 266 mol  kg−1 10 min  before reperfusion. (A) Area at risk as a percentage of the total ventricular volume. (B) Myocardial infarction expressed
as  a percentage of the area at risk. Numbers in histograms indicate sample size. ** P < 0.01 versus Control; †  p < 0.05 versus GYY4137 266 mol kg−1 (one way ANOVA with
Newman  Keuls post hoc test).
ment of H2S in mediating any responses. The dose range employed
in these studies was derived from previous studies in the rat heart
ex vivo by our group [50] and in vivo studies conducted by oth-
ers [33,38]. Animals were randomly assigned to one of ﬁve groups
(Fig. 1A):
• Group 1: Control (n = 9). Animals were subjected to coronary
occlusion and reperfusion with saline given as a slow i.v. bolus
10 min  before reperfusion.
• Group 2–4: Each group (n = 8) received GYY4137 at 26.6, 133 or
266 mol  kg−1, respectively as a slow i.v. bolus (500 L min−1)
10 min  before reperfusion.
• Group 5: Depleted GYY4137 (n = 6). GYY4137 solution
(100 mg  mL−1) was prepared in saline and left uncovered for
72 h at room temperature to dissipate all H2S, then administered
at a dose of 266 mol  kg−1 i.v. 10 min  before reperfusion.
The second series of experiments explored the involvement
of RISK pathway components in the cardioprotective effect of
GYY4137. The optimum dose of GYY4137 (266 mol  kg−1) was
selected from the ﬁrst series and animals were randomised into
six treatment groups (Fig. 1B).
Group 6: Control (n = 7). Animals were subjected to coronary
occlusion and reperfusion with saline or DMSO 5% given as a slow
i.v. bolus 15 min  before reperfusion. DMSO was used as vehicle
for LY294002. Since DMSO exerted no effect on cardiodynamics
or infarct size, saline and DMSO treated animals are reported col-
lectively.
• Group 7: GYY4137 (n = 7). A slow bolus dose of GYY4137
(266 mol  kg−1, 500 L min−1) was administered at 10 min
before reperfusion.
• Group 8: GYY4137 + L-NAME (n = 7). An intravenous bolus dose
of L-NAME (20 mg  kg−1) was administered 15 min  before reperfu-
sion followed by GYY4137 (266 mol  kg−1, 500 L min−1) 10 min
before reperfusion.
• Group 9: L-NAME (n = 6). An intravenous bolus dose of L-NAME
(20 mg  kg−1) was administered 15 min  before reperfusion.
• Group 10: GYY4137 + LY294002 (n = 6). An intravenous bolus
dose of LY294002 (0.1 mg  kg−1 in 5% DMSO) was given
15 min  before reperfusion followed by GYY4137 (266 mol  kg−1,
500 L min−1) 10 min  before reperfusion.
• Group 11: LY294002 (n = 6). A bolus dose of LY294002
(0.1 mg  kg−1 in 5% DMSO) was administered intravenously
15 min before reperfusion.
In a parallel series of experiments, rats were subjected to the
same interventions as in groups 6–11 to prepare samples for bio-
chemical analysis. After 5 min  of reperfusion, the experiment was
terminated and myocardial biopsies were harvested from the left
ventricle, rapidly frozen in liquid nitrogen then kept at −80 ◦C for
Western blotting of Akt, eNOS, GSK-3 and ERK1/2.
2.6. Western blotting analysis
To investigate the involvement of Akt, eNOS, GSK-3 and
ERK1/2, protein immunoblotting was carried out to analyse pro-
tein phosphorylation at 5 min  of reperfusion. Myocardial biopsies
were homogenised and lysed using a hard tissue lysing kit (Stretton
Scientiﬁc Ltd, Stretton, UK). Equal amounts of protein were loaded
onto 10% w/v  sodium dodecyl sulfate-polyacylamide gel, separated
electrophoretically (120 mV)  and transferred onto nitrocellulose
membrane (Amersham, Germany). The membrane was then
blocked with 5% skimmed milk for 2 h and probed with the primary
antibody overnight at 4 ◦C. The following antibodies were used:
Akt (1:1000), phospho- ser473Akt (1:1000), endothelial nitric oxide
synthase (eNOS 1:500), phospho- ser1177eNOS (1:500), glycogen-
synthase kinase-3 beta (GSK-3 1:1000), phospho- ser9GSK-3
(1:1000), extracellular signal-regulated kinases ERK 1/2 (1:1000),
phospho- Thr202/Tyr204 ERK 1/2 (1:1000) and GAPDH (1:50000).
The immunoblots were probed with secondary antibody (goat anti-
rabbit HRP, 1:15000, Cell Signalling UK) for 1 h then probed with
Super Signal West Dura Extended Duration Substrate (Thermo Sci-
entiﬁc) to visualise the bands on X-ray ﬁlm. The ﬁlm was  scanned
and densitometry was conducted in a blinded fashion using Image
J software (1.48 v, National Institutes of Health USA). Phosphory-
lated and total protein bands were normalised to corresponding
GAPDH bands and to baseline samples, harvested after 20 min  of
stabilisation, loaded at either side of each gel.
2.7. Statistical analysis
All data are reported as arithmetic mean ± SEM. Data were ana-
lysed using GraphPad Prism® software (2007, Version 5.01, USA).
Cardiodynamics including rate-pressure product (RPP, heart rate
446 Q.G. Karwi et al. / Pharmacological Research 111 (2016) 442–451
0
10
20
30
40
50
60
70
In
fa
rc
t s
iz
e
(%
 o
f a
re
a 
at
 r
is
k)
7 7 7 6 6 6
***
**
†
0
10
20
30
40
50
60
70
AA
R
(%
 o
f t
ot
al
 v
en
tr
ic
ul
ar
 a
re
a)
7 7 7 6 6 6
BA P=NS
Fig. 3. Infarct size data: GYY4137 with pharmacological inhibitors (Series 2). Area at risk was  determined Evans’ blue exclusion and infarction was assessed by TTC staining.
GYY4137 was  administered at 266 mol  kg−1 10 min  before reperfusion. LY294002 or L-NAME were given 15 min  before reperfusion. (A) Area at risk expressed as a percentage
of  the total ventricular volume. (B) Infarct size expressed as a percentage of the area at risk. Numbers in histograms indicate sample size. ** p < 0.01 versus Control; *** p < 0.001
versus control; †  p < 0.01 versus GYY4137 (one way ANOVA with Newman Keuls post hoc test).
* systolic blood pressure) and mean arterial pressure (MAP, dias-
tolic pressure + 1/3[systolic pressure – diastolic pressure]) were
statistically analysed using repeated measures ANOVA supported
by Bonferroni’s post hoc test. Baseline data including body weight,
RPP, and MAP  passed the Kolmogorov-Smirnov normality test of
distribution. Infarct size data were analysed using one way  ANOVA
supported by Newman-Keuls post hoc test. Differences between
groups were considered signiﬁcant if p < 0.05.
3. Results
In series 1, 42 rats were used, of which two were excluded
from ﬁnal analysis, one due to failure of TTC staining and one rat
which did not survive the ischemia-reperfusion protocol. Thus data
for 40 successfully completed experiments are reported. In series
2, 66 rats were employed, of which three did not complete the
ischemia-reperfusion protocol. Thus, data from a total of 63 com-
pleted experiments are reported in series 2: these comprised 39
completed infarct size experiments and 24 preparations for West-
ern blot analysis.
3.1. Hemodynamic parameters
Baseline hemodynamics for series 1 and 2 are summarised
in Table 1. There was no signiﬁcant difference in any of the
parameters among the experimental groups. Cardiodynamics (MAP
and RPP) measurements before ischemia, during ischemia and at
the end of reperfusion are also presented in Table 1. GYY4137
had no detectable effect on cardiodynamics during the ischemia-
reperfusion protocol.
3.2. Infarct size following GYY4137 postconditioning
Series 1 examined the response to three doses of GYY4137
on infarct size (Fig. 2). AAR constituted approximately 40–60%
of the total ventricular volume with no signiﬁcant differences
among the treatment groups (Fig. 2A). Control infarct size (%I/AAR)
was 52.5 ± 4.7% (Fig. 2B). GYY4137 (266 mol  kg−1) produced sig-
niﬁcant infarct limitation when given 10 min  before reperfusion
compared to control hearts (27.9 ± 3.8% vs 52.5 ± 4.7%, p < 0.01).
This represents a 47% relative reduction in infarct size. In contrast,
depleted-GYY4137 (produced as described in [1] which lacked H2S
donating potential but was otherwise structurally identical had no
effect on infarct size at the same dose (51.9 ± 3.1%), conﬁrming the
dependency of GYY4137’s infarct-limiting action on H2S release.
3.3. Involvement of PI3K/Akt and eNOS in GYY4137
postconditioning
The second series of experiments was  undertaken to exam-
ine components of the RISK signalling pathway in the protective
effect of GYY4137 (Fig. 3). There was no signiﬁcant difference
in the AAR among the experimental groups (Fig. 3A). GYY4137
(266 mol  kg−1) elicited a signiﬁcant reduction in%I/AAR com-
pared to control (27.6 ± 2.0% vs 56.8 ± 3.5%, respectively, p < 0.001,
Fig. 3B). Pharmacological inhibition of eNOS with L-NAME prior
to GYY4137 almost halved the cardioprotective effect of GYY4137
(41.1 ± 6.3% vs 27.6 ± 2.0%, respectively, p < 0.05), but did not abol-
ish it (41.1 ± 6.3% vs 56.8 ± 3.5%, respectively, p < 0.01, Fig. 3B).
Concomitant administration of LY294002 to inhibit PI3K activ-
ity completely abrogated the cardioprotective effect of GYY4137
(49.8 ± 4.2% vs 56.8 ± 3.5%, respectively, p > 0.05). Neither L-NAME
nor LY294002 had any effect on infarct size when given alone
(55.7 ± 3.3% and 51.2 ± 2.7% respectively, both p > 0.05 vs control).
The extent of phosphorylation of Akt, eNOS, GSK-3  and ERK1/2
in early reperfusion was investigated with phospho-speciﬁc anti-
bodies to determine the possible roles in cardioprotection by
GYY4137. Immunoreactivity measurements were performed using
myocardial tissue samples harvested from the left ventricle 5 min
after reperfusion and are presented in Fig. 4A–D. There was no
signiﬁcant difference in protein expression to GAPDH of Akt,
eNOS, GSK-3 or ERK1/2 among any of the experimental groups.
There was a signiﬁcant 2.8-fold increase (p < 0.001 vs.  control) in
phospho-ser473Akt at reperfusion following GYY4137 treatment
(Fig. 4A). Prior administration of L-NAME did not limit this increase
in Akt phosphorylation. However, administration of LY294002
alone or prior to GYY4137 abolished Akt phosphorylation (Fig. 5A).
Postconditioning with GYY4137 also increased eNOS phosphory-
lation at the activating ser1177 site by 2.2-fold in early reperfusion
(p < 0.01 vs.  control; Fig. 4B). This activation was  abrogated by prior
administration of either L-NAME or LY294002. Ser9 phosphoryla-
tion of GSK-3 was  also increased 2.2-fold by GYY4137 (Fig. 4C).
This phosphorylation, leading to inactivation of GSK-3,  was not
affected L-NAME. However, pre-treatment with LY294002 prior
to GYY4137 abrogated GSK-3 phosphorylation. GYY4137 had no
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Fig. 4. Western blot analysis of left ventricular myocardium harvested from the area at risk 5 min  after reperfusion. Histograms show densitometric ratios of phosphorylated to total protein. GAPDH was  used as loading control
for  all determinations. (A) p-Akt, total Akt and GAPDH. (B) p-eNOS, total eNOS and GAPDH. (C) p-GSK-3, total GSK-3 and GAPDH. (D) p-ERK1/2, total ERK1/2 and GAPDH. * p < 0.05, ** p,0.01, *** p < 0.001 versus control. In all
groups,  n = 4.
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Fig. 5. GYY4137, a donor of H2S, induces marked limitation of myocardial infarct
size when given shortly before reperfusion. Based on the present experimental data,
we  present a mechanistic scheme by which GYY4137 mediates its cardioprotection
against reperfusion injury. GYY4137 releases H2S which triggers a key component
of  the reperfusion injury salvage kinase cascade, namely PI3K/Akt activation at
reperfusion. Downstream of activated Akt, phosphorylation of eNOS and GSK-3
are  induced by GYY4137 treatment. Although not yet determined, it seems plausi-
ble that GYY4137 eventually inhibits the opening of mPTP at early reperfusion as a
result of the increase in NO level and inhibition GSK-3 activity, resulting in reduced
cardiomyocyte susceptibility to lethal reperfusion injury.
signiﬁcant effect on the phosphorylation of ERK1/2 at early reper-
fusion (Fig. 4D).
4. Discussion
The principal observations of this study can be summarised as
follows:
1 GYY4137 limited myocardial infarction in vivo when given specif-
ically prior to reperfusion indicating potent attenuation of lethal
reperfusion injury in a postconditioning-like manner.
2 The infarct-limiting effect of GYY4137 at early reperfusion was
mediated through activation of the PI3K/Akt survival cascade.
3 There was a partial dependency of GYY4137’s protective effect
on increased eNOS activation.
4 GYY4137 inhibited GSK-3 activity at early reperfusion by
increasing the phosphorylation of its ser9 site downstream of
PI3K/Akt signalling.
These ﬁndings support the hypothesis that administration of
GYY4137 at reperfusion can protect the heart against reperfu-
sion injury by activating the key components of the RISK cascade
(PI3K/Akt/NO) and inhibition of GSK-3 activity.
4.1. Infarct limitation by GYY4137
The results show for the ﬁrst time the effect of GYY4137, as a
slow-releasing H2S donor, on myocardial infarction in an in vivo
model. Intracellular levels of H2S are reported to be decreased
during ischaemia-reperfusion as a results of overwhelming ROS
generation which limits H2S synthesis and increases its degradation
[51]. GYY4137 elicited signiﬁcant infarct limitation when admin-
istered prior to reperfusion. Depleted GYY4137 [1] was employed
as a control to ensure that any detectable effect was  due to H2S
released and not by the parent molecule or by-products formed
from GYY4137 decomposition. Depleted GYY4137 had no effect
on infarct size and this is consistent with previous studies where
loss of H2S from GYY4137 was shown to be associated with loss of
biological activity [32,53,13,23,1].
This is the ﬁrst study of pharmacological postconditioning
against reperfusion injury in vivo using GYY4137 as a stable H2S
donor. Although inorganic H2S generators (NaSH and Na2S) have
been used in different experimental species, the speciﬁc targeting
of reperfusion injury by GYY4137 in this study is novel. Several
studies have investigated the effect of H2S against myocardial
ischemia-reperfusion when commercially available sulﬁde salts
were perfused or given pre-ischemia. For example, Johansen et al.
[24] were the ﬁrst to show that NaSH limited infarct size in a rat iso-
lated heart preparation, while Pan et al. [40], Sivarajah et al. [46],
Zhuo et al. [59] and Yao et al. [55] all showed that NaSH limited
infarct size in an in vivo rat model through diverse mechanisms.
Part of this variation is arguably due to the unstable nature of these
H2S sources, in addition to the different experimental conditions
and end-points of interest. Using garlic derivative as an organic
source of H2S, Zhang et al. [57] and Chuah et al. [9] reported that
allitridum and S-allylcysteine respectively also elicited cardiopro-
tection against myocardial infarction when given before ischemia.
Preconditioning the heart with the thiol derivative S-diclofenac
was also protective partially through the opening of mitochondrial
KATP channels [45]. Investigators also have examined the possibil-
ity of postconditioning the myocardium using NaSH and Na2S. For
example, Elrod et al. [11], Sodha et al. [48] and Lambert et al. [28]
all reported that Na2S protected mouse heart against myocardial
infarction in vivo when given at reperfusion. Bibli et al. [4] showed
that a bolus dose of NaSH 10 min  before reperfusion then contin-
uous infusion of NaSH till the end of reperfusion was required to
signiﬁcantly exert cardioprotection in rabbit. In comparison with
these results, in this study we showed that a single bolus dose of
GYY4137 at reperfusion had a signiﬁcant cardioprotective effect
against myocardial infarction in the rat. To our knowledge, the
only other long-lasting H2S donors that have been reported are the
polysulﬁde diallyl trisulﬁde (DATS) and SG-1002, a thiol-activated
H2S donor. Despite generating 10 times less H2S than Na2S, DATS
was shown to improve mitochondrial respiration and stimulate
eNOS at reperfusion in an in vivo mouse model of ischemia-
reperfusion injury. However, DATS is a polysulﬁde compound,
and thus cannot be considered a pure H2S donor with the possi-
bility of off-target effects. Moreover, H2S release from GYY4137
is reported to last longer compare to DATS [33,43]. In the set-
ting of pressure-overload-induced heart failure, SG-1002-treated
hearts were protected during transverse aortic constriction via trig-
gering VEGF/Akt/eNOS/NO/cGMP pathway. Recently, SG-1002 has
successfully passed Phase I clinical study in patient with heart
failure (ClinicalTrials.gov #NCT01989208 and #NCT02278276), by
increasing blood H2S level and circulating NO bioavailability [42].
However, none of these studies have shown that the observed
effects are due to H2S release due to the lack of negative control
(like depleted GYY4137, for example). Therefore, there is persua-
sive experimental evidence that a stable level of H2S release confers
effective cardioprotection against ischemia-reperfusion injury. The
present study conﬁrms for the ﬁrst time that administration of
GYY4137 prior to reperfusion (postconditioning), rather than prior
to coronary artery occlusion (preconditioning), exerts a marked
cardioprotective effect due to H2S-releasing capacity.
4.2. GYY4137 postconditioning activates PI3K/Akt signalling
The second series of experiments aimed to explore the signalling
mechanisms underpinning the protective effect of GYY4137. The
involvement during early reperfusion of speciﬁc kinase mecha-
nisms, notably activation of PI3K/Akt and/or ERK1/2, activation of
eNOS and inhibition of GSK-3,  has attracted considerable atten-
tion in relation to cardiac conditioning phenomena, especially
Q.G. Karwi et al. / Pharmacological Research 111 (2016) 442–451 449
postconditioning. Elucidation of the RISK pathway has conﬁrmed
that it is a key modulator of protection against reperfusion injury
in many species, although not all. Here, we explored the effects
of pharmacological inhibition of two key components, PI3K/Akt
and eNOS, conﬁrmed by assessment of the phosphorylation sta-
tus of these proteins. We  found that the PI3K inhibitor LY294002
abrogated the infarct-limiting effect of GYY4137 which indicated
the involvement of PI3K/Akt survival pathway in cardioprotection
established by GYY4137. This was supported by the observation
that GYY4137 increased Akt phosphorylation in left ventricu-
lar myocardium during early reperfusion, an effect abolished by
LY294002. Li et al. [30] showed that NaSH at reperfusion limited
cell death by activating PI3K/Akt pathway in aging rat heart and
cardiomyocytes. However, Lambert et al. [28] demonstrated that in
diabetic rats NaSH-induced postconditioning might signal through
the other arm of the RISK pathway, namely ERK1/2. LY294002 alone
had no signiﬁcant effect on either the infarct size or Akt phosphory-
lation compared to control which is consistent with the ﬁndings of
other investigators [52,2]. This suggests that the PI3K/Akt pathway
is almost inactive at basal physiological levels of H2S.
We  also investigated the involvement of ERK1/2 in cardiopro-
tection established by GYY4137. In contrast to Akt phosphorylation,
we observed no signiﬁcant increase in ERK1/2 phosphorylation at
early reperfusion following postconditioning with GYY4137. It has
been reported by others that a bolus dose of Na2S at reperfusion
could activate ERK1/2 and also inhibit GSK-3 [28,31,4]. However,
since in our hands GSK-3 phosphorylation (leading to enzyme
inhibition) by GYY4137 was abrogated by LY294002, this suggests it
is downstream of PI3K/Akt, rather than ERK1/2. It again emphasises
the physiological differences between bolus sulﬁde (with NaSH or
Na2S) and H2S generated in a more physiological manner (with
GYY4137).
4.3. Dependency of GYY4137-postconditioning on NO
Inhibition of NO synthesis using L-NAME had no effect on
the infarct size per se which is consistent with other investiga-
tors [14,21]. This observation implies that NO does not afford
any cardioprotection against myocardial infarction at basal phys-
iological levels. GYY4137 treatment induced an increase in the
phosphorylation of eNOS at its activating site, ser1177 suggesting
that NO bioavailability is increased following GYY4137 treatment.
L-NAME prior to GYY4137 administration limited the phosphory-
lation of eNOS and partially attenuated infarct limitation but did
not completely abolish the protective effect. These data suggest
that enhancing NO bioavailability synergises the cardioprotection
of GYY4137 against reperfusion injury but blocking eNOS phos-
phorylation only partially limits the cardioprotection of GYY4137,
suggesting the involvement of parallel NO-independent path-
way(s). There has been considerable interest in cross-regulation of
NO and H2S but the nature of their interactions is uncertain, at least
in part because of the large variation in experimental conditions.
SG-1002, H2S donor, was protective and increased NO bioavail-
ability in an in vivo model of heart failure [27]. An increase in NO
metabolites following DATS treatment was also observed by Lefer
and co-workers [43]. in mouse heart. King et al. [26] found that
H2S did not limit infarction in eNOS phospho-mutant (S1179A) or
eNOS knockout mice. Considered together, these studies suggest
that an increase in one of the gaseous mediators can eventually
lead to an increase in the other but the picture is obscured by vari-
ations across species, pathological models and tissue types. The
NO-dependency of H2S has recently been studied by Bibli et al. [4] in
an in vivo model of myocardial infarction using two  species, rabbit
and mouse. Pharmacologically limiting NO availability with L-
NAME did not limit the protection of NaSH in rabbits, while genetic
mutation or pharmacological blockade of eNOS totally abolished
H2S-induced protection in mice. Dependency of NaSH-induced car-
dioprotection on NO in mice was  previously reported by Sojitra
et al. [49]. Together and in line with our data, it seems plausible
that NO involvement in the infarct-limiting effect of H2S could be
tissue and/or species-dependent. Further detailed work needs to be
carried out for better understanding of the molecular pharmacol-
ogy of these molecules and to enhance the clinical implementation
of H2S-delivering systems.
4.4. GYY4137 postconditioning attenuates GSK-3ˇ
phosphorylation
GSK-3 has been proposed as one of the key end effec-
tors of some cardioprotective manoeuvres, particularly ischemic
conditioning phenomena. It has been demonstrated that GSK-
3 promotes the opening of mPTP during reperfusion, an event
thought to be a major determinant of cell death [7]. In isolated
cardiomyocytes, Yao et al. [54] and Li et al. [31] found that NaSH
protected against hypoxia/reoxygenation induced cell death by
inhibiting GSK-3-dependent opening of mPTP. In line with these
results, the present study demonstrated that GYY4137 increased
the phosphorylation of GSK-3 at Ser9 site at reperfusion. This
was abolished by LY294002, but not by L-NAME, suggesting that
GYY4137 induced inhibition of GSK-3 is downstream of PI3K/Akt.
There is evidence that the increase in Akt phosphorylation [18]
and NO bioavailability [6] at early reperfusion may  also inhibit
the opening of mPTP. Considering these data together, it seems
plausible that postconditioning with GYY4137 is associated with
a reduced susceptibility of mPTP opening, although this remains to
be determined by speciﬁc measurements of mPTP opening.
4.5. Study limitations
There are still questions which this study did not address and
they could be interesting topics for further investigations. This
study found that GYY4137 activates the RISK pathway at early min-
utes of reperfusion to limit the infarct size where infarction was
quantiﬁed after 2 h of reperfusion. Nevertheless, whether GYY4137
could exert a comparable cardioprotection via similar or different
mechanism(s) with longer reperfusion protocol, where there could
be no-ﬂow phenomena or late apoptosis, needs to be investigated.
Although spent-GYY4137 did not exert any cardioprotection, the
direct effect of GYY4137 administration on the level of H2S in the
heart and circulation needs to be measured. Similarly, measuring
the proposed elevation in NO bioavailability as a result of acti-
vating eNOS at reperfusion by GYY4137 administration could also
underpin the conclusion.
5. Conclusion
In summary, we  have demonstrated that the slow-releasing H2S
donor GYY4137, but not its H2S-depleted control, protected the
heart against lethal reperfusion injury when administered as an
adjunct treatment prior to reperfusion. This cardioprotective action
is dependent on activation of PI3K/Akt signalling pathway at early
reperfusion, which in turn, increases NO bioavailability by increas-
ing eNOS phosphorylation, and increases the phosphorylation of
GSK-3 (see Fig. 5, Graphical Abstract). Thus, stable slow-releasing
H2S donor compounds may  be promising candidates for the devel-
opment of adjunct therapies to reperfusion for the treatment of
acute myocardial infarction.
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Infarct Limitation by GYY4137 at Reperfusion, a Slow-Releasing Hydrogen Sulfide 
Donor, in the Rat In Vivo 
 
 
Administration of exogenous hydrogen sulfide (H2S) donors has been shown to protect the heart against 
ischaemia/reperfusion injury when given at reperfusion by a mechanism that is not fully defined. We 
sought to characterise the effect of GYY4137, a slow-releasing H2S donor (morpholin-4-ium 4 
methoxyphenyl (morpholino) phosphinodithioate), when given specifically at reperfusion and the 
involvement of PI3K/Akt signalling in mediating its effects. . All the handling and procedures were carried 
out in accordance with Home Office Guideline of the Animal (Scientific Procedure) ACT, 1986. Adult male 
Sprague Dawley rats were anaesthetised with thiobutabarbital (800 µmol/kg, i.p.) and regional myocardial 
ischaemia was induced by occluding the left descending coronary artery for 30 minutes followed by 2 
hours of reperfusion. Animals were randomly assigned (n=6 per group) to receive: 1) no further 
intervention, 2) GYY4137 (266 µmol/kg, i.v.) 10 minutes before reperfusion, 3) Endothelial nitric oxide 
synthase (eNOS) inhibitor (L-NAME, 74.2 µmol/kg, i.v.) 5 minutes prior to GYY4137 dose, 4) PI3K 
inhibitor LY294002 (872.6 nmol/kg, i.v.) 5 minutes prior to GYY4137 dose. In two additional groups, L-
NAME and LY294002 were given alone as previously. In a parallel series of experiments (n-4 in per 
group), tissue samples were harvested from the left ventricle at 5 minutes of reperfusion and snap frozen 
for biochemical analysis. Infarct size is reported as a percentage of the area at risk. Data, reported as 
mean±SEM, were analysed using one-way ANOVA supported by Newman Keuls post hoc test, when 
appropriate. In GYY4137-treated hearts, the phosphorylation of Akt, eNOS and GSK-3β increased at 5 
minutes of reperfusion. GYY4137 significantly limited infarct size by 51% compared to untreated-hearts 
(27.6 ± 2.0% vs 56.8 ± 3.5%, p<0.001). Co-administration of L-NAME with GYY4137 attenuated but did 
not abolish the cardio protection established by GYY4137 (41.1 ± 6.3% vs 27.6 ± 2.0%, p<0.05) by 
limiting the phosphorylation of eNOS. LY294002 totally abrogated the infarct-limiting effect of GYY4137 
(55.7 ± 3.3%) and inhibited the phosphorylation of Akt, eNOS and GSK-3β. These data indicate that 
GYY4137 can protect the heart against ischaemia/reperfusion injury through activating the PI3K/Akt/NO 
signalling pathway and increasing the phosphorylation of GSK-3β at early reperfusion. 
 
  
 
